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Abstract: 
Diet and lifestyle factors are well documented for their impact on health and wellbeing. 
Epigenetics provides the added connection between personal genetics and environmental 
factors, including food, interacting with health and disease. 
Functional foods is a growth area of food development, augmentation and 
supplementation. However, more scientific validation of the claims made for functional 
foods and functional components is required to properly inform consumers and healthcare 
practitioners.  
There is also growing consumer acceptance of personalised genetic analysis for health and 
wellbeing. The commerciality of providing cost-effective genetic diet and lifestyle advice is a 
new and developing area in the health industry. 
All diseases have a genetic link, and genome-wide association studies (GWAS) are 
discovering genetic variations linked to complex diseases. However, nutrient information is 
absent for the development of dietary advice and the management and prevention of 
disease. The development of nutrigenomics provides information on the gene/nutrient 
interaction essential for the design of personalised nutrition. 
Functional nutrition from a combination of personalised genetic analysis and nutrigenomic 
interventions, represent an important new nexus for improving public health and the future 
of disease prevention. 
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1.1 The effects of diet on health 
Diet is an important factor in promoting health and preventing chronic diseases such as 
cardiovascular disease (CVD), diabetes, obesity and cancer. Food products may be defined as 
functional if together with the basic nutritional impact it has beneficial effects on one or more 
functions of the human organism, thus either improving general health and physical 
conditions and/or decreasing the risk of the evolution of diseases.  
The rapid growth of the global ageing population and the limited efficacy of available 
pharmacological therapies for age-related cognitive decline and neurodegenerative diseases 
means that there is an increasing interest and public demand for  ‘functional foods’ that 
promote cognitive wellbeing and longevity (Cannella et al., 2009, Alles et al., 2012, Feart et 
al., 2015). Conversely, evidence supports the hypothosis that early nutrition during prenatal 
development, infancy and childhood affects both cognitive development and cognitive 
function and behaviour in later life (Anjos et al., 2013, Prado & Dewey, 2014, Barker et al., 
2013, Jacka et al., 2013). Understanding the biological effects of nutrition throughout 
development and in later life has major implications for physical and mental health and is 
therefore of great importance for the public health sector, food product development, 
economic progress and consumer interest.  
The beneficial effects of certain food groups, including plant foods and oily fish which 
provide high sources of plant bioactive compounds (e.g. polyphenols, glucosinolates and 
antioxidant vitamins) and omega-3 fatty acids, are well documented (Pallauf et al., 2013, 
Vauzour et al., 2010, Feart et al., 2013, Feart et al., 2015). Many modern diets and food 
supplements enriched with these bioactive compounds, claim to be beneficial to health by 
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boosting the immune system, supporting cardiovascular function, protecting cells against 
oxidative stress and promoting healthy skin, teeth and bones (Roll et al., 2011, Lamprecht et 
al., 2007, Chapple et al., 2012, Lamprecht et al., 2013, Cui et al., 2012, De Spirt et al., 2012, 
Esfahani et al., 2011). Addressing the synergistic effects of certain functional foods and 
supplements consumed in combination for health and wellbeing is of growing interest in the 
field of nutrition (Alles et al., 2012).  
The purpose of this study is to provide an updated review surrounding the effects of 
functional dietary compounds on phenotypic outcomes relating to health. Further, this study 
addressed the potential biological effects of diet and functional foods using a pathway 
analysis approach to better our understanding of how nutrition can influence different 
regulatory mechanisms including development, immune responses, metabolic processing, 
hormonal control and Deoxyribonucleic Acid (DNA) repair. The findings of this analysis will 
have implications for public health, disease intervention, therapeutic management, nutrition-
related behaviours, marketing strategy, economic growth and food development.  
 
 
1.2 The role of functional food & nutriceuticals in the diet. 
 
The Functional Foods Industry is an important and evolving area of food development 
intended to have a positive impact on health. The implications for the future of the food 
industry and the public health sector are extensive.  The market for functional foods is 
growing. Despite initial scepticism about functional foods, many existing brands and 
products perform well in this competitive market. Customers choose functional foods over 
basic alternatives as a simple way to improve their health, with 82% of adults now 
consuming a functional food on a weekly basis (Mintel 2013). The global functional food 
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market is estimated to reach $149bn by 2018. (Business Communications Company (BCC) 
Research, 2008) 
             The top twelve key trends in food, nutrition and health comprise naturally functional 
foods, dairy, protein, energy, weight management, snacking, slow energy release, sugar 
alternatives, indulgent, free-form, seniors and kids-nutrition (New Nutrition Business, 2013).   
Similarly, functional food trends highlighted in 2014 were; speciality nutrition, real food, 
high protein, kid-specific, nutraceuticals, meat alternatives, performance nutrition, weight 
reduction and millennials (Institute of Food Technologists (IFT), 2014). The future landscape 
of functional foods will continue to focus on key public health concerns: weight 
management, cognitive health and cardiovascular health.   
             In the last decade, more consumers believe that foods contribute directly to their 
health. The growing trend for the purpose of food is not only to satisfy hunger and provide 
necessary nutrients, but also to improve health and reduce the risk of nutritional-related 
diseases. Many studies exist on different functional food components and their beneficial 
factors for improving health.  
            Food manufacturers are utilising these scientific backgrounds to develop new 
products which claim to have functional food health benefits. The functional food market is 
growing worldwide, and functional products exist in virtually all food categories. As new 
products are launched into the market every year, competition is becoming more intense. 
Health claims have become an important piece of product marketing, providing information 
to attract consumers to purchase.  Health claims on food products are often used to 
highlight scientifically proven health benefits associated with consuming those products. It 
is also a way to promote awareness to the public about the benefits they will gain after 
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consumption. It is critical that the validity of claims is regulated to avoid misrepresentation 
of scientific fact.  
Consumer acceptance is important for the successful development of functional 
foods in alignment with consumer needs. Therefore, consumer research is crucial to the 
product development process. Consumers understanding, perception and acceptance, is 
critical to the propensity of purchase and the development of the industry 
             Americans are accepting of functional foods and are prepared to include them in 
their diets. However, consumer studies reported lower frequency of consumption of 
functional food based upon lower perceptions of taste and enjoyment from functional 
foods. In Europe, food choice of functional food is growing continuously. Europeans are 
more critical of new products and technologies. They are suspicious of the safety of novel 
foods and their production processes. Therefore, it is fair to hypothesise that Europeans 
acceptance of functional foods is less unconditional compared to Americans (Siro et al. 
2008), 
             Surveys confirm that consumer opinion on the healthiness of a product greatly 
depended on the carrier product itself. The healthiness of the carrier products might 
override the effect of enrichment with functional components (Ares & Gambaro, 2007). 
Surveys from different countries demonstrate different consumer attitudes and acceptance 
towards functional foods. Different socio-demographic parameters, gender, education, 
income levels etc., also have an effect on the customer acceptance level of functional foods 
(Siro et al., 2008) 
             Consumer knowledge and awareness of the health effects of newly developed 
functional ingredients seems to be rather limited (Siro et al., 2008). Willingness to try 
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functional food is driven by its attractiveness, credibility and uniqueness, which suggests 
that the healthy image of a functional food determines positive consumer acceptance (van 
Kleef et al., 2005). 
Nutraceuticals are an important development in functional foods. Pharmaceutical 
products have traditionally been the established intervention for disease prevention and 
treatments. However, there is increasing awareness of the importance of a balanced diet 
and of foods that could potentially reduce the risk and assist in the treatment of disease. 
The term nutraceutical is used where there is overlap between pharmaceutical and food 
relative to health. 
             Cardiovascular disease (CVD) and diabetes are on the list of top 10 causes of death in 
the world (World Health Organisation (WHO), 2011). Obesity is believed to be a significant 
contributor to these diseases; according to WHO, obesity is the fifth leading risk for global 
deaths. Every year, there are around 2.8 million fatalities caused by obesity. By 2020, 
obesity and obesity-associated complications are estimated to attribute two-thirds of global 
diseases.  The Global Functional Food Survey (2014) has acknowledged the role of 
nutraceuticals in the areas of weight management, cognitive health and cardiovascular 
health. 
            There is a growing awareness of cognitive decline with ageing in society. There are 
also links to cognitive decline and other dementias with diet. The most common cause of 
dementia is Alzheimer’s disease which affects approximately half a million people in the UK 
(Alzheimer’s Society, 2012).  There is evidence to suggest that these diseases could 
potentially be prevented or reduced by functional food interventions. New technologies in 
nutraceuticals can also improve the bioavailability of functional foods in diets. 
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1.3 Nutritional importance of epigenetics & nutrigentetics. 
 
Epigenetics and its association with functional foods, nutrigenetics and nutrigenomics, is a 
new and interesting area for next stage of development of functional foods. The human 
genome is made up of approximately three billion nucleotide pairs containing bioinformatic 
codes to control gene expression. A consensus definition of the concept of epigentic trait as 
“stably heritable phenotype resulting from changes in a chromosome without alteration in 
the DNA sequence” was formulated at the Cold Spring Harbor meeting in 2008.  The 
changes in chromatin structures include DNA methylation, histone modifications and 
chromatin remodelling resulting in a change in somatically heritable states of gene 
expression.  
             Figure 1.1 shows a summary of the epigenetic mechanism of activating and 
repressing gene expression. Throughout our life cycle, development, environmental 
chemicals, drugs or pharmaceuticals, diet and maturation are factors that can influence the 
dynamic epigenetic phenotype.  Epigenetics appears to be an important mechanism in many 
diseases for example, Tokunaga et al. (2013) reported that food and nutraceutical 
components are key determinants of enzyme function, which can suppress the expression 
of harmful genes.  Therefore, epigenetics is an important mechanism in many diseases such 
as obesity, diabetes, cardiovascular diseases, degenerative diseases and immune diseases. 
Also, including the unknown aetiology of many others; of which may lead to the 
development of personalised disease prevention and treatment strategies (Choi and Friso, 
2010).  
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Figure 1.1. Epigenetic Mechanisms (Andersen, 2013) 
 
             Over recent generations, human diet has experienced some profound changes, and it 
is believed this will continue in the 21st century (Haggarty, 2013). Diabetes, obesity, 
cardiovascular diseases and cancer can all be categorised as non-communicable diseases 
(NCDs) because they are multifactorial and polygenic (Tokunaga et al., 2013). Epigenetic 
alterations change gene expression without altering DNA sequences, through DNA 
methylation, histone modifications and chromatin remodelling, which can mediate the 
pathogenesis of NCDs.  
             Recent research findings show that several nutrients and nutraceuticals can 
modulate gene expression, despite whether it is adversely or beneficially affected. 
Epigenetic changes by external or internal environmental factors can be inherited during cell 
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division, which will remain permanently in the acquired phenotype. Thus, environmental 
associated disease, as well as embryonic development and ageing, could be impacted by 
epigenetics. The discovery of epigenetic phenomena, which can be modified by nutrients 
and bioactive components, and the associated altering of gene expression at the 
transcriptional level is exceptionally important to nutritional science. 
Nutrigenetics consists of three stages: nutrigenomics, proteomics and metabolomics. 
The main concept of nutrigenetics is to personalise nutrition such that dietary interventions 
can be made at an individual level.  This technology might be able to provide tailored 
nutrition for individuals or population groups with the same health issue.  
Reducing the risk of diet-related diseases and the associated healthcare costs will be 
of significant benefit to society (Wang and Bohn, 2012). Nutrigenomics describes how 
dietary nutrients affect the protein profile of an individual. Proteomics focuses on how 
altered protein profiles affects the biological system, and metabolomics is a cellular 
response to those changes.   Nutraceutical companies are utilising nutrigenomic technology 
to develop new food ingredients according to an individual’s genetics. This personalised diet 
could help the prevention or treatment of diseases such as diabetes, obesity and 
cardiovascular disease. It is clear that the genomic impact of diet is an important factor in 
promoting health and preventing chronic diseases such as cardiovascular disease (CVD), 
diabetes, obesity, cognitive decline and cancer.  
There is rapid growth of the global ageing population. There is also limited efficacy of 
pharmacological therapies for age-related cognitive decline and neurodegenerative diseases. 
This is leading to increasing interest and public demand for functional foods that promote 
cognitive wellbeing and longevity (Cannella et al., 2009, Alles et al., 2012, Feart et al., 2015). 
Chapter 1                                                                                                                         Introduction 
10 
 
Understanding the biological effects of nutrition throughout development and in later life has 
major implications for physical and mental health and is therefore of great importance for the 
public health sector, food product development, economic progress and consumer interest. 
There also is a growing body of evidence that supports that early nutrition during prenatal 
development, infancy and childhood affects both cognitive development and cognitive 
function and behaviour in later life (Anjos et al., 2013, Prado & Dewey, 2014, Barker et al., 
2013, Jacka et al., 2013). 
 
1.4      Nutrient impact on genomics assessed through pathway analysis. 
The beneficial effects of certain food groups, including plant foods and oily fish which provide 
sources of bioactive nutrients such as polyphenols, antioxidants, vitamins and omega-3 fatty 
acids, are well documented (Pallauf et al., 2013, Vauzour et al., 2010, Feart et al., 2013, Feart 
et al., 2015).  Many modern diets and food supplements are enriched with these bioactive 
compounds and claim to be beneficial to health through boosting the immune system, 
supporting cardiovascular function and/or protecting cells against oxidative stress. (Roll et al., 
2011, Lamprecht et al., 2007, Chapple et al., 2012, Lamprecht et al., 2013, Cui et al., 2012, De 
Spirt et al., 2012, Esfahani et al., 2011).  
Addressing the synergistic effects of certain functional foods and supplements 
consumed in combination with health and wellbeing is of growing interest in the field of 
nutrition (Alles et al., 2012). The purpose of conducting pathway analysis was to provide an 
updated review surrounding the effects of dietary compounds on phenotypic outcomes such 
as longevity, mental health, body composition and cardiovascular function to inform on the 
health potential of different food groups. Further, we addressed the potential biological 
effects of diet and functional foods using a pathway analysis approach to better our 
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understanding of how nutrition can influence different regulatory mechanisms including 
development, immune responses, metabolic processing, hormonal control and DNA repair. 
The findings of this analysis will have implications for public health, disease intervention, 
therapeutic management, nutrition-related behaviours, marketing strategy, economic 
growth and food development.  
Correctly channelled, functional foods and nutrigenomic applications could have a 
hugely positive impact on public health. Consumers are increasingly aware that food can 
contribute directly to their health. Today, the purpose of food is not only to satisfy hunger 
and to provide necessary nutrients, but also to improve health and reduce the risk of 
nutrition-related diseases. The current increase in NCDs and the associated rising cost of 
funding the NHS is an economic imperative that must be addressed. 
The aim of this study was to investigate the effects of nutrition on phenotypic 
outcomes relevant to health and wellbeing through a systematic review. Also, an overlay of 
UK and global trends in eating patterns with morbidity/mortality rates of NCDs to address 
the correlation between diet and disease risk was reviewed. This study investigated 
consumer attitude to functional foods and genomic interventions to improve health and 
wellbeing. The predominant focus of this study is how the interconnection between 
functional foods, consumer acceptance and genomic technologies can have a positive and 
lasting impact on public health. 
 
1.5        Consumer acceptance of diet based on personal genetics. 
The application of genotype-based personalised nutrition could potentially revolutionise 
health promotion, healthcare and the food industry. If accepted, genomic-based personalised 
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nutrition could directly affect consumer food choice when health becomes the driving factor 
in food selection (German & Watkins, 2004). Conceptually, nutritional genomics is still in its 
infancy, and it is unclear how this rapidly developing science will be accepted by society 
(Castle & Ries, 2007; Ronteltap, van Trijp & Renes, 2007; Moskowitz, German & Saguy, 2005). 
A considerable number of studies have investigated the attitudes, knowledge and the interest 
of people in genetic testing within the US and European countries. However, this study has 
focused on the concept of genomic-based personalised nutrition within the UK population.  
 
1.6  Implications for the future of public health, the NHS and the food industry. 
The deterioration in public health has a clear impact on the associated escalation in the 
running cost of running the NHS and social care systems in the UK. While government 
addresses how to elicit a population effect to improve the nation's health, the reality is that 
the NHS is in continued financial distress. 
Diet and its effect on health is a multifaceted area of research. This study aims to 
review the links by which the food industry, nutrigenomics technologies and the public 
sector could overlap to bring about a population effect improvement in health by focusing 
on individual nutrition and wellbeing.  
The process flow of following chapters aims to assess the current and future situation in 
both science & business of nutrigenomics and how the benefits can be translated in to 
direct benefit to public health. This study will address: 
1. The current situation of the UK and Global health trends with an associated review 
of the current functional food market and neutraceuticals. 
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2. An appraisal of the epigenetic importance and impact of food on health. A review of 
the epigenetic mechanism and nutrition, followed by a novel investigation of 
pathways analysis linked to nutritional interventions for health promotion and 
disease prevention. 
3. An assessment and translation of this new nutrigenomic science combined with 
consumer acceptance to new and future genomic applications in the private and 
public health sectors with recommendations for improvements in public health. 
 
  
     
 
Figure1.2 Chapter Process Flow Diagram 
1 & 2.
Introduction & Methods
5. Epigenetics, Functional Foods
& The Mediterranean Diet
3. Effects of Diet on Health4. The Functional Foods Market & Nutraceuticals
6. Genomic Analysis of Functional 
Food Interaction with Disease 
Pathways.
7. Consumer Acceptance of 
Functional Foods
& Personal Genomics
8. Genomic Business Models
9. Public Health Imperatives
10. Discussion
ScienceBusiness
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2.1 Consumer Research  
Consumer research was conducted using VYPR, a novel smart phone technology. The 
platform is designed to collect real time consumer feedback for new product development 
for FMCG applications. The resulting data collection can be used for demographic 
interpretation of consumer acceptance of new product concepts. 
2.1.1 Sampling 
The questionnaire was distributed to the general population of the UK between November 
2017 and December 2017. Random sampling was used throughout. Participants were able to 
access the questionnaire through the VYPR application (see: https://www.vypr.it/#opinions-
rewarded) on a ‘first come first served’ basis.  
The questionnaire was designed to assess consumer’s attitudes and preferences 
towards nutritional genomic products, services and activities. The questionnaire was 
developed using questions developed by existing studies (Roy et al., 2016; Stewart-Knox et 
al., 2008; Moran 2009; Cherkas et al., 2010; Henneman and Timmermans 2006; Castle, 2007; 
Petersen, 2005; Skirton et al., 2005; Rose et al., 2005; Catz et al., 2005). A theoretical 
framework from Berezowska et al., (2015) was adapted into the survey to assess consumer’s 
intention to adopt nutritional genomics considering privacy risk, personalisation benefit, and 
the ability of service provider (Xu et al., 2009; Mayer and Davis, 1999).  
          Before responding to the questionnaire participants input their demographic data when 
downloading the app. In more detail, demographic data consists of gender and age. The 
questionnaire itself consisted of 15 questions on nutritional genomic products, services and 
activities. The questions were presented on a Likert scale whereby participants had the option 
of selecting ‘agree’, ‘neutral’ or ‘disagree’. Due to the restrictions of the VYPR app, each 
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question was sent out separately therefore individual responses could not be tracked 
between questions. All respondents were anonymised and participated voluntarily.  
2.1.2 Data Analysis 
Respondents were categorised by age range (18-24, 25-34, 35-44, 45-54,55-64 and 65+) and 
gender (male and female) for comparison purposes. Responses by demographic were 
converted into percentages.  
2.2  Systematic review 
A reference search for the term ‘diet’ was performed using the PubMed search tool available 
through the National Centre for Biotechnology Information (NCBI) database 
(http://www.ncbi.nlm.nih.gov/pubmed/, accessed April 2015). The PubMed Advanced 
Search Builder was used and the following filters selected: species, human; article type, meta-
analysis; publication dates, Jan 2012 to April 2015; journal categories, core clinical journals. 
Appropriate journals for inclusion in the systematic review were manually selected. 
 
2.3  Gene expression arrays and databases 
2.3.1 ArrayExpress 
Human microarray data for dietary interventions with omega-3, flavonoids and resveratrol 
was downloaded from the ArrayExpress database (https://www.ebi. ac.uk/arrayexpress/). 
Datasets were analysed using the GEO2R function, available at 
http://www.ncbi.nlm.nih.gov/geo/info/geo2r.html, to determine gene expression changes 
between baseline measurements (control group) and following treatment intervention 
(treatment group) within the same individuals. Datasets were analysed using default 
parameters which generated a table of the top 250 genes ranked by significance (p-value). 
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Only genes that were significantly regulated (p<0.05) were included in the pathway analysis.  
Unadjusted p-values were used in this study in order to address extended biological networks 
associated with the dietary interventions. Datasets were filtered to include genes with a fold 
change in expression of more than 1.6 between the control and treatment groups. For 
treatment groups with large numbers of gene expression changes, only genes that were 
common across two or more studies for the same treatment condition were considered for 
analysis. For gene replicates within individual studies or duplicates across different studies for 
the same treatment group, data points with the least significant p-value were excluded. If 
replicates within individual studies had fold changes that were opposing (i.e. positive and 
negative values for the same gene) both data points were excluded from the analysis. 
 
2.3.2 Bar Harbor BioTechnology 
Candidate genes involved in obesity, diabesity and CVD were downloaded from Bar Harbor 
gene expression array systems available at https://www.bhbio. 
com/BHB/GUI/SP/Search.aspx, accessed May 2015. The panel of genes included on these 
gene expression arrays are based on experimental evidence from the literature. The gene list 
for CVD was compiled using the following plate descriptions: Blood Coagulation, Hypertension 
and Inflammatory Cytokines & Receptors. Duplicate gene entries were removed. 
 
2.3.3 NHGRI-EBI GWAS Catalogue 
The National Human Genome Research Institute (NHGRI)-European Bioinformatics Institute 
(EBI) catalogue of published GWAS was downloaded from 
http://www.ebi.ac.uk/gwas/docs/downloads (accessed August 2015). Reported genome-
wide associated genes for ageing, breast cancer, cognitive function, CVD, diabesity, 
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neurodegeneration and psychiatric disorders were compiled and duplicates removed. GWAS 
included in this analysis are detailed in Tables A1-A7). Gene lists were compared against those 
associated with omega-3, flavonoids and resveratrol dietary interventions using 
hypergeometric distribution testing. 
  
2.4 Significance testing of overlapping gene sets 
2.4.1 Phyper test in R 
The hypergeometric distribution test phyper available through the R package (https://www.r-
project.org/) was used to compute statistical significance between the overlap of two gene 
sets using the command:  
> phyper(q, m, n, k, lower.tail=FALSE)  
where, q = overlap between list 1 and list 2, m = size of list 1, n = population size – list 
1, and k = size of list 2. If ‘phyper(q, m, n, k)’ gives the probability of x overlap or fewer, 
‘lower.tail=FALSE’ gives the probability of x + 1 or more.  
The p-value represents the probability of obtaining the observed number of overlap or larger 
by random chance. A p-value of <0.05 was considered significant. The reference gene set in 
the PANTHER database (20,814 genes) was selected as the population size based on 
subsequent pathway analysis methods using this reference list. 
 
2.4.2   GeneOverlap in R 
To address significant overlap of multiple gene sets, the GeneOverlap package in R which 
allows for testing and visualisation of gene overlaps was downloaded from 
https://www.bioconductor.org/packages/release/bioc/html/ GeneOverlap.html (accessed 
September 2015). Gene lists were saved as text files and uploaded into R. The GeneOverlap 
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function tests whether two variables are independent, which can be represented as a 
contingency table and then uses Fisher's exact test to find the statistical significance. The 
strength of the association is determined by the odds ratio; an odds ratio of ≤ 1 indicates no 
association between the two gene lists, an odds ratio of > 1 indicates a positive association. 
 
2.5 Pathway analysis 
2.5.1 Ingenuity Pathway Analysis (IPA) 
Gene expression data obtained from ArrayExpress was analysed using the Core Analysis 
function of the IPA software (QIAGEN) under default parameters, detailed below: 
1. General settings:  a) Reference set, ingenuity knowledge base of genes and 
endogenous chemicals and b) Direct and indirect relationships 
2. Networks: Interaction networks, include endogenous chemicals (default settings, 
35 molecules per network; 25 networks per analysis) 
3. Data sources: default settings (select all) 
4. Confidence: experimentally observed 
5. Species: default settings (select all) 
6. Tissues and cell lines: default settings (unselected) 
7. Mutation: default settings (select all) 
Significance testing of the association between the uploaded dataset and the canonical/ well-
established pathways available in the IPA library was measured using the following methods: 
1) a ratio of the number of differentially expressed genes from the dataset that map to the 
pathway divided by the total number of genes that exist in the canonical pathway.  The ratio 
is useful for determining which pathways overlap the most with the differentially expressed 
genes in a given dataset. 2) Fischer’s exact test used to calculate a p-value determining the 
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probability that the association between the genes in the uploaded dataset and the canonical 
pathway is explained by chance alone. P-values of <0.05 were considered significant. 3) z-
score analysis, used as a statistical measure of the match between expected relationship 
direction and observed gene expression of the uploaded dataset. It is a statistical measure of 
a score’s relationship to the mean, i.e. the number of standard deviations from the mean of 
a normal distribution curve. Positive and negative z-scores indicate upregulated and 
downregulated pathways, respectively. In line with IPA cut-off values, z-scores of >2.0 or < -
2.0 were considered significant. 
 
2.5.2 PANTHER Classification System 
Gene sets relating to CVD, obesity/diabesity and neurogenesis were subjected to pathway 
analysis using the freely available PANTHER (Protein ANalysis THrough Evolutionary 
Relationships) platform (Myi et al., 2009), available at http://www.pantherdb.org/ (accessed 
May 2015). This platform allows for analysis of gene function on a genome-wide scale. Gene 
lists were parsed into the Gene List Analysis tool and analysed using the Functional 
Classification method and Statistical overrepresentation test (Mi et al., 2013). The former 
returns the uploaded dataset as a gene list detailing the protein class, molecular functions, 
biological processes, cellular components or pathways that each gene in the user-defined list 
is associated with. Statistical overrepresentation testing compares the user-defined gene list 
to a reference gene list within the PANTHER database and determines whether a particular 
class of genes is over- or under-represented concerning a particular biological process or 
pathway. The significance is determined by the ‘expected’ number of genes within the test 
list to fall within a particular biological process or pathway based on the number of genes 
within the reference list for that process against the total number of genes within the 
Chapter 2                                                                                                                         Materials and Methods  
 
21 
 
database (Mi et al., 2013). If more genes (from the test list) than expected (relative to the 
reference list) associate with a particular pathway, there is an overrepresentation; if less, 
there is an underrepresentation. P-values of <0.05 were considered significant. 
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3.1 A systematic review of the effects of diet on different phenotypic outcomes relevant 
to health. 
Certain dietary compounds such as plant foods (cereals, fruits, vegetables, legumes, tree nuts, 
seeds and olives) and oily fish have been linked to general health and wellbeing and the 
prevention of chronic diseases (Pallauf et al., 2013, Vauzour et al., 2010, Feart et al., 2013, 
Feart et al., 2015). A systematic review undertook to provide an up-to-date overview of the 
beneficial and adverse effects of dietary components on some phenotypic outcomes relevant 
to cardiovascular, cellular, cognitive, metabolic and immune system functioning. A reference 
search for the search term ‘diet’ was performed using the PubMed search engine within the 
NCBI database. Journals were filtered to include human-based meta-analyses performed 
between January 2012 and April 2015. To identify articles addressing phenotypic outcomes 
relating to dietary patterns, core clinical journals were selected and manually reviewed. 
Figure 3.1 illustrates the selection criteria for articles included in the systematic review. A 
total of 41 articles were eligible for inclusion and are detailed in Table 3.1. 
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Figure 3.1 Selection of eligible articles for inclusion in the systematic review addressing the effects of diet on 
health and wellbeing. A flow diagram depicting reasons for exclusion of articles identified under the search term 
‘diet’ in NCBI PubMed, specifically the CCJ subset (Accessed May 2015). Articles were filtered by species, article 
type, publication date and journal categories. Non-eligible are articles not addressing the effects of diet on 
phenotypic outcomes associated with health and wellbeing were manually excluded. A total of 41 articles were 
selected for inclusion.  
INCLUDED
394,224 Articles 
for search term 
‘diet’
175,008 
Non-human 
studies
219,216 Human 
studies
217,794  Non 
meta-analysis 
articles 
EXCLUDED
1, 422 
Meta-analysis 
articles 
822 articles 
Publication date 
before 01.01.2012
600 articles
Publication date 
after 01.01.2012
502 Non-core 
clinical journals
98 Core clinical 
journals
57 Non-eligible 
articles
41  Eligible articles 
with phenotypic 
outcomes relevant 
to health and 
wellbeing 
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Table 3.1. Effects of diet on phenotypic outcomes relevant to health and well-being 
Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Whole-grain: 
     
Whole-grain vs. 
non-whole 
grain control 
diet  
400,492 participants including 
14,427 cases 
CHD  Higher whole-grain intake has a protective 
effect against CHD.  
CHD risk (highest vs. lowest whole-grain 
intake): -0.79 [-0.74, -0.83]  
(Tang et al., 2015) 
2,060 participants Weight and body 
composition 
Whole-grain consumption has a small 
beneficial effect on total body fat but not 
body weight compared with controls. 
Fat (%): −0.48 [−0.95, −0.01] 
Weight (kg): 0.06 [−0.09, 0.20] 
(Pol et al., 2013) 
OBG content: 
oat bran; 
oatmeal; oat 
flour 
2,506 individuals (healthy, 
diabetic or high cholesterol) 
Cholesterol Adding ≥3 g OBG/day to the diet reduces 
LDL and total cholesterol without changing 
HDL cholesterol or triglyceride 
concentration (mmol/L). The effect is 
significantly greater for individuals with 
type-2 diabetes (P=0.004). 
LDL:  -0.25 [-0.20, -0.30] 
HDL: -0.03 [-0.08, 0.01] 
Total: -0.30 [-0.24, -0.35] 
Triglyceride: -0.02 [-0.06, 0.01] 
(Whitehead et al., 
2014) 
Fruit and vegetables:     
Fruit and 
vegetables 
833,234 participants Mortality from all 
causes, CVD and 
cancer 
Higher consumption of fruit and vegetables 
was significantly associated with a lower risk 
of all-cause mortality, particularly CVD but 
not cancer. 
All-cause mortality (increment of one serving 
per day of F/V): 
F/V: -0.95 [-0.92,-0.98]  
Fruit: -0.94 [-0.90, -0.98]  
Veg: -0.95 [-0.92, -0.99]  
Disease mortality (for each additional serving 
of F/V per day):  
CVD: -0.96 [-0.92, -0.99] 
Cancer: -0.97 [-0.90, 1.03] 
(Wang et al., 
2014) 
275 individuals (healthy or 
cardio-metabolic disorders) 
Weight and body 
composition  
Increased fruit and vegetable intake do not 
affect body weight. 
Weight: 1.04 [−1.10, 1.17] (Kaiser et al., 
2014) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
1,290,045 participants including 
3,912 cases 
Liver cancer (HCC) Increased vegetable but not fruit intake is 
associated with reduced risk of HCC. 
Vegetable intake:  
High vs. low: -0.72 [-0.63, -0.83] 
Daily increase (100 g/d): -0.92 [-0.88, -0.95] 
Fruit intake: 
High vs. low: -0.93 [-0.80, 1.09] 
Daily increase (100 g/d): -0.99 [-0.94, 1.05] 
(Yang et al., 2014) 
Whole fruit and 
fruit juices 
187,382 healthy participants (at 
baseline) 
Type-2 diabetes Greater consumption of specific whole 
fruits, particularly blueberries, grapes and 
apples, is significantly associated with a 
lower risk of type-2 diabetes, whereas 
greater consumption of fruit juice is 
associated with a higher risk. 
Diabetes risk (for every three servings/week of 
fruit consumed):  
Whole fruit: -0.98 [-0.96, -0.99]  
Blueberries: -0.74 [-0.66, -0.83] 
Grapes/raisins: -0.88 [-0.83, -0.93] 
Prunes: -0.89 [-0.79, 1.01]  
Apples/pears: -0.93 [-0.90, -0.96] 
Bananas: -0.95 [-0.91, -0.98] 
Grapefruit: -0.95 [-0.91, -0.99] 
Peaches/plums/apricots: -0.97 [-0.92, 1.02] 
Oranges: -0.99 [-0.95, 1.03]  
Strawberries: 1.03 [-0.96, 1.10]  
Cantaloupe: 1.10 [1.02, 1.18]  
Fruit juice: 1.08 [1.05, 1.11]  
(Muraki et al., 
2013) 
Vegetarian diet 21,915 participants Blood pressure 
(systolic and 
diastolic) 
Consumption of vegetarian diets may lower 
BP relative to omnivorous diets. 
Observational studies of BP (mm Hg): 
Systolic: −6.9 [−9.1 to −4.7] 
Diastolic: −4.7 [−6.3 to −3.1]  
For RCTs of BP (mm Hg):  
Systolic: −4.8 [−7.6 to −3.1]  
Diastolic: −2.2 [−3.5 to −1.0] 
(Yokoyama et al., 
2014) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Carotenoids 924,969 participants including 
21,218 cases 
Breast cancer Dietary β-carotene and blood 
concentrations of carotenoids (α- and β-
carotene and lutein) significantly associated 
with reduced risk of breast cancer. 
Dietary β-carotene (increment of 5 mg/day): 
-0.95 [-0.91, -0.99]  
Blood concentrations of carotenoids:  
Total (per 100 μg/dL): -0.78 [-0.61, -0.99] 
β-carotene (per 50 μg/dL): -0.74 [-0.57, -0.97] 
α-carotene (per 10 μg/dL): -0.82 [-0.73, -0.92] 
Lutein (per 25 μg/dL): -0.68 [-0.52, -0.89]  
(Aune et al., 2012) 
Plant sterols/ 
stanols (dietary 
and 
supplement 
form) 
263 participants (normal to high 
baseline cholesterol) 
Cholesterol Plant sterol/stanol intake from dietary 
sources and supplements effectively lower 
'bad' LDL-cholesterol (mmol/L). 
Supplements: -0.31 [−0.39, −0.23] 
Dietary: −0.31 [−0.35, −0.27] 
(Amir Shaghaghi 
et al., 2013) 
Resveratrol 388 participants including 79 
cases 
Glucose control and 
insulin sensitivity 
Resveratrol supplements significantly 
improve glucose control and insulin 
sensitivity in diabetic individuals but do not 
affect glycaemic measures in non-diabetics. 
Fasting glucose concentration (mg/dL):  
All participants: -9.67 [-21.09, 1.74] 
Non-diabetics: -0.58 [-3.41, 2.26]  
Diabetics: -35.22 [-52.13, -18.30]  
Fasting insulin concentration (µl U/ml):  
All participants: -1.51 [-3.53, 0.51]  
Non-diabetics: -0.47 [-1.82, 0.87]  
Diabetics: -4.55 [-6.54, -2.56] 
(Liu et al., 2014) 
Fat: 
     
Saturated fat 
(MCT vs. LCT) 
239 individuals on MCT diet; 250 
individuals on control diet (LCT) 
Weight and body 
composition  
Replacement of LCTs with MCTs in the diet 
can reduce body weight and composition 
without adversely affecting blood lipid 
levels. 
Weight (kg): –0.51 [–0.80, –0.23] 
Waist (cm): –1.46 [–2.04, –0.87] 
Hip (cm): –0.79 [–1.27, –0.30]  
Body fat (d):  
Total: –0.39 [–0.57, –0.22] 
Subcutaneous: –0.46 [–0.64, –0.27]  
Visceral: –0.55 [–0.75, –0.34]  
(Mumme & 
Stonehouse, 2015) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Total fat 73,589 participants Weight and body 
composition 
Lowering total fat intake can reduce body 
weight and composition without adversely 
affecting lipid levels or BP. Correlation 
between high total fat intake and weight 
gain also observed in children and young 
people. 
Weight (kg): -1.60 [−2.00, −1.20] 
BMI (kg/m2): −0.51 [−0.76, −0.26]  
Waist (cm, only tested in women):  
-0.30 [−0.58, −0.02] 
(Hooper et al., 
2012) 
TFA (natural 
and industrially 
produced) 
208 participants (healthy, 
overweight/ obese or 
hyperlipidaemic) 
Glucose homeostasis 
and triglyceride and 
cholesterol (total, 
LDL and HDL) 
concentrations  
TFA intake (2.59% to 7.8% total energy 
intake) does not significantly change 
circulating glucose and insulin 
concentrations. High TFA intake increases 
circulating total and LDL-cholesterol and 
decreases HDL-cholesterol concentrations. 
TFAs from natural sources (up to 4.19 % of 
daily energy intake) have no adverse effects 
on risk markers for CVD in healthy adults. 
Glucose levels: 1.08 [−1.14, 1.29] 
Insulin levels: −1.02 [−1.23, 1.19]  
Cholesterol levels: 
Total: 1.28 [1.04, 1.51]  
LDL: 1.36 [1.13, 1.60]  
HDL: −1.25 [−1.48, −1.01] 
(Aronis et al., 
2012, Gayet-Boyer 
et al., 2014) 
Dairy products 
426,055 participants including 
26,976 cases 
Type-2 diabetes The inverse relationship between risk of 
type-2 diabetes and consumption of dairy 
products (400 g total daily intake), low-fat 
dairy products (200 g daily intake) and 
cheese (50 g daily intake).  
Total dairy (400 g/day): -0.93 [-0.87, -0.99] 
High fat dairy (200 g/day): -0.98 [-0.94, 1.03]  
Low fat dairy (200 g/day): -0.91 (-0.86, -0.96]  
Milk (200 g/day): -0.87 [-0.72, 1.04]  
Cheese (50 g/day) -0.92 [-0.86, -0.99]  
Yoghurt (200 g/day): -0.78 [-0.60, 1.02] 
(Aune et al., 2013) 
RCTs for 2,101 participants Weight and body 
composition  
Overall, increasing dairy consumption does 
not significantly reduce body weight and fat 
loss in long-term studies or studies without 
energy restriction. However, dairy products 
have modest effects on reducing body fat 
and may be beneficial in facilitating weight 
loss in short-term interventions or energy-
restricted diets. 
Weight (kg): -0.14 [-0.66, 0.38]  
Fat (kg) −0.45 [−0.79, −0.11] 
 (Chen et al., 
2012) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Calcium intake 9,095 cases Stroke Dietary calcium intake was shown to be 
inversely associated with stroke in 
populations with low to moderate calcium 
intakes and in Asian populations but 
positively correlated (weak association) with 
stroke in populations with high dietary 
calcium intake. 
<700 mg/day: -0.82 [-0.76, -0.88] 
≥700 mg/day: 1.03 [1.01, 1.06] 
(Larsson et al., 
2013) 
Omega-fatty acids:  
    
Linoleic acid 
(omega-6 fatty 
acid) 
310,602 participants; 12,479 
total CHD events including 5,882 
CHD deaths 
CHD Dietary LA intake inversely associated with 
CHD risk in a dose-response manner; 15% 
lower risk of CHD events and 21% lower risk 
of CHD deaths. The beneficial effect of LA on 
lowering CHD risk may only be effective in 
combination with high n-3 in the diet.  
CHD events: -0.85 [-0.78, -0.92]  
CHD mortality: -0.79 [-0.71, -0.89] 
(Farvid et al., 
2014, Ramsden et 
al., 2013, Fattore 
et al., 2014) 
Fish 
consumption 
408,305 participants CHD The inverse association between fish 
consumption and risk of the acute coronary 
syndrome. Fish consumption appears 
beneficial in the primary prevention of acute 
coronary syndrome and a higher 
consumption (≥4 times per week) is 
associated with greater protection. 
≥4 times per week: -0.79 [-0.70, -0.89]  
100g serving per week: -0.95 [-0.92, -0.97] 
(Leung Yinko et 
al., 2014) 
Omega-3, 
omega-6 or 
combined 
supplements 
723 and 294 cases (ages 3-18 
years) for fatty-acid and artificial 
colour exclusion diets, 
respectively.   
ADHD Fatty acid supplementation and exclusion of 
artificial food colour may reduce symptom 
severity in children with ADHD. 
Fatty acid supplementation: -1.21 [-1.05, -
1.36] 
Artificial colour exclusion: -1.32 [-1.06, -1.58]  
(Sonuga-Barke et 
al., 2013) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Simple sugars: 
Fructose † 
 
637 participants for isocaloric 
trials and 119 participants for 
hypercaloric trials  
 
Weight and body 
composition in 
diabetic, 
overweight/obese 
and normal weight 
individuals 
 
Fructose intake does not affect body weight 
relative to isocaloric diets for other 
carbohydrate comparators, except in 
overweight or obese individuals. Excess 
energy in the diet from fructose intake 
increases body weight, although 
confounding from excess energy cannot be 
excluded. 
 
Fructose vs. any carbohydrate comparator on 
body weight (kg):  
Diabetics 0.12 [-0.32, 0.56]  
Overweight/obese: -0.55 [-1.09, -0.02]  
Normal weight: -0.13 [-0.37, 0.10]  
Normal diet with excess energy from fructose 
on body weight (kg): 
Obese/overweight: 1.26 [0.70, 1.81]  
Normal weight: 0.37 [0.15, 0.58]  
 
(Sievenpiper et al., 
2012) 
Dietary sugars 
and sugar-
sweetened 
beverages 
Not stated Weight and body 
composition  
Intake of free sugars or sugar-sweetened 
beverages is a determinant of body weight. 
Change in body fatness that occurs with 
modifying intakes seems to be mediated via 
changes in energy intakes since the 
isoenergetic exchange of sugars with other 
carbohydrates was not associated with 
weight change. 
Sugary beverages and overweight/obesity risk 
in children: 1.55 [1.32, 1.82]  
Dietary sugar intake and weight (kg) in adults: 
Reduced intake: −0.80 [−0.39, −1.21]  
Increased intake: 0.75 [0.30, 1.19] 
(Te Morenga et 
al., 2013) 
Protein: 
     
Meat 1,932,391 participants including 
13,313 cases  
Meat intake and risk 
of oesophageal 
cancer 
Meat consumption is associated with 
oesophageal cancer risk. High red meat and 
low poultry intake are associated with an 
increased risk of oesophageal squamous cell 
carcinoma. High meat intake, especially 
processed meat, increases the risk of 
oesophageal adenocarcinoma. 
Highest vs. lowest consumption categories:  
Total meat: 1.19 [-0.98, 1.46] 
Red meat: 1.55 [1.22, 1.96]  
Processed meat: 1.33 [1.04, 1.69]  
White meat: -0.72 [-0.60, -0.86]  
Poultry: -0.83 [-0.72, -0.96]  
Fish: -0.95 [-0.76, 1.19] 
(Zhu et al., 2014) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Meat; low-fat 
diets with high-
protein vs 
standard-
protein intake 
1,063 participants  Weight and body 
composition, resting 
energy expenditure, 
satiety and appetite 
and cardio-metabolic 
risk factors 
High protein diets relative to calorie-
matched standard protein diets provide 
modest benefits for reductions in body 
weight, fat mass and triglycerides 
concentration. 
Weight (kg): −0.79 [−1.50, −0.08] 
Fat mass (kg): −0.87 [−1.26, −0.48]  
Triglycerides (mmol/L): −0.23 [−0.33, −0.12] 
(Wycherley et al., 
2012) 
Nuts 
1) 83,445 participants 
including 12,655 type-2 
diabetes; 8,862 CVD; 6,623 
IHD; 6,487 stroke and 
48,818 mortality cases 
 
2) 40,102 participants and 
12,814 hypertension cases 
  
3) RCTs for 1,006 participants 
Mortality from all 
causes, type-2 
diabetes, stroke, IHD 
and hypertension  
1) Nut intake is inversely associated with 
all-cause mortality, overall CVD, IHD 
and hypertension but not significantly 
associated with diabetes and stroke. 
  
2) Higher consumption of nuts was 
associated with reduced risk of CHD 
and hypertension but not stroke or 
type-2 diabetes. 
 
3) Nuts do not affect body weight or waist 
circumference.  
1) Type-2 diabetes (accounting for BMI): 
1.03 [-0.91, 1.16] 
IHD: -0.72 [-0.64, -0.81]  
CVD: -0.71 [-0.59, -0.85] 
Stroke: -0.91 [-0.81, 1.02] 
All-cause mortality: -0.83 [-0.76, -0.91]  
 
2) Hypertension: -0.66 [-0.44, 1.00] 
 
3) Weight (kg) –0.47 [–1.17, 0.22] 
BMI (kg/m2): –0.40 [–0.97, 0.17] 
Waist (cm): –1.25 [ –2.82, 0.31] 
(Luo et al., 2014, 
Flores-Mateo et 
al., 2013, Zhou et 
al., 2014, Afshin et 
al., 2014)  
Legumes; 
dietary pulse 
intake 
1,037 participants IHD, stroke, type-2 
diabetes, cholesterol 
1) Legume intake (4 weekly 100 g 
servings) inversely associated with IHD 
but not significantly associated with 
stroke or diabetes. 
 
2) Dietary pulse intake (130 g per day) 
significantly reduces 'bad' LDL 
cholesterol levels. 
1) IHD: -0.86 [-0.78, -0.94]  
Stroke: -0.98 [-0.84, 1.14]  
Diabetes: -0.78 [-0.50, 1.24] 
 
2) LDL (mmol/L): −0.17 [−0.25, −0.09] 
(Afshin et al., 
2014, Ha et al., 
2014) 
Vitamins and minerals: 
Vitamin B RCTs for 54,913 participants Homocysteine levels 
and cerebrovascular 
disease 
Vitamin B supplementation significantly 
reduced overall stroke events. 
Stroke: -0.93 [-0.86, 1.00] (Ji et al., 2013) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Vitamin D 5,292 participants and RCTs for 
13,033 participants 
CVD; cardiac failure, 
MI and stroke 
Vitamin D supplementation offers 
protection against cardiac failure in older 
people (mean or median age ≥60) but does 
not appear to protect against MI or stroke. 
Cardiac failure: -0.75 [-0.58, -0.97] 
MI: -0.97 [-0.75, 1.26]  
Stroke: 1.06 [-0.80, 1.32] 
(Ford et al., 2014) 
Iron-fortified 
foods *  
11,750 iron-fortified subjects 
and 9,077 control subjects 
Effects on 
haemoglobin and 
serum ferritin, iron 
deficiency and 
anaemia, zinc and 
iron status, infections 
and mental and 
motor development  
Associated with significant increases in 
haemoglobin and serum ferritin, reduced 
risk of anaemia and iron deficiency and 
improvements in other indicators of iron 
nutrition. No observable effect on serum 
zinc concentrations, infections, physical 
growth and mental and motor development. 
Haemoglobin (g/dL): 0.42 [0.28, 0.56]  
Serum ferritin (μg/L): 1.36 [1.23, 1.52] 
Anaemia: -0.59 [-0.48, -0.71]  
Iron deficiency: -0.48 [-0.38, -0.62]  
(Gera et al., 2012) 
Magnesium 
313,041 individuals and 11,995 
CVD, 7,534 IHD, and 2,686 fatal 
IHD events 
CVD Circulating (per 0.2 mmol/L increment) and 
dietary (per 200 mg/day increment) 
magnesium are inversely associated with 
CVD risk. 
Circulating magnesium and risk of: 
CVD: -0.70 [-0.56, -0.88]  
IHD: -0.83 [-0.75, 1.05]  
Fatal IHD: -0.61 [-0.37, 1.00] 
Dietary magnesium and risk of:  
CVD: -0.89 [-0.75, 1.05]  
IHD: -0.78 [-0.67, -0.92] 
Fatal IHD: -0.73 [-0.62, -0.86]  
(Del Gobbo et al., 
2013) 
1,703 cases and 2,253 control 
subjects 
Colorectal tumours Higher intakes of dietary magnesium (100 
mg/day increase) are associated with lower 
a 12-13% lower risk of colorectal tumours. 
Colorectal cancer: -0.88 [-0.81, -0.97] 
Colorectal adenomas: -0.87 [-0.75, 1.00]  
(Wark et al., 2012) 
Selenium 13,254 participants including 
5,007 cases 
Prostate cancer Increased selenium concentrations are 
associated with lower risk of prostate 
cancer. 
Prostate cancer risk: -0.29 [-0.14, -0.61]  (Hurst et al., 2012) 
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Food group Number of individuals Phenotypic outcome Direction of outcome Relative risk [95% CI] Reference 
Sodium 5,508 participants including 
1,478 hypertension cases 
Blood pressure, CVD 
and adverse 
biomarker levels, e.g. 
blood lipids, 
catecholamine levels 
and renal function 
Decreased sodium intake significantly 
reduces resting systolic and diastolic BP in 
adults and children and has no adverse 
effects on blood lipids, catecholamine levels 
or renal function. Increased sodium intake is 
associated with an increased risk of stroke 
and fatal CHD in adults. 
Reducing sodium intake in adults: 
Systolic BP (mm Hg): -3.39 [-2.46, -4.31]  
Diastolic BP (mm Hg): -1.54 [-0.98, -2.11] 
Increasing sodium intake in adults: 
Stroke risk: 1.24 [1.08, 1.43]  
Stroke mortality: 1.63 [1.27, 2.10] 
CHD mortality: 1.32 [1.13, 1.53] 
Reducing sodium intake in children  
Systolic BP (mm Hg): -0.84 [-0.25, -1.43]   
Diastolic BP (mm Hg): -0.87 [-0.14, -1.60] 
(Aburto et al., 
2013, He et al., 
2013) 
Healthy vs 
unhealthy diet 
127,733 participants, excluding 
cases (n= ~14,846) 
Depression  Higher intake of fruit, vegetables, fish and 
whole-grains has the potential to reduce the 
risk of depression. 
Risk  of depression: 
Healthy diet: -0.84 [-0.76, -0.92] 
Western diet: 1.17 [-0.97, 1.68] 
(Lai et al., 2014) 
 
 
Note: Data based on randomised controlled trials (RCT) or observational studies. Data presented as relative risk or change in the continuous variable being measured.  
*Common iron-fortificants used across studies were: ferrous sulfate (28%); NaFeEDTA (20%); electrolytic iron (13%); ferric pyrophosphate (8%); hydrogen-reduced iron, 
heme (3%) or ferric orthophosphate (3%); ferrous fumarate (7%); amino acid chelates (2%); iron gluconate (1%) and ammonium citrate (1%). † Comparators in isocaloric 
trials: starch, sucrose, glucose, high-fructose corn syrup, dextromaltose and galactose; diet alone was the comparator in hypercaloric trials. Abbreviations: BMI, body mass 
index; BP, blood pressure; CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; d, standard mean difference; F/V, fruit and vegetables; HDL, high-
density lipoprotein; HCC, Hepatocellular carcinoma; IHD, ischemic heart disease; LA, Linoleic acid; LCT, long-chain triglycerides; LDL, low-density lipoprotein; MCT, medium-
chain triglycerides; MI, myocardial infarction; OBG, oat beta-glucan; TFA, trans fatty acid. 
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3.1.1 Effects of diet on CVD and diabetes 
The main findings of the systematic review on the effects of diet and risk of CVD, diabetes and 
obesity are summarised below and in Figures 3.2 and 3.3. In general, increasing the daily 
consumption of whole-grains, fruit and vegetables, dairy (including low-fat dairy and cheese), 
oily fish, protein (including nuts, legumes and pulses) and certain vitamins and minerals can 
have a protective effect against CVD, hypertension, high cholesterol, type-2 diabetes and 
body weight and fat mass.  
Foods that are high in salt, free sugar and trans-fatty acids (TFA) should be consumed 
in moderation and prepared from naturally sourced ingredients (as opposed to industrially 
processed) concerning fats and simple sugars. Lowering salt intake can reduce the risk of 
stroke, coronary heart disease (CHD) and hypertension; cutting-down on dietary sugar intake 
particularly sugary beverages can decrease obesity risk in adults and children; and reducing 
total fat and TFA intake can reduce body weight and composition in adults and children and 
lower cholesterol in healthy and overweight/obese individuals, respectively. These findings 
are dependent on multiple factors including age, sex, health status, genetics, environment 
and culture and should only be considered as a guideline.      
3.1.1.1 Whole-grain 
Beneficial effects: 
§ Increasing whole-grain intake has a protective effect against CVD and diabesity (Figure 
3.2A and 3.3B):  
Ø Reduces ‘bad’ low-density lipoprotein (LDL) and total cholesterol levels without 
changing ‘good’ high-density lipoprotein (HDL) cholesterol levels. 
Ø This beneficial effect of whole-grain on cholesterol levels is significantly greater 
(p<0.01) for individuals with type-2 diabetes. 
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§ Whole-grain consumption has a small beneficial effect on reducing total percentage body 
fat but not body weight, Figure 3.3B. 
 
3.1.1.2 Fruit & vegetables 
Beneficial effects: 
§ Higher consumption of fruit and vegetables significantly lowers the risk of all-cause 
mortality (Figure 3.2A): 
Ø Particularly CVD; the average reduction in mortality risk is 4% for each additional 
serving per day of fruit and vegetables (combined effect). 
§ Greater consumption of specific whole fruits, particularly blueberries, grapes and apples, 
significantly lowers risk of type-2 diabetes, Figure 3.3A. 
§ Resveratrol supplements significantly improve glucose control and insulin sensitivity in 
diabetic individuals, Figure 3.3A. 
§ Consumption of vegetarian diets may lower blood pressure (BP) relative to omnivorous 
diets, Figure 3.2B. 
No or adverse effects:  
§ Fruit and vegetable intake does not affect weight and body composition in healthy adults 
and individuals with CVD, Figure 3.3A. 
§ Greater consumption of fruit juice significantly increases the risk of type-2 diabetes, Figure 
3.3A. 
3.1.1.3  Simple sugars 
Beneficial effects: Consumption of fructose, found naturally in honey, fruits, berries and 
most root vegetables, relative to isocaloric diets for other carbohydrate comparators 
promotes weight loss in overweight/obese individuals (Figure 3.3B). 
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No or adverse effects: 
§ Fructose intake does not affect body weight relative to isocaloric diets for other 
carbohydrate comparators in healthy or diabetic individuals (Figure 3.3B). 
§ Dietary sugar intake is positively correlated with body weight in adults, including excess 
energy from fructose intake (Figure 3.3B). 
§ Sugary beverages increase obesity risk in children (Figure 3.3A). 
 
3.1.1.4 Dietary fat 
Beneficial effects: 
§ Replacement of long-chain triglycerides/fatty acids (LCTs, e.g. butter, rapeseed oil and 
soybean oil) with medium-chain triglycerides (MCTs, e.g. palm kernel oil and coconut oil) 
or lowering total fat intake can reduce body weight and composition in adults, Figure 3.3B 
Ø Does not adversely affect other cardiovascular risk factors such as BP or lipid 
levels. 
Ø A positive correlation between total fat intake and weight gain also observed in 
children and teenagers/young adults. 
No or adverse effects: 
§ TFAs from natural sources (milk and body fat of ruminants, as opposed to industrially 
produced from vegetable fats) have no adverse effects on risk markers for CVD in healthy 
adults (Figure 3.3A):  
Ø Based on TFA consumption of up to 4.2 % of daily energy intake. 
Ø The current recommended daily allowance is 0·5 to 1.0 %. 
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§ High TFA intake (natural and industrial sources) at a range of 2.59 to 7.8 % of total energy 
intake: 
Ø Does not affect circulating glucose and insulin concentrations in healthy or 
overweight/obese adults, Figure 3.3A. 
Ø Does increase total and ‘bad’ LDL-cholesterol concentrations and decreases ‘good’ 
HDL-cholesterol concentrations, Figure 3.3A. 
 
3.1.1.5  Omega-fatty acids 
Beneficial effects: 
§ Fish consumption is inversely associated with risk of the acute coronary syndrome, 
Figure 3.2A. 
§ Dietary omega-6 intake lowers CHD risk. However, this beneficial effect may be 
dependent on high levels of dietary omega-3, Figure 3.2A. 
 
3.1.1.6 Dairy 
Beneficial effects: 
§ Increasing total dairy intake including low-fat dairy products (300–400 g/day) or cheese 
(~50 g/day) may protect against type-2 diabetes (Figure 3.3A):  
Ø Possibly due to the high content of calcium, magnesium, vitamin D and whey 
proteins which may reduce body fat and insulin resistance. 
§ Dairy products have modest short-term effects on reducing body fat, Figure 3.3B. 
§ Calcium intake is inversely associated with risk of stroke in Asian populations which have 
low-to-moderate average calcium intakes (<700 mg/day), Figure 3.2A. 
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No or adverse effects: 
§ Increasing dairy consumption does not significantly reduce body weight and fat loss in 
long-term interventions or diets without energy restriction, Figure 3.3B. 
§ Consumption of high-fat dairy products, milk or yoghurt, has no effect on the risk of type-
2 diabetes, Figure 3.3A.   
§ Calcium intake is weakly positively associated with increased risk of stroke in populations 
with high calcium intakes (≥700 mg/day), Figure 3.2A. 
 
3.1.1.7 Protein 
Beneficial effects:  
§ High protein diets provide modest benefits for reducing body weight, fat mass and 
circulating blood triglyceride concentrations, Figure 3.3B. 
§ Higher consumption of nuts is associated with reduced risk of ischaemic heart disease 
(IHD), overall CVD, hypertension and all-cause mortality, Figure 3.2A. 
§ Legume intake is inversely associated with IHD, Figure 3.2A. 
§ Consumption of dietary pulses significantly reduces 'bad' LDL cholesterol levels, Figure 
3.3B. 
 
No or adverse effects: 
§ Legume intake and higher nut consumption is not significantly associated with reduced 
risk of type-2 diabetes and stroke, Figure 3.2A and 3.3A. 
§ Nut consumption does not affect BMI, body weight or waist circumference, Figure 3.3B.     
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3.1.1.8  Vitamins & minerals 
Beneficial effects: 
§ Vitamin B supplementation lowers stroke events; vitamin D supplementation protects 
against cardiac failure, Figure 3.2A. 
§ Iron-fortified foods reduce the risk of anaemia and iron deficiency, Figure 3.2. 
§ Decreased sodium intake significantly reduces resting BP in adults and children with no 
adverse effects on other blood or renal functions, Figure 3.2B. 
§ Higher intakes of dietary magnesium are associated with reduced risk of IHD (200 
mg/day), Figure 3.2A. 
 
No or adverse effects: 
§ Vitamin D supplementation does not appear to protect against myocardial infarction or 
stroke, Figure 3.2A. 
§ Increased sodium intake is associated with an increased risk of stroke, stroke mortality 
and fatal CHD in adults (Figure 3.2A). 
Ø Recommended 3 g/day should become the long-term target for population salt 
intake. 
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Figure 3.2 A 
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Beneficial  effect Adverse effect
Chapter 3                                                                                               The effect of diet on health. 
 
41 
 
 
Figure 3.2 B 
 
 
 
 
Figure 3.2. Dietary risk factors for cardiovascular disease. Data points represent pooled estimates of relative 
risk for categorical variables (A) or weighted mean differences for continuous variables (B) for different food 
groups and their association with CVD based on meta-analyses detailed in Table 1. Horizontal lines represent 
95% confidence intervals. Values are based on the random-effects analysis. Abbreviations: BP, blood pressure; 
CHD, coronary heart disease; CI, confidence intervals; CVD, cardiovascular disease; F/V, fruit and vegetables; IHD; 
ischaemic heart disease; MI, myocardial infarction BMI, body mass index; CI, confidence intervals; d, standard 
mean difference; F/V, fruit and vegetables; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TFAs, 
trans-fatty acids. 
 
 
 
 
 
  
 
-8.0 -6.0 -4.0 -2.0 0.0 2.0
Weighted mean difference [95% CI]
Vegetarian diet and systolic BP (Yokoyama et al., 2014)
Vegetarian diet and diastolic BP (Yokoyama et al., 2014)
Iron-fortified foods and haemoglobin levels (g/dL) (Gera et al., 2012)
Iron-fortified foods and serum ferritin levels (μg/L) (Gera et al., 2012)
Reduced sodium and systolic BP (mm Hg) in adults (Aburto et al.,2013)
Reduced sodium and diastolic BP (mm Hg) in adults (Aburto et al.,2013)
Reduced sodium and systolic BP (mm Hg) in children (Aburto et al.,2013)
Reduced sodium and diastolic BP (mm Hg) in children (Aburto et al.,2013)
Chapter 3                                                                                               The effect of diet on health. 
 
42 
 
 
 
Figure 3.3 A 
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Figure 3.3 B 
 
Figure 3.3. Dietary risk factors in diabetes. Data points represent pooled estimates of relative risk for categorical 
variables (A) or weighted mean differences for continuous variables (B) for different food groups and their 
association with body weight and composition, obesity and type-2 diabetes based on meta-analyses detailed in 
Table 1. Horizontal lines represent 95% confidence intervals. Values are based on the random-effects analysis. 
A, * Data represented as -10 fold; actual value [95% CI] -35.22 [-52.13, -18.30]. B, * Dietary intervention for 
saturated fat refers to the replacement of long-chain triglycerides with medium-chain triglycerides in the diet. 
Abbreviations: BMI, body mass index; CI, confidence intervals; d, standard mean difference; F/V, fruit and 
vegetables; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TFAs, trans-fatty acids. 
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3.1.2 Effects of diet on cancer risk 
The main findings of the systematic review on the effects of diet and risk of cancer are 
summarised below and in Figure 3.4. In general, diets high in fruit and vegetables and low in 
processed meats may have a protective effect against certain cancers including breast, 
colorectal, liver, oesophageal and prostate cancer. 
3.1.2.1 Fruit & vegetables 
§ Higher consumption of fruit and vegetables:  
Ø Does not significantly lower the risk of cancer mortality 
Ø However, may reduce the risk of liver cancer 
§ Dietary intake and blood concentrations of carotenoids (α- and β-carotene and lutein), 
which are naturally occurring pigments synthesised by plants, significantly associated with 
reduced risk of breast cancer 
 
3.1.2.2  Protein 
§ Meat consumption is associated with oesophageal cancer risk:  
Ø High intake of red meat and low intake of poultry are associated with an increased 
risk of oesophageal squamous cell carcinoma 
Ø High intake of processed meat supports an increased risk of oesophageal 
adenocarcinoma 
3.1.2.3  Vitamins & minerals 
§ Higher intakes of dietary magnesium (100 mg/day) are associated with a 12-13% lower 
risk of colorectal tumours. 
§ Increased selenium concentrations associate with lower risk of prostate cancer 
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Figure 3.4. Dietary risk factors for cancer. Data represents pooled estimates of relative risk (dots) and 95% 
confidence intervals (horizontal lines) for different food groups and their association with cancer-based on meta-
analyses detailed in Table 1. Values are based on random-effects analysis. Abbreviations: CI, confidence intervals; 
F/V, fruit and vegetables. 
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3.1.3 Effects of diet on neurological function 
An emerging body of evidence indicates that diet plays an important role in mental health 
(Jacka and Berk, 2007, Jacka et al., 2013, Murakami and Sasaki, 2010). Our systematic review 
of the effect of diet on general health and wellbeing showed that a healthy dietary pattern 
high in fruit, vegetables, fish, whole-grains and low-fat dairy, and low-to-moderate in red or 
processed meats significantly reduced the risk of depression, Figure 3.5. In contrast, Western 
dietary patterns rich in processed meat, high-fat dairy, refined grains, sugary beverages and 
desserts showed a trend towards an increased risk of depression. However, this did not reach 
statistical significance (Figure 3.5). Free fatty-acid supplementation and exclusion of artificial 
food colours in the diet also had a beneficial effect on mental health; reducing the risk of 
attention deficit hyperactivity disorder (ADHD), Figure 3.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Dietary risk factors in neurological disease. Data represents pooled estimates of relative risk (dots) 
and 95% confidence intervals (horizontal lines) for different food groups and their association with depression 
and ADHD based on meta-analyses detailed in Table 1. Values are based on random-effects analysis. 
Abbreviations: ADHD, attention deficit hyperactivity disorder; CI, confidence intervals. 
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3.2 UK dietary patterns and their impact on general health and wellbeing  
As indicated from our systematic review, poor quality diet can increase the risk of non-
communicable diseases such as CVD, diabesity and cancer. It is therefore a global priority to 
promote healthy dietary patterns to reduce disease risk. Dietary patterns in the UK were 
addressed using findings from the most recent National Diet and Nutrition Survey (NDNS), 
which is based on a representative sample of 1,000 individuals per year living in private 
households in the UK (NDNS, 2015). The major findings of the NDNS report covering years 1 
to 4 (2008/2009 to 2011/2012) of the rolling program, based on mean values for age and 
gender assigned groupings, are summarised in Figure 3.6 alongside key findings from our 
systematic review of the literature.  
Overall, the population is consuming more than the recommended amounts of 
saturated fat, added sugars and salt, and not enough fruit, vegetables, oily fish and fibre 
(NDNS, 2015). Household income was shown to influence dietary patterns, with lower income 
quintiles associating with poorer quality diets. However, dietary intakes which failed to meet 
dietary recommendations (see Figure 3.6) were consistent across all income quintiles. In 
comparison to dietary patterns in 2008/2009, mean energy intake and consumption of total 
fat, saturated fat, total meat and red meat were generally lower in 2011/2012, with no 
differences in fruit and vegetable intake or percentage risk of vitamin and mineral 
deficiencies. Mean intakes of saturated fat, TFAs and non-milk extrinsic sugars were lower in 
the most recent NDNS relative to previous surveys, and total fat typically made smaller 
contributions to total energy intakes. Also, intake of fibre was higher, and protein 
consumption contributed greater to total energy intakes in the most recent survey (NDNS, 
2015). 
 
Chapter 3                                                                                               The effect of diet on health. 
 
48 
 
 
 
 
 
 
Figure 3.6. UK dietary patterns based on the National Diet and Nutrition Survey (NDNS). A summary of the 
NDNS covering years 1 to 4 (2008/09 to 2011/12) of the rolling program is represented on the left, representative 
of 1,000 UK participants (500 children aged 1.5 and upwards and 500 adults), NDNS (2015). Beneficial and 
adverse effects of the different food groups are summarised from a systematic review of the literature. a 
Proportion of 11-18 year old girls only; no indication from biochemical status data that this age group was at risk 
of deficiency. b Riboflavin deficiency in women aged 19-64 years. c Iron deficiency risk in girls aged 11-18 years 
and women aged 19-64 years. d Mineral deficiency, particularly magnesium, potassium and selenium, in a 
substantial proportion of older children and adults. † Eaten individually or in combination. *LCTs, e.g. butter, 
rapeseed oil and soybean oil; **MCTs, e.g. palm kernel oil and coconut oil. Image modified from 
http://www.nhs.uk/Livewell/Goodfood/Pages/eatwell-plate.aspx, accessed November 2015.  
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Figure 3.7. UK profile of non-communicable diseases (NCDs). Data based on 2014 World Health Organisation 
NCD country profiles. A, Percentage mortality rates based on all ages and both sexes. B, Age-standardised death 
rates per 100,000 of the population. Image modified from http://www.who.int/nmh/countries/gbr_en.pdf, 
accessed November, 2015.   
 
Non-communicable diseases account for approximately 89% of total UK mortalities, with CVD 
(31%) and cancer (29%) accounting for the greatest proportions of deaths within this disease 
category (Figure 3.7A). Analysis of UK mortality rates for both CVD and cancer showed 
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reductions in the number of deaths per 100,000 of the population from 2008 to 2012, 
particularly concerning CVD (Figure 3.7B). This supports trends towards healthier dietary 
patterns in the UK in 2011/2012 relative to 2008/2009, including reduced intake of red meat, 
saturated fat and TFAs, and increased consumption of fibre (NDNS, 2015). 
 
3.3 Global dietary patterns and disease trends 
Our analysis of dietary patterns and non-communicable disease burden was extended 
globally. A recent study addressing global dietary patterns from 1990 to 2010 found that diets 
based on healthy products improved worldwide. However, diets based on unhealthy products 
worsened and at a rate that outpaced healthy dietary patterns for many countries (Imamura 
et al., 2015), Figure 3.8. High-income nations had better quality diets based on healthy 
products, but significantly poorer diets based on unhealthy products relative to low-income 
nations, with heterogeneity in dietary patterns observed both regionally and globally (Figure 
3.8). In general, older adults and females were reported to have substantially higher quality 
diets relative to younger adults and males, respectively.  
To correlate dietary patterns with disease burden on a worldwide scale, global maps 
representing morbidity and mortality rates for non-communicable diseases were downloaded 
from the World Health Organization (WHO) (http://www.who.int/gho/map_gallery/en/,  
accessed   November   2015).    
 
 
 
 
 
Chapter 3                                                                                               The effect of diet on health. 
 
51 
 
Fig 3.8 A 
 
 
 
 
 
 
 
 
Fig 3.8 B  Dietary patterns based on more healthy products 
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Figure 3.8. Global dietary patterns are relative to global income. A Global income based on gross national 
income (GNI) per capita for 2013. Low-, middle- and high-income economies are respectively defined as those 
with a GNI per capita of $1,045 or less, $1,045 to $12,746, and $12,746 or more. Lower-middle-income and 
upper-middle-income economies are separated at a GNI per capita of $4,125. Image modified from 
http://data.worldbank.org/maps2015, accessed November 2015. B, Global dietary patterns among men and 
women in 2010. Values represent degrees of adherence to healthy and unhealthy diet trends, ranging from 0 
(least healthy) to 100 (most healthy). Global mean scores were 44·0 (SD, 10·5) and 52·1 (SD, 18·6) for healthy 
and unhealthy dietary patterns, respectively, with weak inter-correlation between countries. Image is taken 
from Imamura et al. (2015).  
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The overlap between dietary patterns based on consumption of fewer unhealthy products 
and the prevalence of raised cholesterol showed a strong positive correlation, i.e. the fewer 
unhealthy products consumed, the lower the prevalence of raised cholesterol; the more 
unhealthy products consumed, the higher the prevalence of raised cholesterol (Figure 3.9). 
This was particularly apparent for low- to middle-income countries including India, Pakistan, 
Afghanistan, China and African countries, where healthier dietary patterns (based on 
consumption of fewer unhealthy products) correlate with the lower prevalence of raised 
cholesterol. The opposite trend was observed in high-income countries, with the highest 
prevalence of raised cholesterol reported in several European countries, including the UK 
(Figure 3.9). In contrast to blood cholesterol levels the prevalence of raised BP was high in 
African countries, and also in parts of Europe (Northern and Eastern) and Asia (Central, 
Northern and Eastern; excluding China). Global mortality rates for CVD were largely 
comparable to trends observed for the global prevalence of raised BP, Figure 3.9. Global 
cancer mortality rates again identified Central, Northern and Eastern Asia (including China) 
and Northern and South-Eastern Europe as most at risk, in addition to parts of South America 
and Africa. The strong correlation between unhealthy eating patterns and the prevalence of 
overweight adult males based on body mass index (BMI) was also observed Figure 3.10. This 
was particularly apparent in upper-middle- to high-income nations, excluding China (see 
Figure 3.8A for a map of global income). In North America, South America and parts of Europe, 
there is also a positive correlation between unhealthy eating patterns, high BMI and 
morbidity rates for the major depressive disorders (Figure 3.10). High levels of depression are 
also observed in Southern Asia. 
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Fig 3.9 
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Figure 3.9. Global burden of non-communicable diseases about global dietary patterns. Top panel, Global 
dietary patterns among men and women in 2010. Values represent degrees of adherence to healthy and 
unhealthy dietary patterns, based on consumption of fewer unhealthy products, ranging from 0 (least healthy) 
to 100 (most healthy). Image modified from Imamura et al. (2015). Middle panel, Age-standardised prevalence 
of raised blood cholesterol (age 25 and over, both sexes) in 2008 and raised blood pressure, BP, (age 18 and 
over, males) in 2014. Lower panel, Age-standardised mortality rates per 100,000 of the population for cancer 
and cardiovascular disease, CVD, in 2012. Data is representative of both sexes. Images downloaded and modified 
from the World Health Organisation (http://gamapserver.who.int/mapLibrary/app/searchResults.aspx, 
accessed November 2015). 
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Figure 3.10 
 
 
 
 
 
 
 
 
Figure 3.10. Global burden of weight gain and major depressive disorder about global dietary patterns. Top 
panel, Global dietary patterns among men and women in 2010. Values represent degrees of adherence to 
healthy and unhealthy dietary patterns, based on consumption of fewer unhealthy products, ranging from 0 
(least healthy) to 100 (most healthy). Image modified from Imamura et al. (2015). Bottom panel, Age-
standardised overweight males based on body mass index (age 18 and over) in 2014 and age-standardised 
disability-adjusted life year rates for the major depressive disorder (both sexes) in 2004. Images downloaded 
and modified from the World Health Organisation. 
 
 (http://gamapserver.who.int/mapLibrary/app/searchResults.aspx, (accessed November 2015). 
 
https://en.wikipedia.org/wiki/Major_depressive_disorder#/media/File:Unipolar_depressive_disorders_world_
map_-_DALY_-_WHO2004.svg, accessed November 2015.  
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3.4 Summary 
Diet can influence the risk of chronic diseases, such as CVD and cancer, which account for an 
estimated 89% of total deaths in the UK. Although UK dietary patterns are becoming 
healthier concerning lower intakes of fat and red meat, and higher intakes of fibre, 
consumption of fruit, vegetables, saturated fat and salt do not meet national dietary 
recommendations. 
Both in the UK and globally, dietary patterns are linked to the economic status which has 
implications for disease burden, particularly in low-income quintiles.  There is an 
opportunity in the market to promote affordable, healthier food choices to reduce the 
disease burden of dietary-related non-communicable disease 
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4.1 Natural Functional Food and Drinks 
   Natural functional foods are expected to be the greatest trend set to impact 
the food industry.  Products that sit within this category are considered to have inherent 
characteristics that boast naturally healthy ingredients promoted for their natural 
occurrence; inherent nutrition benefit, simple formulation or nothing added declaration.  
For example, oatmeal contains beta-glucan, this has been clinically proven to reduce blood 
cholesterol levels.  Additionally, blueberries are considered a natural functional food or 
informally a ‘superfood’ as they are rich in antioxidants, phytoflavinoids, potassium, vitamin 
C and act as an anti-inflammatory. 
Another example is Goji berries which have an extensive and impressive list of 
nutritional benefits.  These include 19 amino acids and 21 minerals, including germanium 
which is an anti-cancer fighting component. Goji berries have 13% protein which is more 
than whole-wheat and a beta-carotene content which is higher than carrots. They also 
provide vitamin C and Beta-Sisterol, an anti-inflammatory which aids in lowering 
cholesterol, Cyperone which reduces blood pressure, Solavetivone an anti-bacterial/fungal 
compound, Physalin a natural active compound against leukaemia, Betaine which reduces 
homocysteine and Lycium Barbarum Polysaccharide which is protective in Hepatoma Cancer 
cell lines. 
Water consumption is essential for the body to function optimally, especially as an 
adult human body’s weight is made up of between 50-70% water.  Coconut water is an 
example of a natural functional food which has been re-discovered by the general public 
looking for water alternatives.  Sales of this product in the US had a dramatic increase from 
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$0 in 2007 to an impressive $390m in 2013.  Its success is believed to have been encouraged 
by the ‘naturally healthy – nothing added image’.   
4.2 Heart Health 
According to The British Heart Foundation, Heart and Circulatory disease combined 
contribute to more than a quarter of all UK deaths, on average 161,000 annually.  The cost 
of this is estimated to be £19bn each year which includes premature death, loss of 
productivity, hospital treatment and prescriptions. The main risk factors associated with 
CHD are having high blood pressure, high blood cholesterol levels, diabetes, being 
overweight/obese, lack of exercise, unhealthy diet and stress.  Many of these factors are 
influenced by the environment, ethnicity or genetic predisposition. However, diet can have 
a major impact.  Reducing the associated dietary risk factors could impact drastically on the 
mortality rate of CHD and related illnesses globally.  
4.2.1 Cholesterol 
Cholesterol is a lipid substance which is secreted by the liver and found in some 
foods.  It is not a harmful substance. However, having excessively high amounts of lipids in 
the blood, known as hyperlipidaemia can cause detrimental health effects.   
Cholesterol is transported around the body by proteins and when the two combine, 
they are known as lipoproteins; there are two types known as LDL and HDL.  Low-Density 
Lipoproteins (LDL) carries cholesterol from the liver to cells which require it, if it transports 
more than the cells need, it can build up on artery walls which can cause atherosclerosis – 
narrowing of the arteries, which in turn can restrict blood flow and potentially cause heart-
attack or stroke.  Therefore, low levels of LDL are crucial to maintaining healthy bodily 
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function.  High-Density Lipoproteins (HDL) are required in high levels as it is beneficial for 
bodily function, it removes unneeded cholesterol away from cells and back to the liver, 
where is it broken down or excreted as waste (NHS A, 2013).  
Plant sterols and stanols (phytosterols) can aid in the reduction of blood cholesterol.  
These components are naturally occurring in plants and similarly structured to cholesterol; 
therefore, they can compete for absorption, which in turn can reduce the amount of 
cholesterol that is absorbed.  Many manufacturers have included phytosterols in their 
products to create functional foods with the additional ‘cholesterol reducing’ benefit.  
Scientific evidence suggests that consuming between 1.5g and 2.4g of plant sterols daily can 
significantly reduce LDL by up to 10%.            ‘ 
4.2.2 High Blood Pressure 
Up to 30% of people in the UK suffer from hypertension.  It is a measure of the 
strength of blood pressure against the artery walls and if left untreated, can increase the 
risk of heart attack/stroke. (NHS 2015).  The factors which increase the likelihood of 
hypertension include age, high caffeine, salt or alcohol intake, poor exercise level, certain 
ethnicities or being overweight. 
4.2.3 Salt 
Salt consumption is considered a substantial factor which contributes to increased 
blood pressure. (Desmond 2006). Salt can be reduced in food subsequently reducing dietary 
intake in the following ways: 
Chapter 4                                                                                  The Functional Food Market & Nutraceuticals 
62 
 
4.2.3.1 Reducing Salt Content 
Possibly the easiest way to reduce the amount of salt in food would simply be to not 
add so much in the first place.  The trend for convenience ready-meals are commonly 
associated with high salt contents to improve shelf-life and reduce wastage.  In these pre-
packed products, the consumer has limited control over the amount of salt ingested.   
4.2.3.2 Salt Substitutes 
Potassium Chloride (KCl) is the most common salt substitute for low or reduced 
sodium/salt food. (Desmond, 2006). Flavour enhancers such as yeast extracts, lactates, 
monosodium glutamate and nucleotides, used in addition to salt can enrich the overall 
flavour and result in less salt being added.    
 4.2.3.3 Optimising the physical form of salt 
Salt is characterised by crystal size and shape (Desmond, 2006).  The size of salt 
crystal can influence the delivery of the salty taste that is imparted when consumed.  Finer 
salt crystals are believed to give a more rapid release of saltiness in comparison to large 
crystals.  (Campden BRI, 2012).  Optimised sodium chloride in a restructured format, has no 
bitter aftertaste often associated with potassium alternatives.  Overall salt content can be 
reduced by 25-50%, using a re-engineered salt particle whose physical structure has been 
altered to facilitate a hollow centre in microscopic particles, therefore acting with the same 
functionality and properties as salt.             
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4.3 Weight Management  
Weight management is a key trend for the functional food market  (Canadean Ltd, 
2013), (IFT, 2014), (Nutraceuticals, 2012).  Estimates are that half the UK population will be 
obese by 2050.   Being overweight is defined as having a BMI (Body Mass Index) of 25.0 – 
29.9, obesity is defined as having a BMI of 30 or above. (BBC A, 2014). A survey published in 
2012 found that just over a quarter of all adults (26%) in England are obese and a further 
41% of men and 33% of women are overweight. Functional foods can help aid in weight loss 
in three areas: 
4.3.1 Reducing energy intake 
Developing food products which increase satiety is hypothesised to increase fullness 
when consumed and the individual will be encouraged to cease eating sooner (Choudhary 
and Grover, 2012). Therefore, total energy intake will be reduced.  This can be accomplished 
by increasing the main non-caloric value, e.g. water, fibre and reducing the caloric value, 
e.g. fat and sugar.  Insoluble fibre is considered non-caloric as is not digested by the body, 
carbohydrates and protein provide 4 calories per gram and fat contribute 9 per gram, as 
shown in table 4.1. 
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Table 4.1 Calories per Gram of Macronutrients 
Food Group Calories Per Gram  
Fat 9 
Alcohol 7 
Carbohydrate 4 
Fat 4 
4.3.2 Increasing the main non-caloric value 
4.3.2.1 Water  
Water is an essential nutrient for the human body, and as it is not stored, it needs to be 
regularly consumed to keep the body replenished for optimum efficiency.  Liquids can 
promote satiety in the short term, while long-term structured snacks help individuals lose 
weight. (Choudhary and Grover, 2012).   
The COMMISSION DIRECTIVE 96/8/EC of 26th February 1996, has stringent regulations on 
the name, energy value, nutritional value, labelling and advertisement of any product 
presented as a replacement for one or more meals of the daily diet.  It stipulates that the 
energy provided shall be no less than 200kcal and no more than 400kcal per meal.  Protein 
content should be no less than 25% or any more than 50% of the total energy, and the total 
energy derived from fat should not exceed 30%.  Finally, any replacement meal substitute 
should provide at least 30% of the vitamins and minerals as specified in table 4.2. 
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Table 4.2 COMMISSION DIRECTIVE 96/8/EC of 26th February 1996, Vitamin and Mineral Requirements 
Vitamin/Mineral Measure Amount 
Vitamin A μg (RE) 700 
Vitamin D μg 5 
Vitamin E mg (TE) 10 
Vitamin C mg 45 
Thiamin  mg 1.1 
Riboflavin mg 1.6 
Niacin mg (NE) 18 
Vitamin B6 mg 1.5 
Folate μg 200 
Vitamin B12 μg 1.4 
Biotin μg 15 
Pantothenic acid mg 3 
Calcium mg 700 
Phosphorus mg 550 
Potassium mg 3100 
Iron mg 16 
Zinc mg 9.5 
Copper mg 1.1 
Iodine μg 130 
Selenium μg 55 
Sodium mg 575 
Magnesium mg 150 
Manganese mg 1 
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4.3.2.2 Fibre  
Fibre is another non-caloric component in food. Insoluble-fibre, as a dietary material 
containing substances such as cellulose, lignin, and pectin, which is resistant to the action of 
digestive enzymes.  Fibre is often used in functional foods as it is believed to aid with weight 
loss for several reasons; firstly, fibre is a tough and chewy material, requiring maximal 
mastication to break it down, this stimulates the sensory glands which prepare the body for 
food intake.  Secondly, fibre is not digested by the body which means that any fibre 
consumed will not contribute to the daily caloric intake. Additionally, fibre empties the 
gastric tract at a slower rate than other macronutrients meaning the nutrients derived from 
fibre are absorbed by the body slowly.  These qualities mean that increasing fibre in the diet 
reduce caloric intake and leaves the consumer with a longer sensation of satiety and a slow 
constant supply of essential nutrients.   
4.3.3 Decreasing the main caloric value 
As shown in table 4.1, fat contains over double the calories per gram (9) than protein and 
carbohydrate (4).  Food brands have developed ranges to reduce the fat, salt and sugar in 
their products, creating lower fat versions labelled: Low fat, lite, light, reduced fat, low 
sugar. Cheese is an example of a high fat and high calorie product that can be reformulated 
to deliver low fat versions as in figure 4.3 
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Figure 4.3: Nutritional Comparison of Cheese. 
4.3.4. Incorporating compounds 
Many naturally occurring ingredients and compounds are believed to be helpful in weight 
management. Incorporating these ingredients into new products is considered an ideal way 
to build a substantial health claim into a new product. (Choudhary and Grover, 2012) 
4.3.4.1 Caffeine and ephedrine  
A combination of the ingredients caffeine and ephedrine are thought to be effective in long-
term weight management.  This is due to caffeine’s ability to inhibit the phosphodiesterase-
induced degradation of cAMP and ephedrine’s capability of enhancing the sympathetic 
release of catecholamines.  When operating synergistically, studies have shown that they 
are effective in long-term weight loss. 
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4.3.4.2 Green tea 
Green tea contains both tea catechins and caffeine which operate synergistically to prevent 
the inhibition of enzymes which break down body mass.  Furthermore, tea catechins have 
antiangiogenic properties that may prevent the development of obesity (Choudhary and 
Grover, 2012). 
4.3.4.3 Calcium 
A diet high in Calcium (Ca) is associated with lower BMI (Choudhary and Grover, 2012).  
Results from clinical trials suggest that calcium supplementation generates small, 
statistically significant weight loss in obese and overweight individuals (Daniels, 2014). 
4.3.4.4 Conjugated linoleic acid 
Conjugated linoleic acid (CLA) is a fatty acid which reduces body fat mass while preserving 
lean body mass.  CLA affects two enzymes – one which breaks down fat in cells and another 
which breaks down fat in the blood.  CLA prevents fat from being stored. 
4.3.4.5  Glucomannan 
A compound produced from the konjac root; the fibre can absorb a large amount of water 
which creates a feeling of satiety which in turn can suppress appetite and reduce energy 
intake.  Glucomannan also reduces carbohydrate absorption which prevents insulin spiking 
and balances cholesterol and triglyceride levels. 
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4.3.4.6  Chitosan 
Chitosan is a dietary fat inhibitor derived from shellfish, which cannot be digested by the 
body.  If consumed in unison with a fat-laden meal it can allow dietary lipids to pass through 
the body unabsorbed and undigested.  
 4.4 Protein 
The consumer trend continues for meat-free food alternatives to meat, minced beef, 
chicken and fish (Butler & Smithers, 2014). Meat and protein alternatives are the trends that 
will drive functional food purchases, with eggs being the most popular alternative followed 
by beans, lentils and legumes (IFT, 2014), (New Nutrition Business, 2013).  The term 
‘flexitarians’ is fast becoming a descriptive title for meat-eaters who are actively seeking 
non-meat alternatives. Some of the current trending meat alternatives include Seitan, 
mushroom and mycoproteins which are processed to mimic the texture of meat. The 
recommended GDA for protein is 45g (figure 4.4), and functional alternatives to meat 
protein play an important role in modern diets. 
 High protein functional foods are prevalent in sports nutrition. Products are 
consumed in the format of whey protein isolate powders, shakes, and supplements.  
Developments in this market have fulfilled the need for more convenient, on-the-go, ready-
to-eat formats.   
Other high protein products may also come from dairy sources such as ‘Quark’ a 
naturally fat-free soft cheese. Oat milk is a non-dairy product made from soaked and 
blended oats which are soy, dairy, milk and lactose-free. The milk is often enriched with 
calcium, vitamin D, riboflavin and vitamin B12.  It is high in fibre and protein and low in 
unsaturated fat. It is rich in beta-glucans which are heart healthy, due to their blood 
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cholesterol reducing abilities. Similarly, sales of almond milk rose from $0 in 2009 to $407m 
in 2013 (Boothroyd, 2013). 
Table 4.4: Recommended Daily Amount (Source: FDF) 
Food Group Recommended Daily Amount  
Protein 45g 
Carbohydrate 270g 
Fibre 24g 
Calories 2,000 
Sugar 90 
Fat 70 
Sat Fat 20 
Salt 6 
                  
4.5 Free-From 
Whether it’s free-from gluten, dairy, egg, nut, soya or even suitable for vegans/vegetarians, 
cutting out problematic ingredients or those which many are sensitive, allergic or intolerant 
is a growing market.  A food allergy is an adverse immune response to a food protein. 
Whereas food intolerance or non-allergic food hypersensitivity where an individual has 
difficulty digesting a particular food or food composite.   
Any food which contains a protein can cause an allergic reaction however only eight types of 
food account for 90% of all food allergies in the United States.  These include peanuts, tree 
nuts, milk, eggs, wheat, soy, fish and shellfish (FARE, 2014). Food intolerances have fuelled a 
£260m sales boom expanding the ‘free-from’ market by 50% in just two years (Kantar 
Worldpanel, 2014). 
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4.5.1 ‘Gluten-free’ 
Gluten is a protein composite found in foods processed from wheat or related grains; many 
individuals react to gliadin, a protein found in gluten where parts of the digestive tract 
become inflamed, which can interfere with the absorption of nutrients.  The number of 
Coeliac disease diagnoses increased 400% between 1990 and 2011 (BBC B, 2014).  The 
‘Gluten-free’ market has huge potential; the market was worth over £175m, a 25% growth 
since 2011 and had the most food launches of any category in 2013 (Carter, 2014). 
4.5.2 Dairy-free 
The dairy industry has an opportunity to grow the market by 273 million gallons by targeting 
the lactose intolerant consumer segment.  There is continued demand for lactose-free milk, 
but also for easily digestible dairy products such as Mozzarella, Cheddar cheese and 
yoghurt.  
 4.5.3 Egg-free 
Egg allergies are common allergic reactions to the proteins in the albumen (egg white). 
However, it is usually recommended that suffers refrain from consuming the entire egg as 
complete separation of the albumen and yolk is difficult. Functional egg replacers substitute 
the function of egg and can include products developed from potato starch, tapioca and 
calcium carbonate. 
  
4.5.4 Nut-free 
Peanuts (a legume) and tree nuts are the two most common food allergens.  They can cause 
severe and potentially fatal allergic reactions known as anaphylaxis (FARE, 2014).  To 
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prevent an anaphylactic reaction, strict avoidance of peanuts and tree nuts, which includes 
but is not limited to, walnuts, almonds, hazelnuts, cashews, pistachios and brazil nuts is 
recommended. Due to entire avoidance being the only known preventative measure, the 
food industry has responded with various functional nut-free products made from roasted 
soy. 
4.6 Children 
Functional food aimed at children has high potential growth rate due to current health 
issues and pressures. Health will be the main driver of the children’s functional food and 
beverage market, bolstered by innovations in four key areas: packaging, fortification, taste 
and trust (TSG, 2008).  Trends in oobesity, hyperactivity, brain function and gut health are 
key aspects of child health that could be addressed by diet. 
4.6.1 Obesity 
One in five children starting school is overweight and latest studies indicating that if a child 
is overweight by age five, they are unlikely to change. Significant interest in child health and 
nutrition has become paramount, and childhood obesity is considered one of the most 
serious global public health challenges.  The latest results from the National Child 
Measurement Programme (NCMP) 2012/2013, suggests that 18.9% of children aged 10-11 
are obese and a further 14.4% are overweight.  Results from the National Health Survey also 
reflects this, finding that 28% of children in the UK aged 2 to 15 are classified as either 
overweight or obese (Public Health England, 2014).  In response to the growing childhood 
obesity epidemic, many functional ‘low fat’ foods aimed at children are now available.   
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4.6.2 Hyperactivity & brain function 
E numbers, additives, colours and flavourings are under scrutiny from parents. 
Healthier children's sweets made from natural grains and fruit juice instead of glucose, 
provide a natural functional alternative to artificial ingredients. Additionally, studies in 
children have shown that essential fatty acid supplements improve focus and concentration. 
4.6.3 Gut health 
Two major concerns in child health are digestion and immunity.  Children’s 
probiotics and omega 3 are commonly used to improve gut function and strengthen the 
immune system. 
4.6.4 Formula milk 
The first functional food that many will have their initial exposure to is infant 
formula.  Infant formula is considered a complete food which is manufactured from purified 
cow’s milk in a powdered format.  Formula milk is the most basic of functional foods as 
despite being a powder when diluted with water it is considered a complete substance in 
providing all essential macro and micronutrients. Formula can be given to an infant 
exclusively for the first six months.  Formula milk for infants and follow-on milk for toddlers 
added nearly $5bn to the functional food market in 2013.  This market ranks first over 
energy drinks ($3.5bn), pre and pro-biotic yoghurts ($2.4bn) and water ($2bn) (Mercola, 
2013).  Functional Baby drinks remain the smallest segment of the baby food market, 
capturing only 2% of spend. There is potential to grow this market by launching non-sweet 
drinks for children, as 21% of parents are interested in this concept (Mintel B ,2014). 
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4.6.5 Baby food 
Baby food is usually the next stage of formula or breast milk.  It is usually in a smooth, soft, 
puree format as infants cannot chew, due to underdeveloped muscles and teeth. 82% of 
parents with a child aged 0-4 feed them homemade food on a daily basis.  36% feed their 
child pre-made food as often (Mintel B, 2014). 
            Figure 4.1, illustrates how the baby food market growth is forecasted from 2012 to 
2017.  Despite monetary growth year on year, from $11.4bn in 2012 to an estimated 
$14.1bn in 2017, the % annual market growth is set to decelerate over the same period. 
Innovation is essential for market growth in this area and functional foods continue to play 
an important role (Mintel B, 2014).   
 
Figure 4.1: Global Baby Food Market Value Forecast: $ Million, 2012 - 2017 
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4.6.6 Ready meals 
 Convenient meals specifically designed for children is an ideal market for functional food. 
There are many aspects of child health which can be enhanced by a diet including dental 
and bone growth, brain development, limiting weight gain and many others.  However, 
targeting children is a sensitive area as any contentious ingredients used, or controversial 
claims will be heavily scrutinised due to the innocence of the target sector and the 
imperative of good quality nutrition needed at this life stage.   
4.7 Energy 
Products providing ‘healthy fuels’ for energy will be a key trend over the coming years. The 
introduction of legislation in 2014 by the EU regarding caffeine in food and drinks, placed 
stringent regulations on the labelling of high caffeine products (Mintel, 2014). If 150mg of 
caffeine per litre is exceeded, products must have a ‘high caffeine content’ label.  
4.7.1 Slow energy release & breakfast biscuits 
Breakfast is often considered the most important meal of the day. The time constraints of 
modern living reduce the opportunity to prepare and eat at this meal occasion.  Lack of 
time, has driven a desire for quick, convenient, food ‘on-the-go’ options.  Products which 
have become popular as a breakfast offering are those which provide a nutritious and 
sustained energy source. The new breakfast biscuits category has grown 78.9% to £76m 
year-on-year in less than four years (Bamford, 2014), (Evans, 2012).       
4.7.2 Bars & snacking 
Many energy-rich products come in bar format which is easy to transport, portion controlled 
and quick to consume.  Snacking is generally accepted as food and drink consumed between 
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main meals (Chaplin and Smith, 2011).  The convenience food culture has encouraged the 
snacking market to grow 3.3% in 2013 (Conlumino, 2014).  It is the least developed market 
for all eating occasions but the most promising regarding long-term growth with 98.8% of 
people eating snacks at some stage of the day; fruit and cereal bars are the most common 
snack in the morning.    
4.7.3   Sugar 
Sugar has several different functions; its broad properties include sweetening products, 
enhancing taste and aroma, affecting the weight and volume, improving texture and colour, 
increasing shelf-life, aiding in the fermentation process, assisting with water retention to 
prevent drying out and reducing the freezing point.  Due to its multi-functioning role, 
substitutes which can replace each property are uncommon.  Natural alternatives are 
known as ‘sugar substitutes’, and synthetic varieties are called ‘artificial sweeteners’.  The 
NHS recommends that an adult male should consume no more than 70g of sugar per day 
and adult females no more than 50g daily (NHS C, 2013).  
Consumers are becoming increasingly sceptical about anything artificial.  A recent study 
involving 2000 participants contends that 38% actively avoid foods or drinks which contain 
artificial sweeteners as they believe it can have a more adverse effect on health than natural 
sugar (Quinn, 2014).  Examples include aspartame, lactitol, xylitol, saccharin and sorbitol.  In 
contrast, consumer opinion of natural sugar alternatives are positive with 40% of 
respondents claiming they would purchase more low sugar variety products if they 
contained natural sweeteners such as stevia, agave nectar or honey instead of artificial 
variations (Quinn, 2014). 
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4.7.3.1 Plant sources for functional sugar replacements 
4.7.3.1.1 Sysepalum Dulficum  
A red fruit berry, commonly known as miracle fruit.  This berry can affect the perception of 
taste due to its innate glycoprotein – miraculin.  This protein binds to the taste receptors on 
the tongue and acts as a sweetness inducer changing the flavour of sour foods such as 
lemon, lime and vinegar to taste sweet when instantly consumed after miracle berries 
(Gayot, 2012).   
4.7.3.1.2  Stevia  
‘Stevia’ is a natural sweetener that is 250-300 times sweeter than normal sugar, without 
providing any calories, carbohydrates, or increased blood sugar level.  The compound is 
made from leaves found on the Stevia Rebaudiana Bertoni plant.  The food additive has 
been approved by the EU since 2011 but has been used in the US since 2008 and sold in 
Japan for over 40 years (BBC D, 2013).   Stevia is approximately 2000% more expensive than 
sugar. Therefore, the price of stevia is a barrier to wide commercial use.  
4.8 Manufacturers 
The global functional food market is dominated by some of largest global food and drink 
manufacturers (table 4.5). Manufacturing products with different functional ingredients to 
provide a range of health benefits. 
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Table 4.5. Samples of functional food and drink products from Danone, Unilever, Kellogg, Kraft, Coca-Cola and 
Yakult. 
 Company Product Functional ingredient or effect Health benefits 
 
 
 
 
 
 
 
 
 
 
 
 
Foods 
Danone Activia 
(yoghurt) 
Bifidus ActiRegularis improve gastrointestinal 
and immune function 
 Actimel 
(yoghurt drink) 
L. Casei cultures, calcium, Vit 
B6 and D 
Strengthen immunity, 
bone health, heart 
health  
Unilever Flora pro.activ Plant sterols Reduce LDL cholesterol 
 Slim fast (meal 
replacement) 
High fibre and protein 
content, low calorie 
Weight management 
Kellogg’s Raisin Bran Omega 3 from flaxseed Reduce LDL cholesterol 
levels  
 Smart Start antioxidant Reduce oxidative stress 
from developing a wide 
range of diseases. 
 Fibre Plus High fibre, 
Antioxidant (Vit E & Zinc) 
Improve gut health; 
Reduce oxidative stress 
from developing a wide 
range of diseases. 
Kraft Mayo Fat-free; olive oil Weight management, 
reduce LDL cholesterol 
level and blood pressure 
     
 
 
 
Yakult Yakult Probiotics: Lactobacillus casei 
and Bifidobacterium 
Improve gastrointestinal 
and immune function 
Coca-cola Powerade ION4 Mineral salts (sodium 
chloride, magnesium chloride, 
Replenish energy level 
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Drinks 
calciukm chloride, potassium 
phosphate) 
 Glaceau Vitamins (B6, C, E, 
pantothenic acid (Vit B5) and 
folic acid) 
Anti-inflammatory 
properties;  
 5 Alive Antioxidant; phenylalanine Anti-infammatory 
properties; Cognitive 
function 
 Relentless Taurine; caffeine; Guarana  Enhance cognitive 
function;  
Kellogg’s To go-breakfast 
shake 
High protein and fibre content Weight management 
 
4.9   Opportunities and market drivers 
Functional food products and ingredients that emphasise health benefits with direct 
scientific evidence are more likely to be successful due to reduced scepticism among 
consumers. Important future developments will be in the area of personalised nutrition 
which will allow manufacturers to capitalise on the growing demand for targeted functional 
foods.  Overall the functional food industry is a remarkably successful and diverse market 
which continues to grow.   
4.10 Nutraceuticals 
Functional foods and ingredients that have a role in the overlap between pharmaceuticals 
and food are commonly referred to as Nutraceuticals. There are a number of common 
conditions where nutraceuticals have a purpose and certain technologies can improve the 
bioavailability of ingredients. 
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4.10.1 Obesity 
4.10.1.1 Epidemiology 
Around 2.8 million people die annually from obesity. Related conditions lead to other 
undesirable metabolic effects on blood pressure, cholesterol and insulin resistance etc. 
Commonly, these conditions are attributed to coronary heart disease, stroke and type II 
diabetes etc. In England, there were approximately 24.7% of adults who were obese in 
2012. Figure 4.2 shows the increasing trend from 1993 to 2012; the trend in obesity is 
increasing and estimated by 2050 to affect 60% of adult men, 50% of adult women and 25 % 
of children (Public Health England, 2007).  
 
Figure 4.2 . Prevalence in obesity, Public Health England, 2012
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4.10.1.2 Treatment 
Although there are drugs which target the treatment of obesity. There are relatively few 
anti-obesity medications that have been approved to be safe and effective, obtainable 
without a prescription in the UK. Many of the currently available pharmaceutical drug 
interventions have deleterious side effects such as gastrointestinal and cardiovascular risk 
factors (NICE). The challenge for nutraceutical companies is to deliver non-pharmacological 
alternatives to obesity drugs without side effects. With the global increase in obesity, 
nutraceutical inventions have an important role for the prevention and treatment of 
obesity. 
Evidence shows that consumption of dietary polyphenols may be beneficial for obesity 
management. Thousands of different types of polyphenols have been identified in a wide 
variety of fruits and vegetables. They can be categorised as flavonoids, phenolic acids, 
lignans and stilbenes (Baboota et al., 2013). Consumption of dietary polyphenols delivers 
multiple benefits, for example, antioxidant, inhibiting free radicals and reactive oxygen 
species and anti-inflammatory. Most importantly, dietary polyphenols may inhibit pre-
adipocyte to adipocyte differentiation causing adipocyte apoptosis, decrease absorption of 
fat from the gut, promote catabolism in adipose and liver tissue and suppress lipid 
biosynthesis. Also, anti-inflammatory molecules may be promoted in adipose tissue to 
reduce oxidative stress under obesity. 
The Polyphenols industry is growing rapidly due to increased public awareness of its 
benefits to maintain good health. In 2011, the global polyphenols market hit $580m; it is 
predicted to reach $873m in 2018. Natural polyphenols can be found in tea, particularly in 
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green tea. It is expected the global tea polyphenols market will hit $368m by 2020 
(Academia, 2013).  
Energy intake has a significant impact on developing obesity. Conventional functional foods 
such as fibre, protein or carbohydrate reduce energy density in food intake. Fibre 
substantially contributes to lower total caloric content. It also leads to slower gastric 
emptying and rate of nutrient absorption. Since protein (7kcal/g) and carbohydrate (4kcal/g) 
are less energy dense than fat (9kcal/g); altering macronutrient composition of the diet 
reduces fat proportion which also impacts on reducing the energy density of the diet.  
4.10.2 Cardiovascular Disease (CVD)  
4.10.2.1 Epidemiology 
Cardiovascular disease remains the leading cause of death in the world. CVD represents a 
group of disorders of the heart and blood vessels, which includes: coronary heart disease, 
cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital 
heart disease, deep vein thrombosis and pulmonary embolism. According to WHO, in 2008 
there were 17.3 million fatalities from cardiovascular disease, which represent 30% of global 
deaths. The increase in CVD mortality rate forecasts that 23 million people will die from CVD 
annually by 2030. Populations affected were predominately from low and middle-income 
countries. 
Figure 4.3 shows the CVD-related cause of death in the UK in 2010 (BHF, 2012). Women 
show a higher risk of CVD than men across all causes of CVD-related deaths; CVD mortality 
rate mainly affects older age groups.  
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Table  4.6  Death by cause, by sex and age, UK 2010 (BHF, 2012) 
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4.10.2.2 Treatment 
CVD can be treated with medications when a patient is at high risk of developing the 
disease. Most common medications prescribed to treat CVD include angiotensin-converting 
enzyme (ACE) inhibitors, which are used to lower blood pressure; statins which are used to 
lower blood cholesterol levels and aspirin to prevent blood clots (NHS, 2012). By 2015, the 
global market for cardiovascular drugs is due to exceed US$111.8bn (GIA, 2010).  
  Nutraceutical products may help prevent cardiovascular disease.  Plant sterols, a 
plant-based substance, has shown a positive effect on reducing CVD risk, by blocking 
cholesterol absorption in the small intestine. Consumption of functional food and beverages 
containing plant sterols can lower cholesterol, especially LDL cholesterol level, by at least 6% 
without lowering HDL cholesterol level. Functional foods with plant sterols include whole 
grain bread, fortified margarine and fortified fruit juices. Globally, sales of plant sterol 
products have reached approximately €2.5bn in 2013. Dietary supplements are another 
approach to obtain adequate amounts of plant sterols to reduce CHD risk (IFICF, 2007). 
Additionally, substances such as catechins in green tea, flavanols in coffee, polyphenols 
(resveratrol, procyanidins and quercetin) found in red wine have all been shown to reduce 
the risk of CVD in clinical trials (Tempest, 2012). 
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4.10.3 Diabetes 
4.10.3.1 Epidemiology 
Approximately 360 million people in the world have diabetes, which is approximately 8.5% 
of the global population. It is a significant impact on both society and economy. The top 5 
countries with the highest number of diabetic patients are China, India, US, Russia and Brazil 
(Diabetes UK, 2011). In the UK, there are 2.9 million people diagnosed with diabetes, and it 
is expected to rise to 4 million by 2025. Diabetes is a lifelong condition where blood sugar 
remains at high levels. There are two types of diabetes: type 1 and type 2. In the UK, type 2 
diabetes accounts for about 90% of all adults who are diagnosed with diabetes, leaving 10% 
for type 1 diabetes. Children who are affected, are commonly diagnosed with type 1 
diabetes. However, there is an increasing number of children and young adults developing 
type 2 diabetes. Type 1 diabetes, where the pancreas does not produce insulin, is not 
curable. Type 2 diabetes is a condition where the pancreas does not produce enough insulin 
to reduce blood sugar level. It usually affects adults over the age of 40 (NHS, 2012).  
4.10.3.2   Treatment 
Diabetes treatment may include lifestyles changes such as regular physical activity and 
healthy diet. However, in some serious conditions, medication and insulin treatment will be 
needed. There are several types of medications for diabetes which include: Biguanide, 
Sulphonylureas, Alpha-glucosidase inhibitor, Prandial glucose regulators, Thiazolidinediones, 
Incretin mimetics, DPP-4 inhibitors, and SGLT2 inhibitors. Diabetes can be preventable by 
altering nutrition and dietary pattern. Figure 4.4 shows foods, nutrients and dietary patterns 
that can reduce the risk of diabetes development (Giacco et al.
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Table 4.7  Foods, nutrients and dietary patterns associated with risk of developing type 2 diabetes. 
 
The Functional Food Market & Nutraceuticals 
 
 Increased Risk Degree of Evidence Decreased Risk Degree of Evidence 
Foods Soft Drinks ++ Whole Grains ++ 
 Red meat and processed meat ++ Tea and Coffee ++ 
 Oil and hydrogenated margarine + Milk and dairy products low in fat ++ 
 Eggs + Fruits, vegetables, legumes + 
   Moderate alcohol consumption + 
     
Nutrients Saturated fatty acids + Fibres ++ 
 Trans fatty acids + Unsaturated fatty acids ++ 
   Antioxidants + 
   Magnesium + 
Dietary Pattern High glycaemic index ++ Low glycaemic index + 
 Western Diet  Mediterranean Diet +++ 
   Diet low in fat +++ 
Degree of evidence from perspective epidemiological studies and clinical trials = +++ High, ++ Moderate, + Reasonable 
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          Food with a low glycaemic index (GI) have a direct effect on reducing the risk of 
diabetes as it does not raise blood glucose to a high level. Cereals such as oats are rich in β-
glucan which is a highly viscous soluble fibre. It plays a significant role in slowing gastric 
emptying and limits the rise of blood glucose level. Glucose has a GI of 84%, and fructose is 
29%; therefore, replacing glucose with fructose is another way to reduce GI of the food 
without affecting the palatability (Giacco et al., 2013).  Slow-release carbohydrate food is 
another healthy option for diabetics.  
There are also dietary supplements with specific types of functional ingredients that are 
beneficial for diabetes (Davi et al., 2010).  
• Vanadium: this mineral is valuable for both type 1 and types 2 diabetes because it 
transports glucose into the cells which is similar to the action of insulin. Reduction in 
fasting glucose level is seen after consumption. 
• Biotin: a member of B vitamin complex, causes an increase in insulin production by 
stimulating live glucokinase activity.  
• Coenzyme Q10: clinical trials show an effect of improved insulin resistance by 
lowering glucose and fasting insulin levels.  
 
4.11 Nutrient interventions for disease (table 4.8– Appendix 1) 
A number of nutrient interventions for diseases ranging from Metabolic Syndrome, 
Alzheimer’s, CVD, Atherosclerosis and Diabetes, can be found in table 4.8.  
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4.12 Nutraceutical technologies  
The bioavailability of certain functional ingredients is reduced or destroyed in food 
processing from heat or oxidation. Capsule technology protects the bioavailability of 
sensitive components, provides improved shelf life and timed delivery of nutrients. 
4.12.1 Microencapsulation  
Microencapsulation technologies have been developed to ensure the bioavailability of 
ingredients. Microencapsulation is a process of enclosing micron-sized particles of solids or 
droplets of liquids or gasses in within an inert shell to isolate and protect the substance 
from the external environment (Wang & Bohn, 2012). The end product of this process can 
be called microparticles, microcapsules or microspheres depending on the forms and 
internal structure. Particle size diameters which are less than 1µm are called nanoparticles, 
nanocapsules or nanospheres. Particle size diameters between 300 - 800 µm are known as 
microparticles, microcapsules or microspheres. Finally, particle size diameters that are 
larger than 1000µm are called macroparticles.  
The main purpose of this technology is to (i) protect sensitive substances from external 
environment; (ii) mask the organoleptic properties like colour, taste, odour of the 
substance; (iii) improve stability and bioavailability of the food ingredient or nutrient; (iv) 
obtain controlled release of the drug substance and (v) target release of the drug.   
Microparticles consist of two parts which are core material and coat material. The 
core material is usually an active ingredient or substance such as pharmaceutical 
ingredients, proteins, peptides, volatile oils, food material, etc. The core materials are 
protected by the coating material such as gelatine, ethyl cellulose or hydroxyl propyl methyl 
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cellulose (Jyothi et al., 2010).  Since most nutrients are sensitive to heat, oxygen, water or 
another physical process, low moisture and high temperature are needed to control and kill 
harmful organisms to aid in extending shelf-life. Therefore, preserving the beneficial 
structures and nutrients of a functional ingredient is important for bioavailability (Onwulata, 
2011).  
Encapsulation also offers targeted delivery and controlled release of nutrients. For 
example, delivery of probiotic bacteria in dairy products has been difficult because of the 
high die-off rate during long-term storage. Types of preparation and protection methods 
must be carefully selected to protect the live bacteria and ensure successful delivery. 
Coating material must be maintained and well tolerated due to environmental stress such as 
acidity and gastric condition in the digestive process (Amin et al., 2013). A fundamental 
understanding of the physical and chemical factors of the core and coating material will 
facilitate the delivery system to the desired site (Augustin et al., 2013).  
4.12.2 Capsule-in-capsule technology 
Capsule-in-capsule technology is a biphasic delivery system suitable for combination or dual 
release products. It is achieved by placing a smaller pre-filled capsule into a larger filled 
capsule. The content of the inner capsule can be in the form of liquid, semi-solid, powder or 
pellets; whereas the outer capsule can only be either a liquid or semi-solid formulation.  
 
Figure 4.3 . Examples of various fills of capsule-in-capsule technology: liquid/liquid; liquid/semi-solid; 
liquid/beads (Rao et al., 2013) 
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This single dosage can deliver 2 different types of substances, released at different times in 
different regions of the GI tract. It is easy to achieve multiple release profiles by using an 
appropriate coating and modifying the release formulation in the outer or inner capsule 
(Rao et al., 2013). For instance, with an enteric coating, the capsule is capable of surviving 
through the low pH in the stomach, upper or lower intestinal tract and delivery to the colon 
to meet target release profile optimising site delivery (Capsugel, 2013). This method is 
suitable for both pharmaceutical and nutraceutical industries.  
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5.1 Epigenetics 
Epigenetics is the study of heritable changes in gene expression that does not involve 
changes to the underlying DNA sequence — a change in phenotype without a change in 
genotype. 
5.1.1 The epigenetic mechanism 
5.1.1.1 DNA methylation 
DNA methylation is essential for cell development and stabilising cell function. It is a DNA 
modification which involves a biochemical addition of a methyl group (CH3) to the 5th carbon 
position of cytosine-phosphate-guanosine (CpG) dinucleotides via the DNA 
methyltransferase (DNMT) enzyme (Choi & Friso, 2010). The purpose of DNA methylation is 
to silence the gene and therefore reduce gene expression; this may be the default state of a 
gene (Zeisel, 2009).  
5.1.1.2 Histone modification 
In contrast to DNA which can only be modified by methylation, there are 6 types of histone 
modification include methylation, acetylation, phosphorylation, biotinylation, sumoylation 
and ADP-ribosylation (Choi and Friso, 2010). However, the functional interaction between 
DNA and histones are modulated mainly by methylation and acetylation. Histones are a 
family of basic proteins which are tightly wrapped around by DNA to prevent transcription. 
When histone is modified by methylation or acetylation, it changes the structure of histone 
protein by adding a methyl or acetyl group to it and exposes the DNA attached to it. This 
creates space through the DNA strands to facilitate transcription factors (Zeisel, 2009). The 
histone acetylation status is maintained by histone acetyltransferase (HAT) and histone 
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deacetylase (HDAC). Histone methylation status is balanced by histone methyltransferases 
and histone demethylase. A study has shown that inhibiting HDAC could repress silenced 
genes in cancer cells. Therefore certain bioactive food components have been investigated 
to determine whether they could act as HDAC inhibitors.  
          Sulforaphane from broccoli and sprouts, diallyl sulphide from garlic and butyrate from 
fibre have all shown association with HDAC inhibitory effects (Choi & Friso, 2010). Histone 
acetylation is also highly associated with inflammation; HDAC regulates proinflammatory 
and anti-inflammatory genes in disease such as cancer.  
5.1.1.3 MicroRNA 
MicroRNA (miRNA) are small non-coding RNA that regulate gene expression by translational 
repression. They play an important role in controlling DNA methylation and histone 
modification (Choi & Friso, 2010).  
          mRNA function via base-pairing with complementary sequences of mRNA; therefore, 
mRNA is silenced because they can no longer be translated into proteins by ribosomes as 
ribosomes are blocked. Aberrant expression of miRNA has shown a positive association with 
development or progression in numerous diseases including cancer by altering cell 
proliferation and apoptosis processes. 
5.1.2 Nutrients in epigenetics 
The epigenetic mechanism is exceptionally important in the nutritional field because food 
and nutrient components are not only able to affect enzymes directly in the system, they 
are also capable of modifying gene expression at the transcriptional level (Choi & Friso, 
2010).  
Chapter 5                                                          Epigenetics, Functional Foods and the Mediterranean Diet 
 
94 
 
 
 
          Maternal diets affect foetal development changing epigenetic marks. A maternal diet 
which is high in choline during pregnancy has been shown to result in changes in gene 
expression that control brain development in the foetus. Choline deficiency during 
pregnancy is associated with a significant and irreversible change in hippocampal function of 
the foetus; and long-term potentiation and altered memory in their adulthood. Therefore, it 
is critical to obtain an adequate amount of choline during pregnancy as it can cause lifelong 
changes in brain structure and function by altering epigenetic marking (Zeisel, 2009).  
5.1.2.1 Nutritional epigenomics.  
Alteration in the process of gene expression can result from epigenetic changes rather than 
a change in DNA sequence.   Nutrients are involved in epigenetic changes that can alter and 
modify the intracellular signalling pathways (García-Segura, Pérez-Andrade & Miranda-Ríos, 
2013). 
5.1.2.2 Molecular targets for bioactive food ingredients  
Bioactive food ingredients and components function to maintain normal cellular activity, 
affect the neoplastic transition of normal cells to cancerous cells, and alter the biological 
behaviour of the neoplasm. The responses to dietary compounds that have a role in 
preventing cancer may be related to the diversity of the enzymes being processed and 
modified (Elsamanoudy et al., 2016). 
Garlic is associated with autoactivation of CYP2E1 but does not affect other CYP450 
isozymes by the same mechanism.  Genetic polymorphisms in the regulatory regions of the 
genes of metabolising 
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the total response to the bioactive food constituents (Yang et al., 2007). Food components 
could modify the neoplastic progression as well as apoptosis (Meeran, 2002) 
 Key points in the cell cycle are regulated by different protein kinase complexes that are 
composed of cyclin and cyclin-dependent kinase molecules. These key cell cycle points are 
also affected by combined dietary components. It has been proved that dietary factors, 
either essential or non-essential, can adjust and modify the cell cycle checkpoints, and 
consequently have a role in reducing the progression and proliferation of a tumour (Meera, 
2008).  
Apigenin (celery, parsley), curcumin (turmeric), epigallocatechin-3-gallate (green tea), 
resveratrol (red grape and berries), genistein (soybean), and allyl sulfur (garlic) have been 
reported to affect the cell cycle by different mechanisms (Elsamanoudy et al., 2016). Some 
bioactive dietary components may also enhance apoptosis by stimulating the free radical 
formation of reactive oxygen/nitrogen species in the cell (Kim, Yim & Chung, 2008). 
5.1.3 Epigenetics response to diet  
DNA methylation patterns have been shown to be influenced by the intake of 
multiple and combined food ingredients such as vitamin A and zinc; even nonessential 
dietary components may have a role (Ross, 2003).  Methyl-deficient diets could lead to an 
evident alteration in the methylation patterns observed in the process of transformation of 
normal cells to cancerous cells (Fang et al., 2007). It is reported that genistein and related 
soy isoflavones through their possible direct regulatory effect on DNA methyltransferase 
enzyme can reactivate methylation-silenced genes. Genistein is a phytoestrogen compound 
of the isoflavone class that is found in plants and has a structure similar to estrogen. 
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Dietary cholesterol performs an inhibitory effect on the transcription of hydroxymethyl-
glutaryl-CoA reductase gene. Dietary polyunsaturated fatty acids repress mRNA production 
of fatty acid synthase in hepatocytes by decreasing mRNA for lipogenic enzymes. This 
process depends on the degree of unsaturation of fatty acids (Leu & Schmidt, 2008).   
5.1.3.1 Resveratrol 
Resveratrol, is a bioactive component in red grape skins and novel potent activator 
of Sirt1, has an anti-inflammatory effect against colitis and colitis-associated colon cancer 
(Cui et al., 2010; Sanchez-Fidalgo et al., 2010). The anti-inflammatory effect of resveratrol is 
conveyed through the inhibitory effects of iNOS, COX-2, and NF-kB (Youn et al., 2009). It has 
been suggested that histone acetylation by activated NF-kB can be repressed by resveratrol. 
Resveratrol has also been shown to inhibit HDAC. Altered enzyme activity by this compound 
may affect physiological and pathological processes during our lifetime by altering gene 
expression. 
Other possible beneficial properties in various pathologies include CVD, type 2 diabetes 
mellitus (T2DM), neurodegenerative disorders and rheumatoid arthritis (Choo et al., 2014; 
Trotta et al., 2015, 2016; Banu et al., 2016).  These benefits are largely ascribed to the 
polyphenol components of these products. Resveratrol exists as two isoforms, cis-
resveratrol and trans-resveratrol. The latter isoform being more biologically active than its 
cis counterpart (Calabrese et al., 2010; Artero et al., 2015). 
5.1.3.2 Nattokinase 
Nattokinase (NK) is a serine protease purified and extracted from natto, a traditional 
Japanese food produced from the fermentation of soybeans with the bacterium, Bacillus 
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subtilis (natto). NK can break down blood clots by directly hydrolysing fibrin, and plasmin 
substrate converts endogenous prourokinase to urokinase (uPA), degrades PAI-1 
(plasminogen activator inhibitor-1), and also increases tissue plasminogen activator (t-PA) 
which supports fibrinolytic activity (Yatagai et al., 2008). 
 Unlike common fibrinolytic proteases, such as t-PA and uPA, which can produce various 
side effects such as bleeding, NK exhibits little to no side effects. Studies also indicate that 
an oral administration of NK can be absorbed by the intestinal tract (Fujita et al., 2011).   
Human trials have demonstrated that NK provides support to the circulatory system by 
thinning the blood and dissolving blood clots (Jensen et al., 2016).  
The effects of NK are similar to the well-known blood thinner, aspirin (Jang et al., 2013). 
Studies also indicate that NK can ameliorate other diseases such as hypertension (Fujita et 
al., 2011), stroke (Chang, 2008), Alzheimer’s disease (Fadl et al., 2013) and atherosclerosis 
(Dogné et al., 2006).  
5.1.3.3 Serratiopeptidase 
Serratiopeptidase or serrapeptase is an enzyme isolated from the non-pathogenic 
enterobacteria Serratia E15 found in silkworms.  It is widely used to combat various kinds of 
inflammation and inflammatory disorders (Jadav et al., 2010). It also plays a vital role in the 
management of atherosclerosis as it possesses fibrinolytic and caseinolytic properties 
(Bhagat et al., 2013).  
Serratiopeptidase was reported to have a direct effect on the movement of immune 
cells and recruitment of other lymphocytes at the site of inflammation (Chappi, Suresh & 
Patil, 2015).  Serratiopeptidase reduces capillary permeability induced by histamine, 
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bradykinin, and serotonin; breaks down abnormal exudates and proteins; facilitates the 
absorption of decomposed products through blood and lymphatics (Nakamuera et al., 
2003).  The clinical use of serratiopeptidase during allergic conditions was shown to reduce 
the viscosity of mucous and improve the elimination of it through bronchopulmonary 
secretions (Klein & Kullich, 2000).  
5.1.3.4  Oats  
Oats (Avena sativa L.) are a commonly consumed wholegrain cereal and contains 
many kinds of phytochemicals that possess antioxidant properties, such as tocotrienols, 
phenolic acids, flavonoids, sterols, and phytic acid (Peterson, 2001). Oats avenanthramides 
(OA), which are unique to oats, are regarded as key phytoalexins in the defence mechanisms 
of oats against certain pathogens (Miyagawa et al. 1995). Recent research shows that OA 
exhibits excellent antioxidant activities both in vitro (Bratt et al., 2003) and in vivo (Ji et al., 
2003). 
5.1.4 Epigenetic Control in disease 
5.1.4.1 Epigenetics in obesity 
The information from exposure to environmental influences during embryogenesis 
and early development is thought to be stored in our epigenome as an archive, and may 
affect health and disease states in adulthood (Bramswig & Kaestner, 2012). Environmental 
influences such as food intake contribute towards obesity, which also plays a major role in 
several pathogenesis of diseases including diabetes.  
 
 
Chapter 5                                                          Epigenetics, Functional Foods and the Mediterranean Diet 
 
99 
 
5.1.4.2 Epigenetics in cardiovascular disease 
DNA methylation patterns can result in permanent phenotype changes in blood 
pressure.  These alterations of gene expression are reversible through dietary compounds to 
reduce risk without any harmful effects. Curcumin, a type of polyphenols found in the spice 
turmeric, has been shown to inhibit HAT activity. In a study using an animal model, 
consumption of 50mg/kg/day of curcumin inhibited p300HAT activity, which leads to 
ventricular hypertrophy prevention and preserved systolic function (Ordovas & Smith, 
2010).  
5.2 Epigenetics of the Mediterranean diet 
Epidemiological and clinical studies have established the health benefits of the 
Mediterranean diet, which is associated with a lower incidence of atherosclerosis, 
cardiovascular diseases, some types of cancer, and overall mortality (Corella & Ordovas, 
2014).  
The Mediterranean diet is largely vegetarian; olives and olive oil derived from the 
olive tree are important components. Olive oil consumption has been associated with a 
decreased risk of cardiovascular disease and certain cancers (Toledo et al., 2015).  
It is now well-established that, in olives and extra virgin olive oil (EVOO), not only the 
monounsaturated fatty acid constituents but also the minor phenolic components and other 
phytochemicals have important health benefits (Lou-Bonafonte, 2012).  In vivo and in vitro 
studies have shown that EVOO components have positive effects on metabolic parameters, 
such as plasma lipoproteins, oxidative damage, inflammatory markers, pro-thrombotic 
markers, platelet function, and antimicrobial activity (Konstantinidou et al., 2013). The 
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Mediterranean Diet was able to reduce the levels of established biomarkers of inflammation 
and resulted in a trend toward normalising the microbiota in Crohn’s disease patients 
(Marlow et al., 2013).  
  The replacement of saturated fatty acids (SFA) with monounsaturated fatty acids 
(MUFA) may improve health, by reducing metabolic stress and oxidative phosphorylation 
activity in peripheral blood mononuclear cells (PBMC). The MUFA diet also changed the 
expression of genes involved in B-cell receptor signalling and endocytosis signalling (Dijk et 
al., 2012).  The Mediterranean diet may have additional antiatherogenic effects by lowering 
proinflammatory plasma proteins (Lou-Bonafonte et al., 2015).  
A Mediterranean diet high in olive oil may reduce the risk of non-alcoholic fatty liver 
disease progression to non-alcoholic steatohepatitis (Moral et al., 2015).   A diet with high 
amounts of olive and fish oils together with butter induced 72 genes and inhibited 180 
genes related to lipolysis or lipogenesis (Eletto et al., 2005). The Mediterranean diet with 
virgin olive oil elicited changes in 241 genes. The most prevalent differentially expressed 
pathways were related to atherosclerosis and hypertension (i.e., ADRB2, IL7R, IFN-gamma, 
MCP1, TNFalpha) and were often associated with an improvement in systemic markers for 
oxidation and inflammation (Castaner et al., 2013).  
 
5.2.1 Influence of monounsaturated fatty acids 
The inclusion of refined olive oil leads to a more anti-inflammatory gene expression 
profile (Van Dijk et al., 2009). Thus, the replacement of dietary saturated fat with a 
Chapter 5                                                          Epigenetics, Functional Foods and the Mediterranean Diet 
 
101 
 
monounsaturated fatty acid diet could prevent adipose tissue inflammation and may reduce 
the risk of inflammation-related diseases (Van Dijk et al., 2009)  
Fish oil consumption decreased gene expression in pathways related to 
mitochondrial physiology and insulin synthesis/secretion, slowed tumour growth and 
increased survival rates in mice with tumours (Lloyd et al., 2013). This suggests the type of 
dietary fat consumed may be important for controlling tumour progression. The fatty acid 
composition of diets modified gene expression patterns of adipocytes, PBMC, coronary 
artery smooth muscle, and human prostate cancer cells. The inclusion of MUFA from olive 
oil led to a lower expression of inflammatory genes and, consequently, to a less atherogenic 
profile, and tumour progression was controlled when compared to other sources of fat. 
Supplementation with either olive oil, eicosapentaenoic acid (EPA), or 
docosahexaenoic acid (DHA) on gene expression significantly affected gene expression in 
the following pathways: (1) interferon signalling, (2) receptor recognition of bacteria and 
viruses, (3) G protein signalling, glycolysis, and glycolytic shunting, (4) S-adenosyl-l-
methionine biosynthesis, and cyclic adenosine monophosphate (cAMP)-mediated signaling 
including cAMP responsive element protein 1 (CREB1), as well as many other individual 
genes, such as hypoxia inducible factor 1 alpha subunit(HIF1A) (Tsunoda et al., 2015). EPA 
supplementation was associated with significant effects on gene expression involving the 
interferon pathway, as well as downregulation of CREB1 and HIF1A, which may relate to its 
beneficial effect on cardiovascular risk reduction. 
5.2.2 Influence of Olive Oil enriched in phenolic compounds 
Olive oil phenolic compounds differentially expressed genes that seemed to be involved in 
inflammatory processes mediated by transcription factor NF-kappaB, activator protein-1 
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transcription factor complex AP-1, cytokines, mitogen-activated protein kinases (MAPK), or 
arachidonic acid pathways which were repressed by phenolic compounds, thereby switching 
the activity of PBMC to a less deleterious inflammatory profile (Camargo et al., 2010).  
  Phenolic compounds modulate levels of mRNA and miRNA which play a role in 
metabolism, inflammation, and cancer. These results indicate that changes in gene 
expression are part of the postprandial protective action of olive oil consumption and 
phenolic compounds exert an influence (D’Amore et al., 2016).  These studies indicate that 
the consumption of virgin olive oil with phenolic compounds, either in a postprandial 
regimen or over a relatively short period, influences the expression of genes related to 
atherosclerosis development and progression, and that this effect is observed at the 
moderate doses consumed in this dietary pattern.  
5.2.2.1. Influence of EVOO isolated phenolic compound extracts 
In bone-marrow mesenchymal stem cells, oleuropein was found to upregulate the 
expression of 60% of adipogenesis-repressed genes (Casado-Diaz et al., 2017). 
 Hydroxytyrosol, the main phenolic compound in minor constituents of olive oil, has been 
shown to be a potent antioxidant and has anti-atherogenic and anti-cancer properties which 
result in the upregulation of numerous antioxidant proteins and enzymes, including heme 
oxygenase-1, glutaredoxin, and glutathione peroxidase. This may account for the reduction 
in oxidative stress and suggests a mechanism for the chemoprevention of cancer by 
hydroxytyrosol. Alteration in the expression of transcription factors such as STAT3, STAT6, 
SMAD7, and ETS-1 may also contribute to anti-cancer and anti-inflammatory effects. 
Furthermore, the downregulation of the telomerase reverse transcriptase subunit, observed 
in the erythroleukemic cell line K562 treated with this compound (Rafehi et al., 2012). 
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Together with changes in the complement system, the Warburg effect, and chromatin 
remodeling, are other candidate genes involved in the prevention of cancer by 
hydroxytyrosol (Nan et al., 2014).  These studies provide evidence that tyrosol and 
hydroxytyrosol can control growth, oxidative stress, and differentiation in different 
experimental models. 
5.3 Summary 
The link between epigenetics and nutrition is an evolving area which has not been 
extensively researched or well understood. However, the epidemiological evidence of the 
importance of diet, nutrition and health is well accepted. Nutritionally complex diets such as 
the Mediterranean diet confers population-level health benefits and provided the  
inspiration and focus for the pathway analysis in this study. 
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Chapter 6 
Genomic pathway analysis of functional foods and their interaction with 
immune response and disease pathways. 
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6.1   Introduction and Aims of the study 
The purpose of this study was to assess the epigenetic potential of key nutitional elements of 
the Mediteranean diet; Resveratol, Flavanoids and Omega 3 fatty acids (EPA & DHA). An 
assessment of their impact on different regulatory mechanisms including development, 
immune response, metabolic processing and disease using a pathway analysis approach. 
Aims: 
§ Identify genes associated with biological and disease processes identified from the 
systematic review to be important dietary responses to nutrition. 
§ Perform pathway analysis of candidate genes for diet-related diseases to determine 
major gene ontology processes associated with these conditions. 
§ Address biological pathways associated with gene expression changes linked to 
functional foods identified from the literature as being beneficial for cognitive health, 
immune function and preventing CVD to identify potential common regulatory 
mechanisms important for nutritional health. 
§ Compare gene sets associated with functional foods to those identified from genome-
wide association studies (GWAS) for common diseases and biological functions to 
identify potential overlap which may have therapeutic implications. 
 
6.2 Pathway analysis of genes implicated in diet-associated chronic diseases identifies 
immune response and developmental pathways 
CVD, diabetes, body composition and weight were identified as major phenotypic outcomes 
associated with dietary composition from our systematic review of the literature. To address 
biological processes associated with these phenotypic outcomes pathway analysis was 
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performed using candidate genes for each of these conditions. Gene lists for CVD, obesity and 
diabesity were downloaded from Bar Harbor BioTechnology expression array systems. CVD 
genes were overlaid with those identified from association studies and/or animal studies to 
be involved in cardiovascular pathologies, accessed from: 
http://tcm.zju.edu.cn/chd/download.   
Pathway analysis of biological processes relating to the gene sets was performed using the 
publicly available PANTHER Classification System software. Gene lists were parsed into the 
Gene List Analysis tool and analysed using the Functional Classification method and Statistical 
overrepresentation test (Mi et al., 2013). 
Candidate genes for CVD were enriched for developmental and immune response 
pathways relating to angiogenesis (the formation of new blood vessels from existing ones) 
and inflammation mediated by chemokine and cytokine signalling, respectively (Figure 6.1). 
Like CVD, analysis of pathways associated with genes implicated in diabesity also identified 
developmental and immune response pathways as well as G-protein signalling to be 
important (Figure 6.2). Enrichment analysis of gene sets for CVD and diabesity was therefore 
performed to identify overlapping pathways for these diet-related conditions. This identified 
signalling along the insulin/IGF-1 (insulin-like growth factor)-protein kinase B (PKB) Cascade 
as a significant pathway (Figure 6.3). 
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Figure 6.1 Gene ontology pathways associated with candidate genes for cardiovascular disease (CVD). Genes 
were analysed using the functional classification tool through the PANTHER pathway analysis software. A total 
of 53 pathways were identified using this method. Pathways with 4 or more target genes from the uploaded 
gene list are displayed. The gene list was enriched for factors implicated in immune response and developmental 
pathways. * Factors and signalling pathways were shown to be involved in the induction or modulation of 
angiogenesis. Abbreviations: CCKR, cholecystokinin receptor; EGF, Epidermal growth factor; FGF, fibroblast 
growth factor; GNRHR, Gonadotropin-releasing hormone receptor; IGF, insulin-like growth factor; PDGF, 
Platelet-derived growth factor; PKB, protein kinase B; VEGF, Vascular endothelial growth factor. 
phosphatidylinositol-3; PKB, protein kinase B; TRHR, Thyrotropin-releasing hormone receptor; VEGF, 
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Figure 6.2 Gene ontology pathways associated with obesity and diabesity candidate genes. Genes were 
analysed using the functional classification tool through the PANTHER pathway analysis software. A total of 85 
pathways were identified using this method. Pathways with 10 or more target genes from the uploaded gene 
list are displayed. The gene list was enriched for factors implicated in immune response, developmental and G-
protein signalling pathways. Abbreviations: CCKR, cholecystokinin receptor; EGF, Epidermal growth factor; FGF, 
fibroblast growth factor; GNRHR, Gonadotropin-releasing hormone receptor; HIF, Hypoxia-inducible Factor; IGF, 
insulin-like growth factor; MAP, mitogen-activated protein kinase; PDGF, Platelet-derived growth factor; PI3, 
Vascular endothelial growth factor; 5HT2, 5-hydroxytryptamine receptor 2.  Figures are p-values.        
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The peptide hormone, insulin, and growth factor, IGF-1, play important roles in several 
biological processes including regulation of metabolism and cell growth, survival and 
maintenance through activation of common signalling pathways within the cell (Taniguchi et 
al., 2006), see Figure 6.4. Certain functional foods, such as those rich in polyphenols (found in 
large quantities in fruit, vegetables, tea extracts, red wine, coffee and chocolate) have been 
shown to act upon the insulin/IGF-1 pathway and may protect against chronic diseases 
including CVD and cancer (Stoclet et al., 2004, Pandey and Rizvi, 2009, Manach et al., 2005). 
Extracts of strawberry, wild blueberry and cranberry have been shown to activate important 
downstream signalling cascades within this regulatory pathway (Figure 6.4), influencing both 
cell migration and angiogenesis (Tulio et al., 2012); important biological processes in age-
related and disease-related vascular repair and wound healing (Kolluru et al., 2012). 
Polyphenols from black tea extracts have been shown to mimic the effects of insulin/IGF-1 
signalling within the cell by activating the longevity-associated gene FKHR/FOXO1a (Cameron 
et al., 2008). Whereas soy and tomato products have been reported to counteract the 
tumour-promoting activity of IGF-1 in prostate cancer cells, inhibiting cell growth and 
proliferation and inducing apoptosis (Wang et al., 2003), Figure 6.4. Collectively these findings 
suggest that polyphenol-rich foods which target insulin-signalling within the cell may have 
therapeutic potential in the treatment of chronic diseases, supporting their role as ‘functional 
foods’.  
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Figure 6.3 Enrichment analysis of statistically significant pathways associated with cardiovascular disease 
(CVD), obesity and diabesity. Statistical overrepresentation testing was performed using the binomial statistics 
tool available through PANTHER to compare classifications of gene lists for CVD, obesity and diabesity. Uploaded 
gene lists were compared to a reference list containing all human genes within the PANTHER database to 
statistically determine over- or under-representation of PANTHER classification categories using the binomial 
distribution test (Cho and Campbell, 2000). The analysis was performed using the PANTHER GO-slim Pathway 
annotation dataset, and Bonferroni correction was applied to correct for multiple testing. The gene list was 
enriched for factors implicated in developmental pathways involving insulin/IGF signalling, outlined in Figure 
6.4.  
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Figure 6.4 Insulin/IGF pathway-protein kinase B (PKB/AKT) signalling cascade pathway map for genes 
associated with cardiovascular disease, diabesity and obesity. The insulin receptor (INSR), insulin-like growth 
factor receptor (IGF-R) and insulin-receptor-related receptor (IRR) are a family of cell surface proteins which 
bind insulin and insulin-like growth factor (IGF). They are involved in regulating tissue homeostasis, metabolism 
and cellular processes including cell growth, proliferation and survival. All of these receptors are structurally 
similar and utilise common downstream signalling cascades, including the phosphatidylinositol-3-kinase (PI3-
K)/PKB (Akt) pathway illustrated in the above schematic. Dysregulation of this pathway has been implicated in 
several pathologies including cancer, neurodegenerative diseases and metabolic disorders. Dietary compounds 
can regulate different components of the insulin/IGF pathway to promote health. Foods listed in red and blue 
respectively mark downregulation and upregulation of pathway components. Uploaded genes involved in 
insulin/IGF signalling are highlighted in bright yellow and include: AKT/PKB, FKHR/FOXO1a, GSK3B, IGF1R, INSR, 
IRS1-2-4, PDPK1, PIK3, PTEN, TSC1/2. Pathway map modified from PANTHER (http://pantherdb.org/). 
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6.3  Enrichment analysis of genes implicated in neurogenesis identified overlapping 
pathways with CVD and diabetes. 
Diet has also been associated with cognitive function and neurogenesis (the generation 
of new neurons), an important process involved in learning and memory (Deng et al., 
2010, Cameron & Glover, 2015). Calorie restriction and certain functional foods such as 
omega-3, flavonoids and resveratrol have been shown to promote neurogenesis (Gomez-
Pinilla, 2008, Mattson, 2005, Mattson, 2008, Greenwood & Parasuraman, 2010, Stangl 
and Thuret, 2009, Beltz et al., 2007, Crupi et al., 2013). The antioxidant properties of 
calorie restriction and these bioactive compounds are believed to support neurogenesis 
by protecting new neurons from cellular damage which is associated with normal ageing 
and disease pathways (Prior, 2003).  
Comparative enrichment analysis was performed using candidate genes for 
neurogenesis against those implicated in CVD and diabesity to identify common biological 
pathways which may be modulated in response to diet. Angiogenesis, important in 
cardiovascular health and disease, and hormonal signalling along the cholecystokinin 
receptor (CCKR) and gonadotropin-releasing hormone receptor (GnRHR) pathways were 
identified as significant pathways (p<0.05) implicated in CVD, diabesity and neurogenesis, 
Figure 6.5. The CCKR and GnRHR signalling pathways are associated with eating patterns 
and reproductive health and disease, respectively (Gibbs et al., 1973, Kissileff et al., 1981, 
Smith et al., 1981, Skorupskaite et al., 2014). Disruption of these hormonal pathways has 
been implicated in a number of common pathological conditions including obesity, cancer 
and neurodegenerative diseases (de Krom et al., 2007, DiVall et al., 2015, Cheung & Wong, 
2008, Nuruddin et al., 2014, Mazurek & Beal, 1991, Hays & Paul, 1982, Geibel et al., 2014, 
Baldwin & Shulkes, 2007). Alzheimer’s and Huntington’s disease were identified as 
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common disease pathways enriched for genes associated with neurogenesis and CVD, 
whereas developmental EGF-receptor signalling was identified as a common pathway 
amongst genes implicated in neurogenesis and diabesity (Figure 6.5). Axon guidance 
mediated by Slit/Robo was identified as the most significant pathway enriched for genes 
involved in neurogenesis along with Notch signalling and TGF-signalling, Figure 6.5.    
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Figure 6.5 Enrichment analysis of statistically significant pathways associated with neurogenesis. Statistical 
overrepresentation testing was performed using the binomial statistics tool available through PANTHER to 
identify pathway classifications for genes associated with neurogenesis. Uploaded genes were compared to a 
reference list containing all human genes within the PANTHER database to statistically determine over- or under-
representation of PANTHER classification categories using the binomial distribution test (Cho and Campbell, 
2000). The analysis was performed using the PANTHER Pathway annotation dataset, and Bonferroni correction 
was applied to correct for multiple testing. The gene list was enriched for factors implicated in developmental 
pathways. CVD, Db and CVD/Db indicate that the corresponding pathways are also statistically enriched for 
genes implicated in cardiovascular disease, diabesity or both. * Fold enrichment only reached statistical 
significance for the neurogenesis gene set. Abbreviations: CCKR, cholecystokinin receptor; CVD, cardiovascular 
disease; Db, diabesity; EGF, Epidermal growth factor; GNRHR, Gonadotropin-releasing hormone receptor; TGF, 
transforming growth factor. 
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6.4 Determining regulatory pathways affected by the functional foods omega-3, 
flavonoids and resveratrol 
Pathway analysis of genes associated with CVD, diabesity and neurogenesis, highlighted 
from the systematic review of the literature to be the major phenotypic outcomes of diet, 
identified processes relevant to development, immune response pathways and 
neurodegeneration to be important. Functional food components such as omega-3, 
flavonoids and resveratrol are well publicised for their beneficial effects on health and 
wellbeing. To explore the potential effects of these functional food components on modifying 
biological systems, human microarray data relating to gene expression changes following 
dietary intervention with these bioactive compounds were downloaded from the publicly 
available ArrayExpress database. Studies included in the pathway analysis are detailed in 
Table 6.1. Datasets for each study were analysed using the GEO2R function; an interactive 
web tool that allows users to compare two or more groups of samples that are publicly 
available in the Gene Expression Omnibus (GEO) repository of microarray data (Davis & 
Meltzer, 2007). It provides a simple interface that enables ‘R’ statistical analyses to be 
performed without command line expertise. This allowed for analysis of differential gene 
expression changes within the same individuals at baseline (control group) and following 
treatment intervention (treatment group). 
The total number of significant gene expression changes across different studies for 
each of the treatment conditions addressed were 3,638 for omega-3 (mean: 1,213; range: 
542 - 1,827), 2,960 for flavonoids (mean: 1,480; range: 915 – 2,045) and 3,704 for resveratrol 
(mean: 925; range: 555 – 1,424). Statistical significance of the overlap between the gene lists 
was determined using R.  
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Table 6.1 
 
Treatment 
 
 
ArrayExpress  
ID 
 
 
Study description 
 
 
Study cohort 
 
 
Supplementation description 
 
 
Array ID 
 
 
Citation 
Omega-3 
E-GEOD-48368 Gene expression profile of 
PBMCs after intake of fish oil   
for seven weeks 
n=17 healthy subjects Fish oil capsules providing a daily intake of     
1.6 g EPA/DHA (0.7 g EPA; 0.9 g DHA) 
Illumina HumanHT-12 
V4.0 expression 
beadchip array 
- 
E-GEOD-12375 Gene expression profile of 
PBMCs after intake of fish oil   
for six months 
n=23 healthy elderly 
subjects (≥ 65 years) 
Fish oil capsules providing a daily intake of 
1.8g EPA/DHA (1,093 ± 17 mg EPA; 847 ± 23 
mg DHA) 
NuGO human 
Hs1a520180 array 
(Bouwens et al., 2009) 
E-GEOD-20114 Gene expression profile of 
PBMCs after DHA 
supplementation for 90 days 
n=4 hypertriglyceridemic 
but otherwise healthy men 
DHA oil capsules providing a daily intake of 
3 g DHA and 0 g EPA 
Affymetrix GeneChip 
Human Genome U133 
Plus 2.0 array 
(Dawson et al., 2012) 
Flavonoids 
E-GEOD-13899 Gene expression profile of 
monocytes after quercetin 
supplementation for 2 weeks 
n=4 healthy subjects Capsules providing a daily intake of 150 mg 
quercetin (naturally occurring polyphenol 
of   the flavonoid subclass flavonols) 
Affymetrix GeneChip 
Human Genome U133 
Plus 2.0 array 
(Boomgaarden et al., 2010) 
E-GEOD-34145 Gene expression profile of 
PBMCs following dietary 
intake of anthocyanins for 8 
weeks 
n=3 overweight female 
subjects 
Daily consumption of bilberry puree and 
dried bilberries equivalent of 400 g fresh 
bilberries (contain the highest levels of 
polyphenols, particular anthocyanins of the 
flavonoid subclass flavanols, amongst the 
commonly consumed berries). Other 
sources of carbohydrates in the subjects’ 
diet were substituted with the provided 
bilberry products. 
Illumina Human-6 v2 
Expression BeadChip 
(Kolehmainen et al., 2012) 
Resveratrol 
E-GEOD-42432 Gene expression profile of 
adipose tissue following 30 
days resveratrol 
supplementation  
n=9 obese but otherwise 
healthy male subjects  
Double-blind randomised crossover study; 
daily intake of placebo and 150 mg/day 
resveratrol [99% resVida] with a 4-week 
washout period in between 
Affymetrix Human Gene 
1.1 ST Array [HuGene-
1_1-st] 
(Konings et al., 2014) 
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Table 6.1 
 
Treatment 
 
 
ArrayExpress  
ID 
 
 
Study description 
 
 
Study cohort 
 
 
Supplementation description 
 
 
Array ID 
 
 
Citation 
E-GEOD-41168 Gene expression profile of 
adipose tissue following 12 
weeks resveratrol 
supplementation  
n=13 healthy, 
postmenopausal female 
subjects 
Daily supplementation with 75 mg/day 
resveratrol  
Affymetrix GeneChip 
Human Genome U133 
Plus 2.0 Array 
- 
Resveratrol 
E-GEOD-41168 Gene expression profile of 
skeletal muscle (vastus 
lateralis) following 12 weeks 
resveratrol supplementation  
n=9 healthy, 
postmenopausal female 
subjects 
Daily supplementation with 75 mg/day 
resveratrol  
Affymetrix GeneChip 
Human Genome U133 
Plus 2.0 Array 
- 
E-GEOD-32357 Gene expression profile of 
skeletal muscle (vastus 
lateralis) following 30 days of 
resveratrol supplementation  
n=10 obese but otherwise 
healthy male subjects  
Double-blind randomised crossover study; 
daily intake of placebo and 150 mg/day 
resveratrol [99% resVida] with a 4-week 
washout period in between 
Affymetrix Human Gene 
1.1 ST Array [HuGene-
1_1-st]  
(Timmers et al., 2011) 
 
Table 6.1 Microarray study descriptions included in the pathway analysis 
Note: Gene expression changes were analysed in the same individuals using baseline measurements verses treatment interventionunless stated otherwise. 
Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; PBMCs, peripheral blood mononuclear cells.hypergeometric distribution test phyper. Significant 
overlap was observed between the gene sets for omega-3 and flavonoids (p = 4.67 x 10-25) and flavonoids and resveratrol (p = 0.015) but not for omega-3 and resveratrol (p 
= 0.624), Figure 6.6. A total of 141 genes were common across the three treatment groups. Analysis of this gene list using the overrepresentation function in PANTHER 
identified flavin biosynthesis (p = 0.02), p53 pathway by glucose deprivation (p = 0.01), Notch signaling (p= 0.03), interleukin signaling (p= 0.03), apoptosis signaling (p = 0.04), 
angiogenesis (p = 0.02) and Alzheimer’s disease (presenilin pathway, p= 0.05) as the most enriched pathways, Figure 6.6. To establish a more manageable number of genes 
for pathway analysis, the datasets were filtered using the following criteria: 1) Select genes that are common across two or more studies for the same treatment condition 
and/or 2) Select genes that have a fold change of more than 1.6 between the control and treatment groups. This resulted in 505 genes for omega-3, 571 genes for flavonoids 
and 307 genes for resveratrol. To define potential regulatory mechanisms which may be operating in response to omega-3, flavonoids and resveratrol, we parsed the gene 
expression data into IPA, an integrated data-mining platform for biological pathway analysis. Enrichment analysis was performed using the Core Analysis function which 
provides an overview of biological relationships, mechanisms, functions and pathways relating to the uploaded dataset based on log fold changes in gene expression. The 
gene lists were also analysed using PANTHER. The top canonical pathways associated with the dietary interventions tested are listed in Figure 6.7. Intervention with omega-
3 enriched for genes implicated in T cell signalling and hypoxia; flavonoids  activated  B  cell signalling and  resveratrol. 
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Figure 6.6 Enrichment analysis of overlapping gene sets associated with dietary interventions with 
omega-3, flavonoids and resveratrol. Gene expression data were downloaded from ArrayExpress 
(https://www.ebi.ac.uk/arrayexpress/). Studies included in the analysis are detailed in Table 6.1. 
Significant gene expression changes are represented as a Venn diagram showing treatment-specific 
and overlapping profiles across the three dietary interventions. Overlapping gene sets (omega-3 and 
flavonoids; omega-3 and resveratrol; flavonoids and resveratrol; all treatments) were subjected to 
statistical overrepresentation testing using PANTHER pathway analysis software. Over-represented 
pathways were determined using the binomial distribution test (Cho & Campbell, 2000). Bold font 
indicates common pathways across the different gene sets. See Figure 6.7 for pathways associated 
with the separate treatment conditions. *Withstood Bonferroni correction for multiple testing. 
Abbreviations: CCKR, cholecystokinin receptor; CRF, Corticotropin releasing factor; JAK/STAT, Janus 
kinase/Signal transducer and activator of transcription; mAChR, Muscarinic acetylcholine receptor; 
PDGF, Platelet-derived growth factor; PKB, protein kinase B; TGF, Transforming growth factor; TRHR, 
Thyrotropin-releasing hormone receptor; 5-HT2, 5-hydroxytryptamine/serotonin. 
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Figure 6.7 Top canonical pathways enriched for genes significantly regulated in response to dietary 
intervention with omega-3, flavonoids and resveratrol. Gene expression data were downloaded from 
ArrayExpress (https://www.ebi.ac.uk/arrayexpress/). Studies included in the analysis are detailed in 
Table 2. Gene sets were filtered to include significant gene expression changes observed in 2 or more 
studies for the same treatment condition and with a fold change of >1.6. These are represented as a 
Venn diagram showing treatment-specific and overlapping gene expression profiles. Each gene set 
was subjected to statistical overrepresentation testing using IPA and PANTHER pathway analysis 
platforms. Bold font indicates common pathways between different intervention groups; * omega-3 
and flavonoids, † omega-3 and resveratrol. Pathways associated with overlapping gene sets (for all 
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significant gene expression changes) are represented in Figure 6.6. Abbreviations: CCKR, 
cholecystokinin receptor; dTMP, deoxythymidine monophosphate; elF4, Eukaryotic Initiation Factor-4; 
GnRHR, Gonadotropin-releasing hormone receptor; HIF, Hypoxia-inducible Factor; iCOS, Inducible 
costimulatory; iCOSL, iCOS ligand; IGF, insulin-like growth factor; Ins(3,4,5,6)P4, D-myo-inositol 
(3,4,5,6)-tetrakisphosphate; MAP, mitogen-activated protein kinase; mTOR, mechanistic target of 
rapamycin; PI3K, phosphatidylinositol-3 kinase; RhoGDI, Rho GDP-dissociation inhibitor; SAPK/JNK, 
Stress-activated protein kinases/Jun amino-terminal kinases.   
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Pathway analysis using IPA indicated overlap between the different treatment 
groups. These were B cell receptor signalling and iCOS-iCOSL signalling in T helper 
cells between the omega-3 and flavonoids treatment groups (Figure 6.8), and 
molecular mechanisms of cancer and G1/S checkpoint regulation between omega-3 
and resveratrol (Figure 6.9). Alanine biosynthesis was also identified as a common 
pathway associated with omega-3 and resveratrol treatment based on statistical 
overrepresentation testing using the Gene List Analysis function in PANTHER.  
Disease mechanisms implicated in immunological diseases and cancer, 
conditions which have been identified from the literature to be targeted by certain 
functional foods (Simopoulos, 2002, Dragan et al., 2007, Shukla & Singh, 2011, Petro, 
2011, Ramos-Romero et al., 2012, Batra & Sharma, 2013, Laviano et al., 2013, 
Tanaka, 2014, Fabian et al., 2015), were overlaid onto the common pathways 
identified from IPA in order to identify potential therapeutic targets for the 
treatment of these pathological conditions (Figures 6.8 and 6.9). Comparative 
analysis was also performed using IPA to identify other common pathways associated 
with all three of the treatment conditions. The top 20 canonical pathways are shown 
in Table 6.2. Again, the overlap between omega-3 and flavonoids (8/20 pathways) 
and omega-3 and resveratrol (3/20 pathways) was observed, with no overlap 
between the flavonoids and resveratrol treatment groups. In addition to the 
overlapping pathways identified in Figure 6.7, there was an enrichment of pathways 
relating to immune response, disease signalling and signal transduction (Table 6.2). 
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Fig 6.8 A 
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Fig 6.8 B 
 
Figure 6.8 Common pathways associated with dietary interventions with omega-3 and flavonoids. 
Significant gene expression changes associated with diets rich in omega-3, flavonoids and resveratrol 
were uploaded into IPA and comparative pathway analysis performed. B cell receptor signalling (A) and 
iCOS-iCOSL signalling in T helper cells (B) were identified as significant pathways common to both the 
omega-3 and flavonoids treatment groups. Red and green nodes represent up- and downregulated 
genes from the uploaded dataset with colour intensity positively correlating with fold change. F, O and 
F/O respectively mark genes regulated in response to flavonoids, omega-3 or both. Nodes outlined in 
purple indicate those associated with immunological disease (A) and cancer (B). Pathway maps modified 
from IPA (http://www.ingenuity.com/). Abbreviations: APC, antigen-presenting cells; ER, endoplasmic 
reticulum. 
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Fig 6.9 A 
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Fig 6.9 B 
 
 
 
Figure 6.9 Common pathways associated with dietary interventions with omega-3 and resveratrol. 
Significant gene expression changes associated with diets rich in omega-3, flavonoids and resveratrol 
were uploaded into IPA and comparative analysis performed. Molecular mechanisms of cancer (A) and 
G1/S checkpoint regulation (B) were identified as significant pathways common to both the omega-3 
and resveratrol treatment groups. Red and green nodes represent up- and downregulated genes from 
the uploaded dataset with colour intensity positively correlating with fold change. O, R and O/R 
respectively mark genes regulated in response to omega-3, resveratrol or both. Nodes outlined in 
purple indicate those associated with cancer (B). Pathway maps modified from IPA 
(http://www.ingenuity.com/).  
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Table 6.2 P-Values for the top 20 common canonical pathways significantly regulated following 
dietary intervention with omega-3, flavonoids and resveratrol 
 
 
 
Note: Functional enrichment analysis for the gene sets differentially regulated by dietary intervention 
with omega-3, flavonoids or resveratrol was performed using IPA software. Statistical significance was 
determined using Fisher’s exact test. Bold font indicates significant pathways (p<0.05). Net effects of 
gene expression changes on pathway activation or repression were determined using activation z-scores 
(threshold, <-2.0; >2.0). ↓ Downregulated pathways; ↑ upregulated pathways. 
  
Functional Group Canonical Pathway Omega-3 Flavonoids Resveratrol 
Cell cycle 
G1/S Checkpoint Regulation 4.19 x 10-3          - 1.31 x 10-2 
CHK Proteins in Cell Cycle Checkpoint Control 3.80 x 10-1 5.02 x 10-2 4.35 x 10-2 
G2/M DNA Damage Checkpoint Regulation 3.27 x 10-1 1.27 x 10-1 6.45 x 10-4 
Developmental 
pathways 
Wnt/β-catenin Signaling 7.56 x 10-3 6.60 x 10-2 ↑ 9.43 x 10-2 
Cardiac β-adrenergic Signaling 9.96 x 10-2 ↑ 6.78 x 10-3 2.94 x 10-1 
Insulin Receptor Signaling 2.17 x 10-1 2.19 x 10-3 2.98 x 10-1 
Disease pathways 
Molecular Mechanisms of Cancer 1.33 x 10-3 3.20 x 10-1 6.34 x 10-3 
Glioma Signaling 2.63 x 10-2 ↓ 1.04 x 10-2 3.93 x 10-1 
Role of NFAT in Cardiac Hypertrophy 2.84 x 10-2 6.01 x 10-3 - 
Immune response 
pathways 
B Cell Receptor Signaling 1.11 x 10-3 4.34 x 10-5 4.59 x 10-1 
iCOS-iCOSL Signaling in T Helper Cells 1.14 x 10-3 1.87 x 10-5 - 
CD28 Signaling in T Helper Cells 2.32 x 10-2 3.10 x 10-3 - 
Fcγ Receptor-mediated Phagocytosis 2.40 x 10-2 2.09 x 10-1 1.06 x 10-2 
PI3K Signaling in B Lymphocytes 1.92 x 10-1 2.24 x 10-5 2.75 x 10-1 
PKCθ Signaling in T Lymphocytes 7.43 x 10-3 1.03 x 10-2 - 
Signal transduction 
Protein Kinase A Signaling 4.53 x 10-2 6.52 x 10-6 - 
PI3K/AKT Signaling 9.44 x 10-3 1.30 x 10-2 - 
3-phosphoinositide Biosynthesis 1.78 x 10-1 2.33 x 10-3 3.91 x 10-1 
mTOR Signaling 2.94 x 10-1 1.04 x 10-3 5.27 x 10-2 
Transcription DNA Methylation and Transcriptional Repression 8.15 x 10-2 9.00 x 10-2 3.24 x 10-2 
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6.5  Disease pathways targeted by the functional foods omega-3, flavonoids and 
resveratrol support a therapeutic role 
To investigate the role of omega-3, flavonoids and resveratrol in the prevention and/or 
treatment of disease, IPA Core Analysis was used to identify the top disease pathways 
and toxicity functions associated with the filtered gene sets for these treatment 
conditions. The net effect of gene expression changes was addressed using z-scores 
which predict an increase (positive z-score) or decrease (negative z-score) in pathway 
activation. Omega-3 was suggested to have anti-viral (decreased viral infection and 
viral replication), anti-tumorigenic (decreased autophagy of colon cancer cell lines and 
differentiation of tumor cells; increased apoptosis of lymphoma cells) and pro-survival 
properties (decreased necrosis and/or cell death of kidney cells and epithelial tissue; 
increased cell viability of fibroblast cell lines), Table 6.4. Flavonoids were strongly 
associated with development (decreased growth failure; increased size of the embryo 
and cell survival/viability) and immune and inflammatory responses (decreased 
chronic inflammatory disorder; the increased immune response of cells and 
phagocytosis, Table 6.4. Resveratrol was enriched for processes involved in cell 
structure (decreased stabilisation of microtubules, microtubule dynamics and 
organisation of cytoplasm and cytoskeleton) and cell cycle (decreased cell cycle 
progression and mitosis), Table 6.5. Common toxicity functions associated with the 
different treatment groups was addressed through comparative enrichment analysis 
which identified processes relevant to cardiovascular, hepatic and renal function 
(Table 6.6). Activation z-scores suggested a beneficial role for omega-3 in reducing 
hypertrophy of the heart and liver cancer, while flavonoids associated with reduced 
inflammation of the liver. 
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   Table 6.3.  Top disease pathways and biological functions enriched for genes significantly regulated following dietary intervention with omega-3 
Note: Functional enrichment analysis was performed using IPA software. Statistical significance was determined using Fisher’s exact test. All pathways reached statistical 
significance (p<0.05). Net effects of gene expression changes on disease pathways and biological functions were determined using activation z-scores (threshold, <-2.0; >2.0). 
Negative values indicate downregulated pathways; positive values upregulated pathways. Molecules represent genes from the uploaded dataset. 
 
Table 6.3.   
 
Disease or Function  
 
 
p-value 
 
 
Activation 
state 
 
 
z-score 
 
 
Molecules 
Necrosis of kidney 1.16 x 10-3 Decreased -2.5 ATF6, ATG7, BNIP3L, CD44, CDC42, GLS, GSK3B, HGF, HIF1A, IER3, IL18, IRF4, KEAP1, MYC, NDEL1, PMAIP1, PPARG, PPP3CA, PSEN1, PTGIS, RASSF4, RHOT1 
Viral Infection 3.13 x 10-3 Decreased -2.4 
ACVR2A, ALOX5, APOC1, AQR, ATG7, ATRX, CAMK1, CD40LG, CD44, CD80, CDC42, CHMP2B, COPB2, 
CRTC3, CTSB, CYP2U1, DLG1, FBXO44, GAB2, GAS6, GRB2, GSK3B, HGF, HNRNPM, IER3, IL10RA, 
IL18, IMPDH1, IRF4, ISG20L2, LAMP2, MAT2A, MDM2, MED14, MED27, MKNK1, MLH1, MSR1, MYC, 
NDUFAF2, OPN1SW, PDE4B, PDE4D, PDE5A, PIGK, PKD1L2, POU2F2, PPARG, PPP1R8, PPP3CA, 
PSMA1, PTPRJ, PVR, RNF10, RPS5, SF3A1, SFXN3, SMARCA2, SMU1, SMURF1, SNRPA1, SNX10, 
SPG7, SYNJ1, TMPRSS2, TMPRSS4, TNFSF14, TRIM25, TUBB4B, TUBG1, YY1, ZC3H12A, ZNF292 
Cell death of kidney cells 1.46 x 10-3 Decreased -2.2 ATF6, ATG7, BNIP3L, CD44, CDC42, GLS, GSK3B, HGF, HIF1A, IER3, IRF4, KEAP1, MYC, NDEL1, PMAIP1, PPARG, PPP3CA, PSEN1, PTGIS, RASSF4, RHOT1 
Contractility of cardiac muscle 4.26 x 10-4 Decreased -2.2 ARSB, ATE1, BTC, COX7A1, GAB2, HBEGF, IER3, IL18, LAMP2, MTMR14, PDLIM5, PLN 
Hypertrophy 6.11 x 10-4 Decreased -2.2 CDK9, CTSB, CYP1B1, EHD4, GRB2, GSK3B, GUCY2C, HBEGF, HGF, HIF1A, IER3, IL18, IL6ST, MBNL1, MDM2, MYC, NFATC3, OSM, PDE5A, PPARG, PPP3CA, PTEN, PTGIS, RHEB, SKP2, SRC, STK3, TPPP2 
Replication of virus 3.37 x 10-4 Decreased -2.1 
ACVR2A, ATG7, ATRX, CD40LG, CDC42, COPB2, CYP2U1, DLG1, FBXO44, GAS6, GSK3B, HNRNPM, 
IL10RA, IL18, LAMP2, MDM2, MED14, MED27, MKNK1, MLH1, MSR1, MYC, OPN1SW, PPP1R8, 
PSMA1, RPS5, SF3A1, SMU1, SMURF1, SNX10, TMPRSS2, TRIM25, ZC3H12A 
Necrosis of epithelial tissue 2.91 x 10-3 Decreased -2.1 
AIFM1, ARHGAP18, ATG7, ATRX, BNIP3L, CD40LG, CD44, CDC42, CTSB, FAAH, GAS6, GSK3B, HGF, 
IER3, IL18, IRF4, KEAP1, KLF10, MDM2, MYC, NDEL1, OSM, PMAIP1, PPARG, PSEN1, PTEN, PTGIS, 
RASSF4, SRC, STK3, TNFSF14 
Autophagy of colon cancer cell lines 2.34 x 10-3 Decreased -2.0 ATG7, BNIP3L, MDM2, MYC 
Differentiation of tumour cells 3.01 x 10-3 Decreased -2.0 CD44, GAB2, MYC, OSM, PDE4D, PPARG, PTEN 
Production of lactic acid 4.66 x 10-3 Decreased -2.0 AIFM1, EWSR1, HIF1A, MYC, PTEN 
Apoptosis of lymphoma cells 2.73 x 10-3 Increased 2.0 CD40LG, IL6ST, MS4A1, MYC 
Cell viability of fibroblast cell lines 6.15 x 10-4 Increased 2.1 CDC42, GAS6, GSK3B, HGF, MLH1, MYC, NARFL, OGG1, PDK4, SRC 
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Table 6.4 Top disease pathways and biological functions enriched for genes significantly regulated following dietary intervention with flavonoids 
Note: See Table 6.3 for the legend. 
Table 6.4 
 
Disease or Function  
 
 
p-value 
 
 
Activation 
State 
 
 
z-score 
 
 
Molecules 
Growth Failure 2.83 x 10-3 Decreased -2.2 ATM, B4GALT1, BCL6, CFLAR, CHM, EGR1, ETV6, H3F3A/H3F3B, HFE, HIST1H1C, HIST1H1D, HNRNPD, 
LTBP3, NFAT5, NUMB, PDS5A, PTGES3, PTPN12, RAF1, RBBP6, REV3L, SLC19A1, SMC1A, SNX27, SOD2, 
STK4, SYNJ1, TIA1, TRIM33, TRIP12, UBR2, VDAC3, ZNF148 
Chronic inflammatory disorder 1.45 x 10-3 Decreased -2.2 ADM, ANXA1, ATM, B2M, BCL6, C17orf59, CAMK2D, CD79A, CELF2, CR1, CYBA, DUSP2, EEF1E1, FOXO3, 
FUBP1, GLUL, GPSM3, GZMA, H3F3A/H3F3B, HAVCR2, HLA-DOA, IKZF1, IL16, IL7R, JAK1, KIR3DL2, LRRK2, 
LTB, MYCBP2, NLRP3, NR3C1, NUMB, NXPE3, PDE4B, PDE4C, PDE5A, PSMD1, PTPRC, RGCC, RPS16, 
RSBN1, S1PR3, SELP, SNRNP200, SOCS3, STK17B, TAGAP, TMEM192, TNRC6B, VIM, XIAP 
Immune response of cells 2.98 x 10-5 Increased 2.1 ANXA1, ATM, ATXN3, BCL6, CBL, CD44, CD47, CD48, CD79A, CLEC7A, CLIP1, CR1, CYBA, CYP2S1, ERAP1, 
FPR1, HAVCR2, IL7R, JAK1, KLRB1, LCP2, LGALS3, MAP3K8, MAP4K1, MLST8, MYO1G, NLRX1, NR3C1, 
PFDN6, PRKCB, PTPRC, REL, RGCC, SERPINB9, SLC11A1, SOCS3, TRIM38, VIM 
Size of embryo 4.32 x 10-3 Increased 2.2 ACVR1, CENPU, HES1, HIST1H1C, HIST1H1D, LAMA5, MDM4, MORF4L2, NUMB, PDPK1, RAF1, RAPGEF2, 
RBBP6, REL, REV3L, SLC8A1, SOCS3, STK4, TGS1, TRIM33, UBR2 
Cell survival 8.83 x 10-5 Increased 2.4 ACVR2A, ATM, ATRX, B2M, BCL6, BCLAF1, CA2, CAMK2D, CAMK2G, CBL, CD44, CD47, CD48, CD79A, 
CFLAR, CR1, CTDSPL, CYBA, DDX3X, DHX9, EGR1, EIF4G1, EMP1, ETV6, EWSR1, FBXO9, FOXO3, HBB, HELB, 
HES1, IGF2BP3, IL7R, IQGAP1, JAK1, KDM4B, LAMA5, LGALS3, LRRK2, MAP3K8, MBP, MDM4, MICAL2, 
mir-21, MTMR6, NFAT5, NR3C1, NT5C3A, NUPL1, PDPK1, PFDN6, PPP2R2A, PPP2R5C, PRKCB, PTGDR2, 
PTPRC, PTPRE, RAF1, REL, REV3L, RSF1, S1PR3, SERPINB9, SLC11A1, SLC19A1, SLC22A3, SMC1A, SMC3, 
SOCS3, SOD2, SPN, TRIM33, VIM, VKORC1, XIAP 
Cell viability 2.31 x 10-4 Increased 2.5 ACVR2A, ATM, ATRX, B2M, BCL6, BCLAF1, CA2, CAMK2D, CAMK2G, CBL, CD44, CD47, CD48, CD79A, 
CFLAR, CR1, CTDSPL, CYBA, DHX9, EGR1, EIF4G1, ETV6, EWSR1, FBXO9, FOXO3, HBB, HELB, IGF2BP3, IL7R, 
IQGAP1, JAK1, KDM4B, LAMA5, LGALS3, LRRK2, MAP3K8, MBP, MDM4, MICAL2, mir-21, MTMR6, NFAT5, 
NR3C1, NT5C3A, NUPL1, PDPK1, PFDN6, PPP2R2A, PPP2R5C, PRKCB, PTGDR2, PTPRC, PTPRE, RAF1, REL, 
REV3L, RSF1, S1PR3, SERPINB9, SLC19A1, SLC22A3, SMC3, SOCS3, SOD2, SPN, TRIM33, VKORC1, XIAP 
Phagocytosis 1.14 x 10-4 Increased 3.1 ANXA1, CBL, CD163, CD44, CD47, CD48, CLEC7A, CLIP1, CR1, CYBA, CYP2S1, DLG1, EPG5, ERAP1, FPR1, 
IQGAP1, LGALS3, MAP1S, MYO1G, NR3C1, PRKCB, PTPRC, RGCC, SLC11A1, SYNJ1, SYNJ2BP, VIM, ZFYVE16 
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Table 6.5. Top disease pathways and biological functions enriched for genes significantly regulated following dietary intervention with resveratrol Note: See Table 6.3 
for legend. 
 
Disease or Function  p-value Activation 
State 
z-score Molecules 
Organization of cytoplasm 3.43 x10-3 Decreased -2.5 AURKA, BCL6, BMP2K, CASP6, CD44, CIT, DRD1, EPHA5, EPHA8, GRK5, HTR6, IFT57, IQGAP1, 
KIF3B, METRN, MTFR2, NEU3, NEUROD1, ONECUT2, PI4K2B, PIP5K1A, PLK1, POU3F2, PRC1, 
RACGAP1, RHOJ, RYR2, TACC3, TESK2, TMEM135, TRPV2 
Organization of cytoskeleton 5.98 x10-3 Decreased -2.5 AURKA, BCL6, BMP2K, CASP6, CD44, CIT, DRD1, EPHA5, EPHA8, GRK5, HTR6, IFT57, IQGAP1, 
KIF3B, METRN, NEU3, NEUROD1, ONECUT2, PI4K2B, PIP5K1A, POU3F2, PRC1, RACGAP1, RHOJ, 
RYR2, TACC3, TESK2, TRPV2 
Microtubule dynamics 4.66 x10-3 Decreased -2.4 AURKA, BMP2K, CASP6, CD44, CIT, DRD1, EPHA8, GRK5, HTR6, IFT57, IQGAP1, KIF3B, METRN, 
NEU3, NEUROD1, ONECUT2, PI4K2B, PIP5K1A, POU3F2, PRC1, RACGAP1, RYR2, TACC3, TESK2, 
TRPV2 
Cell cycle progression 8.42 x10-6 Decreased -2.2 ADARB1, AURKA, BCL6, CALCB, CASC5, CASP6, CCND3, CD44, CDKN3, CIT, GRK5, GYPA, HECW2, 
HERC5, IL11, IRS2, KDM2B, MDM2, MXD1, NEUROD1, NUCKS1, PLK1, PPARA, RACGAP1, RLIM, 
SGOL1, TACC3, TP63, ZBTB16, ZNF274 
Mitosis 1.06 x10-2 Decreased -2.2 AURKA, CASC5, CDKN3, CIT, GYPA, IL11, IRS2, MDM2, PLK1, PPARA, RACGAP1, SGOL1 
Stabilization of microtubules 1.20 x10-2 Decreased -2.0 BMP2K, IQGAP1, PI4K2B, TESK2 
Insulin sensitivity 1.08 x10-2 Increased 2.2 CALCB, CD44, GCGR, IRS2, PPARA 
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Table 6.6 Top 20 common toxicity functions associated with dietary intervention with omega-3, 
flavonoids and resveratrol 
 
 
 
 
Note: Functional enrichment analysis for the gene sets differentially regulated by dietary intervention 
with omega-3, flavonoids or resveratrol was performed using IPA software. Statistical significance was 
determined using Fisher’s exact test. Bold font indicates significant toxicity functions (p<0.05). Net effects 
of gene expression changes on toxicity functions were determined using activation z-scores (threshold, <-
2.0; >2.0). ↓ Downregulated processes; ↑ upregulated processes. 
Biological System Toxicity function Omega-3 Flavonoids Resveratrol 
 Cell death of cardiomyocytes 3.41 x 10-2 4.01 x 10-3 3.80 x 10-1 
 Failure of heart 1.53 x 10-1 6.88 x 10-3 4.68 x 10-2 
Cardiovascular Hypertrophy of cardiac muscle 6.93 x 10-5 ↓ 1.47 x 10-1 2.03 x 10-1 
 Hypertrophy of cardiomyocytes 2.45 x 10-3 ↓ 1.59 x 10-1 3.74 x 10-1 
 Hypertrophy of heart 9.34 x 10-4 ↓ 4.65 x 10-1 3.11 x 10-1 
 Apoptosis of hepatocytes 2.09 x 10-2 ↓ 6.95 x 10-2 3.67 x 10-1 
 Cell death of liver cells 2.64 x 10-3 1.09 x 10-2 3.21 x 10-1 
 Hepatic steatosis (fatty liver) 2.15 x 10-4 1.74 x 10-1 6.56 x 10-2 
 Advanced stage hepatic steatosis 7.00 x 10-2 7.40 x 10-2 2.68 x 10-2 
Hepatic Hepatomegaly (enlargement of the liver) 3.96 x 10-3          - 1.75 x 10-1 
 Steatohepatitis (fatty liver disease) 3.13 x 10-3 4.00 x 10-3 3.17 x 10-1 
 Inflammation of liver 6.00 x 10-2 5.39 x 10-3 ↓ 8.35 x 10-2 
 Liver cancer 1.53 x 10-3 ↓ 1.91 x 10-5 8.69 x 10-2 
 Hepatocellular carcinoma 1.18 x 10-3 ↓ 2.67 x 10-5 6.87 x 10-2 
 Tumorigenesis of hepatocellular carcinoma 2.34 x 10-2 1.40 x 10-1 2.10 x 10-1 
 Proliferation of hepatocytes 6.99 x 10-4 4.16 x 10-1 4.46 x 10-1 
 Apoptosis of kidney cell lines 1.54 x 10-2 4.54 x 10-3 4.52 x 10-1 
Renal IgA nephropathy (inflammation of the glomeruli) 3.41 x 10-2 1.75 x 10-1 2.98 x 10-2 
 Increased quantity of creatinine 3.01 x 10-4 6.32 x 10-1 4.82 x 10-2 
Haematopoietic Increased quantity of red blood cells 8.86 x 10-2 1.29 x 10-2 2.25 x 10-1 
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6.6  Functional foods target biological processes and disease pathways identified 
from GWAS   
To further address how omega-3, flavonoids and resveratrol may converge onto 
major disease pathways, gene expression changes associated with these functional 
foods were compared against GWAS hits for different biological functions and 
diseases. Reported genome-wide associated genes for ageing, breast cancer, 
cognitive function, CVD, diabesity, neurodegeneration and psychiatric disorders 
were downloaded from the NHGRI-EBI GWAS catalog, a publicly available collection 
of published GWAS for more than 100,000 single-nucleotide polymorphisms (SNPs) 
with SNP-trait associations of p<1 × 10-5 (Welter et al., 2014). Hypergeometric 
distribution testing using the GeneOverlap package in R was used to determine the 
significant overlap between the GWAS datasets and genes associated with dietary 
interventions with omega-3, flavonoids and resveratrol. As illustrated in Figure 
6.10A, significant overlap was observed between the two lists representing genes 
regulated in response to omega-3 and those implicated in breast cancer risk from 
GWAS (p = 0.01). A total of 32 genes were identified as being common between the 
two gene lists.  These were uploaded into the PANTHER pathway analysis platform 
and overrepresentation testing performed. Enrichment of genes implicated in 
metabolic processes (Figure 6.10B) and developmental pathways (Figure 6.10C) was 
identified as being significantly associated with this gene set. No other significant 
associations were found between gene lists for the functional foods and 
diseases/biological functions tested. 
The odds ratio analysis in Figure 6.10A, illustrates the significant benefit afforded by 
Omega 3 in breast cancer with a p-value of 0.01.     
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Fig 6.10 A 
 
 
 
 
 
 
 
 
 
 
 
Fig 6.10 B 
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Fig 6.10 C 
 
 
Figure 6.10 Significance testing of overlap between genes regulated in response to functional foods 
and GWAS hits for common diseases/biological functions.  
(A) Gene lists representing all genes significantly regulated in response to dietary interventions with 
omega-3, flavonoids and resveratrol (see Table 6.1 for study details) were compared against gene lists 
identified from genome-wide association studies for ageing, breast cancer, cognition, cardiovascular 
disease (CVD), diabesity, neurodegeneration and psychiatric disorders. Numbers in brackets represent 
the number of genes within each gene list. GeneOverlap and GeneOverlapMatrix functions available 
in R were used to calculate and visualise significant overlap between the gene lists tested. Fischer’s 
exact test was used to calculate p-values which are stated within each panel of the grid. Colour key 
represents odds ratio values. *Significant overlap (p<0.05). B-C, Statistical overrepresentation testing 
was performed using the binomial statistics tool available through PANTHER to identify biological 
processes (B) and pathway classifications (C) for common genes associated with breast cancer and 
dietary intervention with omega-3. Uploaded genes were compared to a reference list containing all 
human genes within the PANTHER database to statistically determine over- or under-representation 
of PANTHER classification categories using the binomial distribution test (Cho & Campbell, 2000). 
Associated genes are listed on the right of the bar charts. Abbreviations: EGF, Epidermal growth factor; 
FGF, fibroblast growth factor; Flav., flavonoids; HIF, hypoxia-inducible factor; IGF, insulin-like growth 
factor; mGluR, metabotropic glutamate receptor, Nb, nucleobase; PDGF, platelet-derived growth 
factor; PKB, protein kinase B; Resv., resveratrol.   
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6.7 Summary 
Dietary intervention with the functional foods omega-3, flavonoids and resveratrol 
target important biological and disease pathways, suggesting a potentially 
important role for these bioactive compounds in the prevention and treatment of 
dietary-related disease such as cancer. 
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7.1 Consumer acceptance of Functional Foods.  
7.1.1 Demographics 
The functional food market can be classified into four key target audiences, figure 
7.1.  “Undecideds” who make up the majority of the market (43%) are unsure 
whether functional food and drink improve health; this group are most likely to 
disagree that natural foods are just as beneficial as functional foods at promoting 
health effects (Mintel, 2011).  “Health Buffs” (20%) are likely to have noticed health 
improvements in their health due to functional food consumption however 
commonly purchases food with added health benefits; this group would purchase 
further products if convinced of the health claim.  “Sprightly Cynics” (24%) are 
people who already consume a healthy diet so don’t believe incorporating 
functional foods into their diet would benefit their health; this group are also very 
sceptical of the health claims made, and believe that these products are overpriced; 
this target group is mainly made up of 65+ males.  Lastly, the “Impassives” (13%) 
are least likely to have noticed an improvement in health after functional food 
consumption and are the least likely of all groups to purchase foods which promise 
a functional health benefit.   
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Figure 7.1 Functional Food Target Audiences 
7.1.1.1 Ageing population 
In 2011, 9.2million (16%) residents in England and Wales were aged 65+, an 
increase of almost 1 million from 2001.  The UK population is estimated to rise to 
more than 73 million by 2037 (The Office for National Statistics, 2013). The elderly 
have specific nutritional requirements due to their altered physiology.  
Furthermore, the composition and activity of their intestinal microbiota differ from 
younger adults, and their immune function is less efficient.  Their nutritional needs 
offer the functional food industry a niche market to target due to their specific 
dietary requirements (Ratts et al, 2008). 
          Globally, there is a seven-year gap between life expectancy and healthy life 
expectancy (Euromonitor International, 2013).  To reduce this substantial 
difference, the ageing population could be targeted with foods that benefit the 
following areas identified with significant potential: cardiovascular health, bone and 
joint health, brain health, memory and vision (Cowland, 2014).   
Sprightly 
Cynics, 24%
Health Buffs, 
20%
Impassives, 
13%
Undecideds, 
43%
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          Despite functional foods aimed at the ageing population being a niche market, 
this demographic can help invigorate growth in the functional food market through 
greater awareness of health benefits, higher disposable income and a desire to live 
longer in better health.  This will help open up a market estimated to be worth 
$20.6bn.  Despite over 577 million consumers globally, sitting in the elderly 
demographic (aged 65+) they remain extremely under-catered for (Cowland, 2014). 
          It is possible to assess the interest and ability of potential consumers in 
specific geographical locations.  This is achieved by correlating per capita spend on 
food and drink with per capita spend on functional food and drink in the same area 
(Cowland, 2014).  In addition to this, the demographics of these regions are mainly 
ageing populations. Functional foods aimed at the ageing or the elderly are under 
catered for, providing an opportunity for market growth.  The current products 
available are minimal with limited use of functional ingredients, The elderly and the 
ageing are particularly susceptible to malnutrition; therefore nutritional 
management is a niche market for functional food manufacturers.   
          Nutricia provide a product portfolio developed to address enhancement of 
nutrition to improve lifestyle changes and diseases.  For example, the product 
‘FortiFit’ is designed to stimulate the rebuilding of muscle to improve muscle 
strength and function for those suffering from sarcopenia, due to its leucine 
enriched amino acid mixture.  The product ‘Souvenaid’ is clinically proven to help 
improve memory for those in the early stage of Alzheimer's disease.  ‘Nutilis’ is an 
effective product for sufferers of dysphagia allowing adequate nutrition and 
hydration. Additionally, it includes amylase-resistant features for safer swallowing.   
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7.1.1.2 Younger generation 
Young adults aged 25-34 are considered the key demographic group that will drive 
functional food and drink sales (Canadean Ltd, 2013). In recent studies, the 
consensus is that the younger generation is a key demographic for the market as 
they are more likely than the elderly to have increased their annual purchases of 
functional foods (Mintel, 2011).  However, three-quarters of consumers believe 
that functional foods are overpriced indicating a key barrier to market growth, a 
factor which is likely to deter young consumers.  
           40% of young consumers are familiar with the functional food concept, 27% 
of them are regular buyers purchasing functional dairy products (Markovina et al, 
2011).  More than half the candidates (51.8%) in the study would purchase 
functional foods in the future.  Female consumers aged 19-30 with higher 
disposable incomes will be a considerable target audience in the future (Markovina 
et al, 2011). Young adults have a general acceptance of functional foods and are 
more price sensitive than the elderly consumers (Mitsunori, 2012).   
          The functional food market at present is directly aimed at female consumers 
over 45 (Mintel, 2011).  Younger consumers and males in particular, are under 
catered for and could be the focus of new product innovation and marketing 
activity.  Younger consumers could lead the market to substantial growth. This 
potential market could be targeted by manufacturers conveying greater lifetime 
value to the benefits that consuming functional foods can provide.   
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7.1.1.3 Income levels 
Higher disposable income increases purchasing power and allows consumers to be 
more adventurous by increasing their propensity to purchase foods with functional 
health improvement benefit.  Global annual disposable income per household by 
the end of 2014 reached 1.2%, a considerable growth from the 0.4% recorded in 
2013 and the 0.3% in 2012 (Euromonitor International, 2014).  This growth is a 
reflection of improved economic performance and a lower unemployment rate, 
which has dropped to 6.9% in the UK (BBC C, 2014). 
          Functional foods often carry a price premium compared to standard 
alternatives, with products costing up to eight times more.  Higher disposable 
incomes allow consumers to afford the higher price premiums associated with 
functional foods.  However, as incomes increase, more economically developed 
countries spend less on food and more on materialistic items.  For example, South 
Koreans spent 33% of their income on food in 1975, but with increased wages and 
economic development, this has reduced to just 12% in 2014 (Plumer, 2014). 
However, an increase in economic prosperity is not necessarily associated with an 
increase in the quality of health in the population as seen in the global increase of 
NCDs. 
          The functional food market has also continued to expand despite economic 
downturns demonstrating that demand is growing; however, the commercial 
failure rate of products is significantly higher than other food sectors.  This indicates 
that despite price premiums, consumers still retain a propensity to purchase if the 
health benefit has been scientifically validated and focuses on a health impediment 
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that affects the consumer.  UK income levels are sufficient for consumers to buy 
functional foods. However, decisions to purchase will not occur unless the product 
in question meets intrinsic consumer needs and will likely result in commercial 
product failure. 
7.1.1.4   Reduced scepticism 
Customer scepticism is a key challenge for the functional food market. 
Comprehensive regulations governing the functional food market have challenged 
the alleged ‘exaggerated’ claims made on some functional food products and have 
established greater consumer confidence.  The rigorous process in which functional 
foods claims are accredited could be leveraged more effectively into marketing 
communications (Mintel, 2011).  This would illustrate to customers how functional 
foods are laboriously tested and have their scientific claims verified by the EFSA 
under the ‘regulation 1924/2006 on nutrition and health claims made on ‘food to 
warrant a health claim’. 
          Consumers remain sceptical about health claims, this is reflected in the results 
of a Mintel survey where 65% of functional food users place more trust in naturally 
sourced foods such as fruit and vegetables than in functional foods. This is partly 
due to accessibility, affordability and familiarity of fruit and vegetables which are 
natural and unprocessed, unlike many functional foods.  However, this distrust is 
mitigated when the health benefits claimed are validated by scientific evidence 
(Mintel, 2011). 
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7.1.2 Commercial challenges  
An online survey recorded the views and opinions towards functional food from 
1,005 Americans (The International Food Information Council, 2013). The 
information recorded, identified the following reasons that frequent functional 
food consumption is not achieved; price, purity, taste and lack of knowledge.  In 
addition to this, regulation governing the functional food industry limits innovation, 
development and launches.   
 
  
Figure 7.2 Adverse Effects Preventing Sales of Functional foods.
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You do not know enough about how…
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If you don't understand some aspect…
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7.1.2.1   Price 
The greatest barrier to consumption of functional foods more frequently is price 
(International Food Information Council, 2013).  Figure 7.2 shows that 55% of subjects claim 
that the higher price charged compared to standard versions is a major reason for 
preventing purchase.  Similarly, 32% state that it is a minor reason.  Overall this is the 
greatest factor affecting sales of functional foods.   
        The functional food market is afflicted by a damaging level of consumer scepticism.  
52% of consumers believe that health claims are merely an excuse for manufacturers to 
charge a price premium; if doubts are not addressed by the industry, then consumers could 
become non-users (Mintel B, 2011).  The price premium is a considerable barrier for the 
functional food market with 75% believing that functional foods are overpriced.  The 
sensitivity to price can be related to economic downturn and low disposable income but is 
also strongly influenced by consumer scepticism (Mintel B, 2011).  The premium price 
premium is a common deterrent across all age and social groups but most common in the 
45-54 age groups.  Interestingly it is not just low-income consumers, i.e. those on salaries of 
between £15,500 and £24,999 that believe functional foods are overpriced, those earning 
£50,000+ are equally likely to agree.  The purchase of functional foods is not just affected by 
the financial affordability of the product, but also whether the consumer believes they are 
receiving value for money.  The ability of product to deliver the benefits of stated claims 
promptly, can be an essential element in providing consumer satisfaction with the product.  
Despite this, a later study by Mintel (2014), stated that 41% of consumers believe “it’s worth 
paying more for added benefits, e.g. vitamins and minerals”. 
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          The price of functional foods exacerbates consumer suspicion; a study found that 75% 
believe they are over-priced suggesting reluctance to pay regardless of the improved health 
benefits (Mintel,2011).  Consumers are focused on receiving value for money on all 
purchases.  Greater trust in product efficacy would make it easier for producers to justify 
the premium. 
          Despite the premium in this sector, sales continue to grow. The consensus from the 
general public is that despite higher product cost, when health claims are supported by 
scientific evidence, then the premium price is considered acceptable (Mintel, 2014). 
7.1.2.2 Taste 
The competing demand for taste and health is a significant barrier to the food industry. 
Consumer food choices are driven primarily by the demands of taste, cost, and convenience; 
however, the major determinant of food selection is taste. Foods that are bitter, acrid or 
astringent tend to be rejected by the consumer. The instinctive rejection of bitter taste may 
not be modifiable because it is a key mechanism for survival (Drewnowski & Gomez-
Carneros, 2000). 
          Bitter taste is the main reason for the rejection of food products.  The bitterness of 
cruciferous vegetables is repeatedly linked to their low acceptance.  However, not all foods 
which have bitter characteristics are a deterrent.  In selected foods and beverages, a certain 
degree of bitterness is expected, e.g. caffeine or alcohol in coffee, beer, and wine 
(Drewnowski & Gomez-Carneros, 2000). Many functional ingredients are compounds 
derived from whole ingredients therefore when consumed within the inherent source are 
tasteless, but when extracted have a pungent flavour.  For example, Stevia leaves in high 
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concentrations can impart a bitter aftertaste that is similar to liquorice or aniseed and many 
find this taste unpleasant.    
          The inclusion and fortification of foods to enhance health represents a major market 
within the food industry; foods which are tailored to contain increased concentrations of 
phytonutrients often have a less than a favourable aftertaste.  Despite the primary function 
of food to provide nutrients, its secondary function concerns sensory attributes such as 
taste and flavour. For the most part, plant-based phytochemicals are bitter and therefore 
aversive to the consumer (Drewnowski & Gomez-Carneros, 2000).  The discovery of a family 
of ≥50 different bitter-taste receptors confirms the importance of sensitivity to bitter taste 
was to evolution and survival. Plant-based ingredients present several challenges with 
sensory qualities having the greatest impact upon food choice; functional food 
manufacturers however also have to balance the taste aspect with health, texture, 
appearance and cost.   
          To bridge the gap between functional products and original versions, manufacturers 
need to improve on the taste and flavour of products; consumers are continually demanding 
and taste should not be a sacrifice consumers have to make when purchasing functional 
food.  Also, consumers are not willing to compromise taste for functionality.  Only 9% of 
consumers will accept a functional food concept if the product tastes worse than the 
conventional counterpart (Saarela, 2011).   
7. 2   Consumer acceptance of personal genetic services 
The application of genotype-based personalised nutrition could potentially 
revolutionise health promotion, healthcare and the food industry. If accepted, genomic-based 
personalised nutrition could directly affect consumer food choice as health will become the 
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driving factor in food selection (German & Watkins, 2004). Conceptually, nutritional genomics 
is still in its infancy, and it is unclear how this rapidly developing science will be accepted by 
society (Castle & Ries, 2007; Ronteltap, van Trijp and Renes, 2007; Moskowitz, German and 
Saguy, 2005). Studies have investigated the attitudes, knowledge and the interest of people 
in genetic testing within the US and European countries. However few have focused on the 
concept of genomic-based personalised nutrition within the UK population.  
7.2.1   Previous research 
Previous research (Table 7.1) indicates that genetic testing, the basis of genomic-based 
nutrition, faces many ethical and moral hurdles including an increase in knowledge towards 
the topic to gain mainstream consumer acceptance. Genetic testing within the American 
population is viewed positively when the information allows individuals to gain control over 
their health alongside disease prevention (Rose et al., 2005; Catz et al., 2005).  Concerns 
around confidentiality, potential misuse of samples and information abuse by employers and 
insurers resulting in discrimination based on genotype were all expressed by UK consumers 
(Castle, 2007; Petersen, 2005; Skirton et al., 2005). Similar concerns were also reported within 
the US population regarding the privacy of genetic testing (Rose at al., 2005; Catz et al., 2005). 
A large population study indicated that 21% of consumers within the US were unwilling to 
undergo any form of genetic testing (Wang et al., 2001). In the Netherlands, more positive 
attitudes towards genetic testing were reported, particularly among individuals who were 
convinced of the benefits of adapting lifestyle based on their genotype (Henneman and 
Timmermans, 2006). Similarly, a study in the Netherlands found positive attitudes toward 
genetic testing among individuals who were younger and had a higher level of education and 
those with chronic disease (Morren et al., 2007).  
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          Studies which have focused on genetic testing regarding well-being, health and 
personalised nutrition found similar results. The majority of respondents (66%) in the 
European Union would be willing to undergo genetic testing, and 27% would be willing to 
follow a personalised diet (Stewart-Knox et al., 2008). Another European study focused on 
the perceived risk-benefit trade-off factors which influence consumer adoption of 
personalised nutrition services (Berezowska et al., 2015). It was reported that consumers 
intention to adopt personalised nutrition services depends more on perceived personalisation 
benefit than on perceived privacy risk. A study on the public interest towards internet-based 
personal genome testing reported that only 13% of respondents were aware of nutritional 
genomics (Cherkas et al., 2010). When considering the cost of the service, 5% were willing to 
pay the current price of £250. This figure rose to 50% if the service was free of charge. 
Demographics of age, sex, education, marital status, region of residence, parenthood, college-
education are predictors of increased awareness of genetic testing (Roy et al., 2016). A study 
using an Italian sample reported that consumers who were more health consciousness were 
more aware and accepting towards genetic tests (Oliveri et al., 2016).  
          The benefits and risks of nutritional genomics were identified by members of the public 
and healthcare professionals in Canada (Morin 2009). For the public, the perceived benefits 
of nutrigenomics were as follows; removal of guesswork from nutrition, provision of 
personalised advice, early diagnoses or disease prevention and encouragement of healthier 
habits. For healthcare professionals, nutrigenomics was perceived to generate wider interest 
in nutrition, encourage preventive care, and potentially trigger behavioural change, target 
interventions and may ultimately result in healthcare savings (Morin 2009).   
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Table 7.1 Review of results of previous investigations into the consumer view of 
personalised nutrition, results and policy implications 
 
 
      
Author/ 
Year 
Country Sample size and 
characteristics 
Study 
design 
methodol
ogy 
Outcome 
measures 
Key findings and policy implications 
Fischer et 
al. (2016) 
Europe 9 
countries 
N = 9381 Quota 
sampled Aged 18– 65 
yrs Mixed gender 
On-line 
survey 
Willingness 
to pay for 
PN 
One third of sample willing to pay as much as 50% more for PN Greece were willing to 
pay most and Netherlands willing to pay least, * Regulation to encourage and control 
commercial PN in Greece * Provide incentive for those in Netherlands to take up PN 
Rankin et 
al. (2016) 
United 
Kingdom 
N = 32 Aged 18–65 
Mixed gender 
Focus 
groups 
Theory to 
inform 
design of 
PN 
Social Cognitive Theory (SCT) best fit model to describe the public perception of PN 
Recommend PN services be designed using SCT 
Berezows
ka et al. 
(2015) 
Europe 8 
countries 
N = 9000+ Quota 
sampled Aged 18–65 
yrs 
On-line 
survey 
Willingness 
to pay for 
PN 
Perceived risk associated with data security higher if genetic data considered * Regulate 
handling of genetic data 
Fallaize et 
al. (2015) 
United 
Kingdom 
and 
Ireland 
N = 73 Aged 18–65 
and 30–65 yrs 
Focus 
groups 
Attitudes 
to PN* 
service 
delivery 
Preference for services to be provided by government and delivered face to face. 
Payment was associated with increased commitment and motivation to comply with 
dietary recommendations. UK participants expected PN to be delivered free of charge 
on the NHS * Provide publicly funded PN in addition to commercial services 
Poínhos 
et al. 
(2014) 
Europe 9 
countries 
N = 9381 Quota 
sampled Aged 18–65 
yrs Mixed gender 
On-line 
survey 
Intention 
to adopt 
PN 
Benefit perception most important determinant of attitude toward adoption of PN. 
Nutrition self-efficacy a predictor of attitude and intention to take up PN. Perceived risk 
related to data security had a negative relationship with attitude and an inverse 
relationship with perceived benefit * Promote benefits of PN. * Regulate data handling. 
Berezows
ka et al. 
(2014) 
Europe 8 
countries 
N = 124 Aged 18–65 
yrs Mixed gender 
Focus 
groups 
Attitudes 
to PN 
services 
Face to face interaction was deemed to reduce perceived risk and increase benefit. 
Qualified experts supported by scientific evidence increased value perception * 
Recommend off-line communication with qualified health professionals 
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StewartK
nox et al. 
(2013) 
Europe 9 
countries 
N = 126 Aged 18–65 
and 30–65 yrs Mixed 
gender 
Focus 
groups 
Attitudes 
to PN 
Positive attitudes toward PN. Benefit: control; anonymity Concerns over data 
protection, service provider Barriers: social; motivational * Promote benefits of PN. * 
Regulate data handling. * Policies to enable PN in society 
Sanderso
n et al. 
(2013) 
USA (NY) N = 205 patients 
Aged 18+ yrs Mixed 
gender 
Structure
d 
interview
s 
Determina
nts of 
uptake of 
genomics 
to treat 
dietrelated 
disease 
Reasons for uptake: altruism; benefit to family members; personal health benefit; 
curiosity; and, understanding. Reasons for rejection: negative perception of research; 
not personally relevant; negative about procedures; practical barriers; and, fear of 
results * Promote benefits of PN. * Regulate use of research. * Recommend qualified 
health professionals communicate results 
Wendel 
et al. 
(2013) 
Netherla
nds 
N = 204 Mixed 
gender M age 38–3 
yrs 
Survey Intention 
to receive 
/use PN 
Usefulness of a system valued PN more and enjoyment valued less when a GP provided 
advice than if used out of their own curiosity. Trade-off between perceived risk and 
usefulness * Recommend employment of qualified health professionals 
Pavlidis et 
al. (2012) 
Greece N = 1504 51% female 
Aged < 35 yrs 
Survey Views on 
nutrigeno
mics 
Majority thought that nutrigenomics should only be offered through health 
professionals not directly online Concern about results being interpreted incorrectly * 
Recommend qualified health professionals communicate results 
Su and Lu 
(2012) 
Taiwan N = 258 63% Male Online 
survey 
Acceptanc
e/preferen
ces for 
nutrigeno
mics 
Perceived benefit contributed to the acceptance of PN Hospital service provider 
preferred over direct sale and DIY * Promote benefits of PN. * Provide publicly funded 
PN in addition to commercial services 
Morin 
(2009) 
Canada N = 90 Mixed gender 
Age: n/a 
Focus 
groups – 
discourse 
analysis 
Knowledge 
Attitudes 
to PN 
Early diagnosis could lead to better diet and disease prevention Concern that validity of 
tests was not established a Potential breach of privacy of concern * Fund and regulate 
the use of research in PN. * Regulate data handling 
Ronteltap 
et al. 
(2009) 
Netherla
nds 
N = 438 Mixed 
gender Age 40–60 
yrs 
Evaluatio
n of 
videos of 
PN 
scenarios 
Perception
s and 
acceptance 
of PN 
Public acceptance of PN is enhanced if perceived a personal benefit, a supportive 
environment, and PN advice that can be easily incorporated into the daily routine. PN 
communication is preferred to be delivered by expert stakeholders * Promote benefits 
of PN. * Recommend qualified health professionals communicate results 
Roosen et 
al. (2008) 
Germany N = 452 Mixed 
gender 
Online 
survey 
Attitudes 
to genetic 
45% would agree to a genetic test to receive PN advice * Fund research to encourage 
the inclusion of nutrigenomic analysis in PN 
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profiling 
and PN 
Brug et al. 
(1999) 
Various N = 8 (studies) Literature 
review 
Behaviour 
change 
theory 
(motivatio
n, self-
evaluation, 
agency) 
Computer-tailored communications were more effective than nontailored interventions 
particularly for a reduction in dietary fat intake Difficult to draw firm conclusions given 
the limited number of studies and reliance on self-report data * Policies and research 
funding to enable digital solutions for PN 
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7.2.2   Aims and objectives of the VYPR consumer research study 
The adoption of nutritional genomics within society faces many hurdles until it can be fully 
accepted and understood by the public. The current study intends to provide insight into the 
attitudes and acceptance of the UK population towards genomic-based nutrition, its services 
and activities, with consideration of how demographic factors may influence acceptance. This 
was approached by using a series of questions to ascertain consumer acceptance of genetic 
testing regarding health and wellbeing to elicit a response which can be compared to previous 
literature.  
7.2.2.1   Results 
In total, 8816 survey responses were collected from November 2017 and December 2017. 
Each question released on the VYPR application received a median response of 591±9. The 
study population between each question consisted of males (15-17%) and females (83-85%). 
The distribution of age group varied between questions, consisting of 18-24 (9-10%), 25-24 
(40-42%), 35-44 (30-32%), 45-54 (11-13%) and 55+ (6-7%) respectively, (see table 7.2).  
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 Table 7.2  
Respondent characteristics for each VYPR 
survey 
 
  
 
 
 
 
Sex  
 
 
 
 
Age  
Survey n Male Female 18-24 25-34 35-44 45-54 55+ 
Genetic testing is important for the future of health science 
585 90 (15%) 495 (85%) 53 (9%) 238 (40%) 183 (31%) 79 (13%) 40 (7%) 
I would take a genetic test 
590 87 (15%) 503 (85%) 52 (9%) 244 (41%) 185 (31%) 80 (13%) 37 (6%) 
I would take a genetic test to improve my health 
581 91 (16%) 490 (84%) 57 (10%) 235 (40%) 187 (32%) 74 (13%) 37 (6%) 
Clean label food is important  
580 86 (15%) 494 (85%) 57 (10%) 235 (40%) 181 (31%) 77 (13%) 38 (7%) 
It is important to know what ingredients go into my food 
586 87 (15%) 499 (85%) 57 (10%) 237 (40%) 183 (31%) 79 (13%) 38 (7%) 
Diet can interact with my genetics to affect my health 
586 91 (16%) 495 (84%) 61 (10%) 238 (40%) 182 (31%) 77 (13%) 36 (6%) 
I would like to know if I am genetically at risk of a disease 
579 89 (15%) 490 (85%) 58 (10%) 234 (40%) 184 (31%) 76 (13%) 36 (6%) 
Do you find nutritional genomics (relationship between 
genome, nutrition and health) appealing 583 94 (16%) 489 (84%) 57 (10%) 237 (40%) 189 (32%) 74 (13%) 35 (6%) 
Genetic companies keep all personal information confidential  
566 91 (16%) 475 (84%) 55 (10%) 232 (41%) 180 (31%) 71 (12%) 34 (6%) 
I would take a genetic test for the purpose of personalised 
nutrition 577 91 (16%) 486 (84%) 58 (10%) 236 (40%) 185 (32%) 72 (12%) 33 (6%) 
Genetic tests for health should be free  
571 91 (16%) 480 (84%) 54 (9%) 234 (40%) 184 (32%) 72 (12%) 34 (6%) 
I feel I may have a food related intolerance  
566 92 (16%) 474 (84%) 56 (10%) 232 (40%) 180 (31%) 71 (12%) 34 (6%) 
I am health conscious  
569 95 (17%) 474 (83%) 55 (10%) 240 (42%) 179 (31%) 67 (12%) 34 (6%) 
I would like to know more about my genetics 
570 95 (17%) 475 (83%) 54 (9%) 240 (42%) 182 (32%) 67 (12%) 34 (6%) 
I would like to know more about nutritional genomics 
565 96 (17%) 469 (83%) 54 (9%) 240 (42%) 179 (31%) 64 (11%) 34 (6%) 
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          Respondents results based on demographics are shown in table 7.2 . Percentages in 
table 7.3 show agreement level within the different groups.  Nearly two thirds (62.21%) of 
respondents agreed that genetic testing is important for the future of health science. This is 
supported by previous literature which reported that public interest in genetic testing and 
research was high (Sanderson et al., 2004; Wilde et al., 2009). More males (67.79%) than 
females (60.79%) agreed that genetic testing is important for the future of health science. 
Participants aged 55+ (67.50%) and 18-24 (66.04%) were more likely to agree that genetic 
testing is important for the future of health science whereas those aged 45-54 (56.25%) had 
the lowest agreement percentage of all groups. Just over half (55.11%) of the sample 
population agreed that they would take a genetic test. More males (57.48%) than females 
(53.67%) agreed that they would take a genetic test. The age group most likely to agree to a 
genetic test were those aged 25-34 (58.69%), and the least likely were those aged 45-54 
(43.20%). The number of participants who agreed to take part in genetic testing increased 
when participants were asked if they would take a test to improve their health, with 60.47% 
in agreement. More males (65.94%) than females (58.17%) agreed that they would take a 
genetic test to improve their health. Respondents aged 55+ (67.57%) and 25-34 (62.14%) 
were most likely to agree to take a genetic test to improve their health, whereas respondents 
aged 45-54 (48.01%) were least likely. However, 55.06% of the population agreed that they 
would take a genetic test for personalised nutrition. More females (54.83%) agreed that they 
would take a genetic test for personalised nutrition than males (49.45%). Respondents aged 
25-34 (62.29%) were more willing to take a genetic test for personalised nutrition whereas 
the age group 34-45 (46.19%) were least willing. 
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          Similar studies reported that the younger demographic (18–34 years) were more likely 
to be interested in genetic testing, which also supports the present study’s results which show 
a high acceptance level with those 18-34 years (Haga et al., 2012). Research found that those 
aged 65+ years had the highest indication of willingness to undergo genetic testing for 
personalised nutrition, which also supports the present study’s results which show a high 
acceptance level in individuals aged 55+ years (Stewart-Knox et al., 2008). However, support 
and willingness varied little among demographic groups which suggest that the relationship 
between age and acceptance of genetic testing is complex and may depend on a variety of 
factors such as the area of genetic testing, location and prior knowledge of genetic research 
(Kaufman et al., 2008). 
          The motivation for the adoption of genetic testing has been reported to be due to 
curiosity and intent to find out personal health risks (Gollust et al., 2011). Furthermore, 
willingness to take part in genetic testing had previously been reported to be dependent 
whether the individual results would be returned to the participants (Kaufman et al., 2008). 
Previous studies also show that the subject area of genetic testing strongly influences public 
attitudes (Condit, 2010). The present study reports that when personalised nutrition is added 
as a service to a genetic test, no change in acceptance level occurred, whereas when the 
improvement of health is suggested, a higher number of participants were willing to take a 
genetic test. This may suggest that knowledge may be a deciding factor as the population may 
not be aware of the health benefits of personalised nutrition.  
          The present study found that around half of the population felt that genetic companies 
kept all personal information confidential. Almost half of both the male (49.45%) and female 
(48.85%) population agreed that genetic companies kept their personal information 
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confidential. Those aged 18-24 (39.99%) were more concerned with the privacy policies of 
genetic testing companies; whereas those aged 55+ (64.71%) were least concerned with 
privacy. This is supported by Mählmann et al., (2006) who found privacy-related concerns 
towards personal genomics in adults 60+ years was low. Results from the present study show 
a significant number of individuals are concerned about the security of their data. This is 
supported by previous studies who reported concerns about the sharing of their health data 
without their permission (Haga et al., 2012). When public expectations towards the benefits 
of genetic testing increased, more positive opinions were formed (Henneman et al., 2013). 
Attitudes were influenced by the assessment of the likely validity of genetic test results and 
its personal healthcare utility (Nicholls et al., 2013). Similar concerns were also reported, 
whereby educational needs in regard to the nature of risk/reward, cost, concerns about 
confidentiality of medical-related results, and access to personal genomic information 
affected both acceptance and attitude (Nicholls et al., 2013). The results from the present 
study present possible areas to build public confidence towards genetic testing, opening 
further market opportunities for the application of nutritional genomics.  Similar concerns 
about the sharing of genetic data suggest the need for more transparency from researchers 
and organisations, along with more education and public information about genetic research 
(Lemke et al., 2010).  
          Around three-quarters of respondents (73.48%) agreed that a genetic test should be 
free. More females (73.38%) than males (69.23%) agree that genetic tests should be free. 
More participants aged 55+ (88.24%) and 45-54 (76.72%) agreed that genetic tests should be 
free; whereas participants aged 34-45 (67.22%) had the lowest agreement score. Previous 
studies support these findings reporting that 5% were willing to pay the current price of £250 
for a genetic test whereas when the service was free of charge, this figure rose to 50% 
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(Cherkas et al., 2010).  Cost is a key factor which influenced whether people decided to 
partake in genetic testing in 40% of cases (McGuire et al., 2009). The present study reports 
similar findings, suggesting that to maximise the acceptance of nutritional genomics, price is 
a key factor to consider.  
          Around two thirds (68.33%) of the population agreed that clean label food is important. 
More males (72.10%) than females (67.80%) agreed that clean label food is important. 
Participants aged 55+ (81.58%) had the highest percentage of agreement that clean label food 
is important. This was followed by the age group 25-24 (69.36%), whereas, those aged 18-24 
(64.91%) had the lowest agreement score. Around three-quarters (76.57%) of participants 
agreed that it is important to know what ingredients go into their food. More females 
(78.75%) are in agreement with this statement than males (72.43%). Females may be more 
aware of the content of food, as statistics indicate that women are more responsible than 
men for all or most of the household shopping (68% compared with 32%) respectively (Prior, 
Phillips & O'Driscoll, 2014). Respondents aged 45-54 (82.50%) had the highest percentage of 
agreement score that it is important to know what ingredients go into your food, whereas 
participants aged 18-24 (70.18%) were least in agreement out of all the age groups. The 
results relate to previous studies which show a continuing trend towards food products which 
fall under the so-called “clean label” umbrella (Varela & Fiszman, 2013; Cheung et al., 2016; 
Joppen, 2006; Zink, 1997).  
          When participants were asked if they felt like they had some form of underlying food 
intolerance, 38.69% agreed with this. More females (38.18%) than males (36.95%) felt like 
they may have an underlying food-related intolerance. A higher percentage of respondents 
aged 24-35 (41.82%) felt that they may have underlying food-related intolerance whereas 
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those aged 18-24 (30.36%) had the lowest agreement percentage. Around two-fifths of the 
sample population reported an underlying food intolerance. Together with the overall 
prevalence of food allergies increasing globally, the use of genome anayisis may be of great 
assistance to evaluate the underlying causality relevant to food intolerances. The application 
of nutritional genomics may become of more importance in this area, especially when 
incorporating the previously mentioned “clean label” trend into the well-being aspect of 
health and functional foods (Sicherer & Sampson, 2014; Li, Maggadottir & Hakonarson, 2016). 
          With the present study reporting that 49.32% of the UK population sample agreed that 
they were health conscious and with 60.47% willing to undergo genetic testing to improve 
their health, nutritional genomics may provide a platform to implement more functional 
foods within an individual’s diet. Males (48.42%) and females (47.99%) similarly felt like they 
were health conscious. A greater percentage of 55+ year olds (76.47%) agreed that they were 
health conscious, whereas 18-24 year olds (41.82%) were shown to be the least health 
conscious.  
          Around half (54.32%) of the respondents agree that diet can interact with their genetics 
to affect their health and 51.45% agreed that the science of nutritional genomics was 
appealing. More males (54.95%) than females (51.71%) agreed that diet can interact with 
their genetics to affect their health. Participants aged 55+ (55.56%) had the highest 
agreement percentage towards the statement diet can interact with their genetics to affect 
their health, whereas participants aged 45-54 (48.70%) had the lowest score of the 
agreement. Nutritional genomics appealed to more males (54.26%) than females (49.49%). 
Participants aged 25-34 (56.11%) were more interested in nutritional genomics, whereas 
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participants aged 35-44 (44.15%) had the lowest interest. Knowledge and awareness are also 
important with only 13% of respondents aware of nutritional genomics (Cherkas et al., 2010).  
          Around two thirds (64.99%) of the population would prefer to know if they were 
genetically at risk of disease. Both males (65.17%) and females (64.09%) would like to know 
if they were genetically at risk of disease. Of the age groups, more participants aged 55+ 
(72.22%) preferred to know if they were genetically at risk of a disease, whereas the age group 
45-54 (50.65%) were less likely to want to know. Public views on genetics and genetic testing 
in Belgium reported that respondents expressed moderate interest in predictive genetic 
testing, with 39.1% willing to learn about their predisposition to diseases through genetic 
testing and 49.5% showing interest in getting tested specifically for preventable/treatable 
diseases (Chokoshvili et al., 2017).  
          The present study indicates a greater uptake when asked about the genetic risk of 
disease within a UK population. A total of 63.95% of the population agreed they would like to 
know more about their genetics and 53.80% of the population agreed they would like to know 
more about nutritional genomics. Both females (63.22%) and males (62.11%) agreed that they 
would like to know more about their genetics. More 25-34 year olds (69.16%) agreed they 
would like to know more about their genetics than all other groups. Participants aged 18-24 
(55.56%) were least likely to want to know more about their genetics. Around half of females 
(53.41%) and males (51.05%) agreed that they would like to know more about nutritional 
genomics. More 55+ year olds (61.76%) agreed they would like to know more about 
nutritional genomics, whereas the age group least in agreement were those aged 35-44 
(45.51%). These results show that more than half of the population sample may be willing to 
consider or participate in nutritional genomics. Knowledge and education may be a crucial 
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factor in gaining higher approval rates in the UK population. However, based on these results, 
attitudes towards testing and the ethics surrounding genetic testing resonate positively with  
a large portion of the sample population. Overall, public attitudes towards genetics are 
largely positive, albeit complex.  Figure 7.3, Questionnaire results. 
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          Collectively, males (58.45%) and females (57.62%) averaged a similar score throughout 
the VYPR survey thus indicating no noticeable differences between the two groups (see table 
7.3). This result contradicts a previous study reporting that the attitude and awareness 
Figure 7.3  Responses to VYPR questions on nutritional genomics, its services and products of the UK population showing percentages for 
‘agree’, ‘neutral’ and ‘disagree’.  
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It is important to know what ingredients go into my food
Clean label food is important
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towards personalised nutrition were higher among female participants, however, this study 
only studied the Indian population (Priyadarshini and Mahjabeen, 2017). Among all the age 
groups, those aged 55+ (65.50%) showed the highest interest in nutritional genomics and 
genetic testing, averaging much higher than all other groups; 25-34 (61.07%), 18-24 (55.52%), 
35-44 (54.63%) and 45-54 (53.15%), respectively. Knowledge has previously been identified 
as a contributing factor which affects attitude towards genetic testing, whereby an increased 
level of knowledge produces more positivity towards genetic testing (Gollust et al., 2011; 
Henneman et al., 2004).  Previous studies report that age was found to be associated with 
factual knowledge, with a higher age-related to a lower level of understanding of genetic 
knowledge (Calsbeek et al., 2007).  
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Table 7.3 Percentage response of 'agree' for each VYPR survey based on age and gender.  
  
Genetic 
testing is 
important 
for the 
future of 
health 
science 
I would 
take a 
genetic 
test 
I would 
take a 
genetic 
test to 
improve 
my health 
Clean 
label food 
is 
important 
It is 
important 
to know 
what 
ingredients 
go into my 
food 
Diet can 
interact 
with my 
genetics 
to affect 
my health 
I would 
like to 
know if I 
am 
genetically 
at risk of a 
disease 
Do you find 
nutritional 
genomics 
(relationship 
between 
genome, 
nutrition 
and health) 
appealing 
Genetic 
companies 
keep all 
personal 
information 
confidential 
I would take 
a genetic 
test for 
personalised 
nutrition 
Genetic 
tests for 
health 
should be 
free 
I feel I may 
have a 
food-
related 
intolerance 
I am 
health 
conscious 
I would 
like to 
know 
more 
about my 
genetics 
I would 
like to 
know 
more 
about 
nutritional 
genomics 
Average 
Sex                
 
Male 67.79% 57.48% 65.94% 72.10% 72.43% 54.95% 65.17% 54.26% 49.45% 49.45% 69.23% 36.95% 48.42% 62.11% 51.05% 58.45% 
Female 60.79% 53.67% 58.17% 67.80% 78.75% 51.71% 64.09% 49.49% 48.85% 54.83% 73.38% 38.18% 47.99% 63.22% 53.41% 57.62% 
Age group 
(years) 
                
18-24 66.04% 57.70% 56.14% 64.91% 70.18% 50.83% 65.51% 50.88% 39.99% 56.90% 72.22% 30.36% 41.82% 55.56% 53.71% 55.52% 
25-34 63.98% 58.69% 62.14% 69.36% 77.30% 55.03% 66.24% 56.11% 52.16% 62.29% 73.50% 41.82% 51.25% 69.16% 57.08% 61.07% 
35-44 59.77% 53.58% 58.06% 66.11% 76.93% 50.27% 65.57% 44.15% 46.36% 46.19% 67.22% 37.99% 42.70% 59.11% 45.51% 54.63% 
45-54 56.25% 43.20% 48.01% 69.24% 82.50% 48.70% 50.65% 45.33% 44.45% 47.95% 76.72% 31.95% 42.65% 57.34% 52.31% 53.15% 
55+ 67.50% 51.35% 67.57% 81.58% 86.84% 55.56% 72.22% 54.29% 64.71% 51.52% 88.24% 38.24% 76.47% 64.71% 61.76% 65.50% 
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7.2.3 Consumer preferences to functional foods (VYPR) 
The majority of consumers were willing to purchase healthy meals which would be delivered 
to their door. Consumers favouring clean label products preferred homemade food 
significantly more than processed food made in a factory. Consumers had a neutral view of 
the use of science within their food, but dislike chemical or scientific nomenclature in the food 
ingredients lists. Convenience was also an important factor. 
 
 
Figure 7.4 Would consumers buy healthy meals delivered to their door?  
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Figure 7.5 Do consumers regard clean label food products to be important? 
 
Figure 7.6    Do consumers prefer homemade food, factory made food or neither? 
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Figure 7.7     How do you consumers feel about the use of science in their food? 
 
 
Figure 7.8    How do consumers feel when they see a chemical or scientific name in the food ingredients list? 
 
0
50
100
150
200
250
300
Dislike Neutral Like
Nu
m
be
r o
f R
es
po
ns
es
Consumer Attitude
0
50
100
150
200
250
300
350
Dislike Neutral Like
Nu
m
be
r o
f R
es
po
ns
es
Consumer Attitude
Chapter 7                                 Consumer Acceptance of Function Foods & Personal Genomics 
 
167 
 
7.2.4   Consumer preferences to personalised genomic nutrition 
Statistical analysis and mean values were used to analyse the collected data from the VYPR 
questionnaire to identify which demographic is most likely to purchase a nutritional 
genomic product/service and their preferences for product/service. 
          Males aged 18-24 were most likely to purchase a nutritional genomic product/service. 
This was closely followed by males aged 25-34.  As age increased the likelihood of buying a 
nutritional genomics product/service decreased. For the general population, consumers 
preferred a personalised nutrition plan with healthy meals delivered to their door. 
          Males aged 18-24 preferred a personalised nutrition plan with healthy meals delivered 
to their door. Males aged 25-34 also preferred a personalised nutritional plan with healthy 
meals delivered to their door.  
7.2.4.1   Influence of demographic 
Respondents answered a series of target questions to assess the effect of age and gender.  
7.2.4.1.1 Effect of gender 
Males (73.24±12.30%) were more likely to buy a personalised nutrition plan that required 
genetic testing than females (65.48±12.70%). However, statistical analysis revealed no 
significant difference between gender groups as determined by an unpaired t-test (p>0.05).  
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7.2.4.1.2   Effect of Age 
Individuals within the age group of 18-24 (72.81±12.92%) were more likely to buy a 
personalised nutrition plan that required genetic testing. As age groups increased, the 
likelihood of buying the product/service decreased; 25-34 (68.08±8.84%), 35-44 
(65.33±14.72%) and 45-54 (63.42±16.53%), 55-64 (63.83±20.23%) and 65+ (63.61±26.25%), 
respectively. However, using a one-way ANOVA test, it was determined that there was no 
statistically significant difference between groups (F(5,24) = 0.223, p>0.05).  
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Figure 7.10       Effect of age on the likelihood of purchasing a nutritional genomics product or service 
 
7.2.4.1.3 Gender and Age 
Within the male population, those aged 18-24 (78.41±13.78%) were the most likely to buy 
the product/service. This was closely followed by males aged 25-34 (78.24±7.12%) and 
subsequently, males aged 35-44 (69.85±18.28%), 55-64 (69.28±24.03%) and 45-54 
(62.64±13.92%). Using a one-way ANOVA test, it was determined that there was no 
statistically significant difference between groups (F(4,20) = 0.832, p>0.05). Due to the low 
number of responses for males aged 65+ (n<5), this group was not included in the analysis.  
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Within the female population, those aged 18-24 (70.05±13.55%) were more likely to buy the 
product/service. Subsequently, as age increased the likelihood of buying the product/service 
decreased; 25-34 (66.43±9.16%), 35-44 (64.37±14.76%), 45-54 (62.97±17.76%), 55-64 
(60.64±20.47%) and 65+ (55.17±27.10%). Using a one-way ANOVA test, it was determined 
that there was no statistically significant difference between groups (F(5,24) = 0.399, p>0.05).  
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Figure 7.11 Effect of age on the likelihood of purchasing a nutritional genomics product or service within males 
Figure 7.12 Effect of age on the likelihood of purchasing a nutritional genomics product or service within females 
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          Males aged between 18 -24 are most likely to buy a nutritional genomic 
product/service. Preference tests were used to assess what product/service consumers 
would choose out of the given options.  
Question:  What product/service would the general population prefer?
 
Figure 7.13 Preference of the general population towards a personalised nutrition plan with meals delivered or 
not delivered. 
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Question:   What product/service would males aged 18-24 prefer? 
Question:    What would males aged 25-34 prefer? 
50%
25%
25%
A personalised nutrition plan based on your genetics with healthy meals delivered to your door
A personalised nutrition plan based on your genetics
None of the above
47%
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A personalised nutrition plan based on your genetics with healthy meals delivered to your door
A personalised nutrition plan based on your genetics
None of the above
Figure 7.14 Preference of males aged 18-24 towards the option of healthy meal delivery as part of a personalised nutrition plan 
Figure 7.15 Preference of males aged 25-34 towards the option of healthy meal delivery as part of a personalised nutrition plan 
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          The present study aimed to assess UK consumer’s attitudes and acceptance towards 
nutritional genomics, its services and activities with consideration on how demographics 
affect these factors. Results showed that the UK population had a high level of interest in 
nutritional genomics. Demographic factors did affect attitudes and acceptance, with those 
aged 55+ showing the most agreement towards nutritional genomics; this was followed by 
the age group 25-34 years. Gender did not affect overall response agreement towards the 
survey. The results of the present study suggest a positive overall outlook towards genomic-
based nutrition, its services and activities within the UK population. Previous research 
suggests that knowledge and education may aid in mainstreaming genomic-based nutrition 
to the public as knowledge is reported to be a deciding factor in consumer acceptance of 
genetic testing. This promotes the importance of public health education programs for 
genomics, which together with the NHS funding more genomic centres may provide potential 
savings for the NHS through early disease prevention. Education may be imperative to ensure 
that the public is interested in this continually evolving science which has the potential to 
bring significant savings to the health service within the UK. 
          Several limitations are worth noting. This survey was only distributed through a mobile 
application to individuals who voluntarily participated in the survey research through VYPR. 
Therefore, it is possible that a selection bias occurred in the sample surveyed. The 
demographics that responded to the VYPR survey were not evenly distributed, with those 
between 18-24 representing 9-10% of the sample and ages 55+ representing 6-7% of the 
population sample. Therefore, the results are not representative and cannot be applied to 
the general population. Lack of understanding of technology may have prevented elderly 
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consumers participating in the survey. Similarly, the distribution of gender was unequal with 
more female’s responding to the survey than males.  
          Further research should consider additional demographic factors such as income, 
education level and ethnicity to gain a greater understanding of the complex reasons which 
affect attitudes towards genetic testing and nutritional genomics. A more varied method of 
distributing the survey would be recommended to avoid sample bias.  
7.2.4.2  Market Research  
The VYPR platform was used to assess customer attitudes, choice and preference towards the 
business activities of nutrigenomic companies. 
7.2.4.2.1 Consumer needs assessment 
Using the VYPR consumer assessment tool and a number of business model parameters 
were tested. Respondents answered the following question. 
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Question: Would you purchase a simple DNA test to improve your health? 
• Result: Yes: Female 66.8%/ Male 68.5% 
 
Figure 7.16   Likelihood of trying a free DNA test to improve health based on gender 
 
Figure 7.17     Likelihood of trying a free DNA test to improve health based on age group 
• Comments: when the DNA test is free more respondents would be willing to try it 
than when it is not free (67.07%). Age group 25-34 were least likely to try a free DNA 
test. Males are more likely to try than females. 
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Question:  Take a free simple DNA test that helps you lose weight? 
• Result:  Yes: Female 77.7%/ Males 85.9% 
 
Figure 7.18 Likelihood of trying a free DNA test which helps you lose weight based on gender 
 
Figure 7.19   Likelihood of trying a free DNA test which helps you lose weight based on age group 
• Comments: When weight loss was mentioned, more people would be interested in 
taking a DNA test. Similarly, age group 25-34 were least likely to try a DNA test. 
Again, males were more likely to try a DNA test.  
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Question: Would you purchase a personalised nutrition plan based on your genetics? 
• Result: Yes: Female 57.9%/ Male 48.4% 
 
Figure 7.20   Impact of gender on the likelihood of buying a personalised nutrition plan based on genetic test. 
 
Figure 7.21 Impact of age group on the likelihood of buying a personalised nutrition plan based on genetic test. 
Comments: As age increases the likelihood of buying a personalised nutrition plan 
decreases. Males would be more likely to buy a personalised nutrition plan. 
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Question:    Would you be willing to undergo genetic testing for personalised nutrition? 
Result: Yes: Female 67.0%/Male 57.6%
 
Figure 7.22 Impact of gender on a willingness to undergo genetic testing for a personalised nutrition plan 
 
Figure 7.23 Impact of age group on a willingness to undergo genetic testing for a personalised nutrition plan. 
• Comments: Females were more likely to undergo a genetic test than males. The age 
group 25-34 were most likely to undergo a genetic test for a personalised nutrition 
plan.  
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Question:    Preference tests - out of the following options, which would you prefer? 
 
Figure 7.24   Assessment of consumer preference between personal nutrition and a general nutrition plan  
 
Figure 7.25 Assessment of consumer preference based on different services/products which tail personal 
nutrition based on genetic testing. 
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• Comments: In both instances, none of the above was the preferred option. However, 
out of the services/products available, consumers preferred a personalised nutrition 
plan over a general nutrition plan.  Of the latter survey, consumers preferred a 
personalised nutrition and workout plan based on their genetics the most. Following 
this, a personalised nutrition and workout plan based on genetics with meals delivered 
was the second most preferred option indicating that consumers may prefer a full 
more encompassing package as opposed to a single service/product. Throughout the 
surveys, the younger generations seem more accepting and interested in genetic 
testing for a personalised nutrition plan. When key words were used such as weight 
loss, the older generations were more accepting of providing genetic information.  
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8.1 Aims of the study 
This report assesses the background and business models of personalised nutrition regarding 
nutrigenomics. Additionally, a brief initial market analysis of customer perception towards 
nutrigenomics was performed. Finally, elements of a nutrigenomic business model were 
identified along with a SWOT (strengths, weaknesses, opportunities and threats) analysis. An 
assessment was undertaken of the potential commerciality for start-up businesses allowing a 
critique to be formed based on the previously mentioned research highlighting the 
importance of a strong business model. The evaluation considers the approach of a 
nutrigenomic start-up company which will provide genetic testing, personalised nutrition, 
exercise advice and supply of healthy meals.  
The focus of the Evaluation 
• Information on personalised nutrition in the marketplace. 
• Competitor assessment. 
• Consumer acceptability of nutrigenomics. 
• Review of business activities and business models. 
• Hypothetical SWOT analysis of nutrigenomic start-up.  
 
8.2   Personalised nutrition in the market 
Personalised nutritional advice based on individual genomics would fit into an emerging trend 
in the marketplace, where customer-supplier relationships are increasingly moving from a 
commodity model towards a personalised model (Sutton, 2007). Additionally, in the context 
of personalised nutritional advice, several studies have suggested that tailoring nutrition 
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advice may be more efficient for influencing individual dietary behaviour more than 
mainstream advice (Brug et al. 1999, 2003; Elder et al. 2009; Oenema et al. 2001; Lustria et 
al. 2009). Personalised nutritional advice can be described as a process with four consecutive 
stages (Vesanen and Raulas 2006). 
1. The consumer is willing to release personal information that is sufficiently diagnostic 
to another party. 
2. The other party can use this diagnostic information as a basis for developing 
personalised nutritional advice. 
3. The customer is willing to incorporate that personalised nutritional advice as a basis 
for food choices. 
4. If the consumer believes that the personalised advice is sufficiently rewarding over 
and above the generic nutritional advice, a learning process can be initiated in which 
a certain level of habit forming behaviours is likely to occur. 
In these stages of interaction between customers and suppliers, personalised nutrition advice 
can add benefits to the value exchange (Van Trijp and Ronteltap 2007). Furthermore, the 
latter stages can open opportunities for subscription-based models whereby the consumer 
may be inclined to continue on a rewarding path avoiding self-interpretation of large amounts 
of nutrition information. Consumers may also feel a sense of pride and ownership based on 
the co-design of their personalised diet based on providing their personal and genetic 
information (Piller & Muller, 2004). Personalised nutrition in the competitive health 
marketplace may provide a differentiation from commodity type competition, thus 
generating added value (Ghosh, 2009). The move away from the dominant business model 
that applies to a population-based nutrition approach to the personalised nutrition model is 
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at the early stages of commercial success (Saukko et al., 2010). According to Ronteltap & Van 
Triip (2007), for personalised nutritional advice to develop, successful commercialisation of 
the proposition is essential and the use of genetic profiling to provide personal nutrition 
advice can encompass two business models: 
1. ‘‘Test and run to the finish’’: This business model provides to the consumer relevant 
feedback on progress towards health improvement on relevant biomarkers, both non-
invasive and invasive phenotypic measures. A key feature is an iterative feedback loop 
that assures follow-up of individual progress and the possibility to adjust the dietary 
advice accordingly. 
2. ‘‘All-in lifestyle guidance’’: This business model extends the ‘‘test and runs to the 
finish’’ in two directions. It includes genotypic information next to dietary intake data 
and phenotypic information as a source of personalised advice and monitoring for goal 
attainment. The personalised advice is also broader in scope; it includes other lifestyle 
factors in addition to dietary improvements such as activity level or stress/ time 
management. A key feature is the inclusion of genetic information for holistic change 
management. 
 
Using a business model approach which delivers; what customers want, how they want it, and 
how the company should be organised to best deliver those consumers needs while 
maintaining profitability may be the best route to commercial success. 
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8.3 Competitor profiling 
A selective review of the business models was undertaken for two UK companies, one EU 
company and two USA company; DNA fit, Fitnessgenes, Karmagene, 23 & Me, and Habit. All 
with overlapping and differentiated applications of personalised genetic information. 
8.3.1 DNA fit  
• Segments Served: Individuals who are concerned about fitness and diet and also others who 
are concerned about their health and well-being.  
• Services Offered, Pricings and Discounts: Diet info (£99-199), fitness Info (£149), diet and 
fitness info (£249). For 23andMe users – Diet info (£49), fitness info (£49-79), diet and 
fitness info (£119). Fastest turnaround once samples have been provided (10 days). 
• Advertising and Campaign Themes: Very sport-based, post their research on social media 
and promote their sponsorships (Egyptian football team), post a health-related blog.  
• Channels of Distribution: Website, social media, offer a free 14-day guide on how genetics 
impact every aspect of fitness and nutrition. Linked with 23&me and Ancestry.com.  
Website - https://www.dnafit.com/. 
8.3.2 FitnessGenes  
• Segments Served: mainly individuals who are concerned about fitness and diet – more sport 
focused. 
• Services Offered, Pricings and Discounts: Genetic Reload System - The world’s #1 
personalised diet and fitness plan based on your DNA - created by FitnessGenes CEO Dr Dan 
Reardon. (£199), get fit (starter £149, keep fit £169, complete £199), lose weight (starter 
£149, momentum £169, complete £199), get lean (starter £169, plus £199, complete £239), 
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build muscle (starter £199, Scott Herman £279, complete £339). Sign up for the newsletter 
and receive 10% off next purchase.  
• Advertising and Campaign Themes:  Q&A by CEO on social media on various health topics, 
recipe videos.  
• Channels of Distribution: Website, social media, newsletter.  
Website - https://fitnessgenes.com/ 
8.3.3   23andMe   
• Segments Served: Health and ancestry. 
• Services Offered, Pricings and Discounts: Personal genome service - £149. 
• Advertising and Campaign Themes:  TV adverts.   
• Channels of Distribution: Website, social media, newsletter.  
Website - https://www.23andme.com/en-gb/ 
8.3.4 Karmagenes  
• Segments Served: Integrates genetics and psychology – career orientation, partnerships and 
relationship, personalised wellbeing 
• Services Offered, Pricings and Discounts: Full personality report ($199), customisable option 
($12.95-$19.95). 
• Advertising and Campaign Themes:  Newsletter.   
• Channels of Distribution: Website, social media, newsletter.  
Website - http://karmagenes.co/ 
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8.3.5 Habit (US-based company) 
Insight into a US-based company which provides a similar service to that proposed in the 
present report – providing genetic testing, personalised advice and healthy meals. 
The protocol Habit provide begins a Nutrition Test kit to assess an individual’s DNA, 
Bloodwork and Body Metrics to see how their body processes food in real time. From this, 
biology results and a nutrition plan is created which can be tailored to meet consumer 
activity and goals. After the test results are produced, customers can take advantage of 
Habit’s holistic offering including Fresh Meal delivery tailored to their biology, personal 
nutrition coaching and digital products.  
• Segments Served: Genotype analysis, personalised nutrition programme, fresh personalised 
meals. 
• Services Offered, Pricings and Discounts: Habitcore ($199), meals – $7.99 per breakfast, 
$13.99 per lunch or dinner (only delivered in the San Francisco Bay Area). Meal plan 
subscription renews automatically every week. Integrated with Fitbit. Ongoing coaching 
from dietitians available.  
• Advertising and Campaign Themes:  Social media, sustainable packaging.  
• Channels of Distribution: Website, social media, email letter, blog.   
Website - https://habit.com/home2 
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8.3.6 Other personal genomic companies. 
Table 8.1 Further companies within the international marketplace: 
Company  Location URL Competitors Price 
   
  
   
  
 
23andMe US https://www.23andme.com/en-gb/ Ancestry/health Ancestry 
£79 
Ancestry 
and health 
£149 
23mofang China https://www.23mofang.com/ admixture, deep 
ancestry, health 
and traits 
¥ 399-1499 
24genetics Spain https://24genetics.com/en/ admixture, 
exome 
sequencing, 
health, paternity, 
pharmacogeneti
cs, whole 
genome 
sequencing 
$199-399 
African 
Ancestry 
US http://www.africanancestry.com/ho
me/ 
deep ancestry $274-680 
Atlas Russia https://atlas.ru/ deep ancestry, 
diet, microbiota, 
rub 9900-
29900  
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health and traits, 
sport 
Atlasbiome UK https://atlasbiomed.com/ microbiome, 
health, nutrition, 
ancestry, 
personal sport 
traits 
£125-149 
Dante labs US/EU https://www.dantelabs.com/ exome 
sequencing, 
health, whole 
genome 
sequencing 
$250-649 
DNA 
consultants 
US https://dnaconsultants.com/ admixture, deep 
ancestry 
$50-539 
DNA 
worldwide 
UK https://www.dna-worldwide.com/ paternity, 
immigration, 
ancestry, 
extended family, 
drug & alcohol  
£99-429.60 
DNAFit UK https://www.dnafit.com/ Fitness/diet £99-249 
DNA health UK http://www.dna-health.co.uk/home/ Health £144-540 
EasyDNA UK https://www.easydna.co.uk/ Paternity, 
relationship, 
ancestry, clinical, 
health, animal   
£99-299 
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Everlywell US https://www.everlywell.com/ Health, fitness., 
well-being 
$199-399 
Family tree 
DNA 
US https://www.familytreedna.com/ admixture, deep 
ancestry, 
genealogy 
$69-199 
FitnessGene UK https://fitnessgenes.com/ Fitness £149-339 
Genebase US https://www.genebase.com/ deep ancestry, 
genealogy 
$119-867 
Geneticoncp
t 
US https://geneticoncept.com/index.htm
l 
Health, fitness, 
well-being 
$134-279 
Genos US https://genos.co/ whole exome 
sequencing 
$499 
Genotek Russia https://www.genotek.ru/ admixture, 
genealogy, diet 
and fitness, 
family planning, 
health, talents 
and sports 
rub 19990-
99000 
Guardiome US https://www.guardiome.com/ admixture, 
whole genome 
sequencing and 
interpretation 
$3100 
Habit US https://habit.com/home2 Diet/meal $299 
Breakfast 
$8.99 
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Lunch/dinn
er $13.50 
Helix US https://www.helix.com/ Ancestry, 
entertainment 
(DNA scarf), 
family, fitness, 
sleep 
 
Igenea German
y 
https://www.igenea.com/en/home admixture, deep 
ancestry, 
genealogy 
£159-1099 
Karmagene US http://karmagenes.co/ Personality  Basic 
personality 
report $199 
Full 
personality 
report $298 
LivingDNA UK https://www.livingdna.com/en-gb admixture, deep 
ancestry 
£99 
My heritage  UK https://www.myheritage.com/dna admixture, 
genealogy 
£45 
Prenetics China https://prenetics.com/ Fitness, health, 
family 
 
Right-angled UK https://www.heartdnatest.com/index
.asp 
Nutrition, drug 
response, health 
£79-169 
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Roots for real UK http://www.rootsforreal.com/ admixture, deep 
ancestry 
£195-390 
Suregenomics US http://www.suregenomics.com/ whole genome 
sequencing and 
interpretation 
$2500 
Ubiome US https://ubiome.com/about-us Microbiome Gut kit $89 
Gut time 
lapse $199 
Five site kit 
$399 
Veritas 
Genetics 
US https://www.veritasgenetics.com/ whole genome 
sequencing and 
interpretation 
$999 
Viome US https://www.viome.com/ Microbiome Annual plan 
£399 
WeGene China https://www.wegene.com/ admixture, deep 
ancestry, health, 
sports, traits 
¥9999 
xcode India https://www.xcode.in/ Health, fitness, 
well-being, 
medicine  
$100-150 
Yoogene China http://www.yoogene.com/ deep ancestry - 
YSTRs and 
mtDNA 
¥299-2699 
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8.4 Nutrigenomic business activities – Process flow  
Selected Genomic Companies Activities 
 
 
 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UK Competitors:  Activities Key Partners: Flows: 
A DNAFit  1 Software Developers   Information Stream 
B DNAhealth 2 Medical Professionals   Cash stream 
C EasyDNA 3 Nutritionalists    Cost stream 
D FitnessGenes 4 Food producers 
E Atlas 5 Genomic Specialist 
F Rightangles 6 Fitness Professionals 
* STARTUP 
 
Figure 8.1 Business Model Process Flow. 
 
CS Health conscious, aware of potential health problem, people who want to improve food choices, athletes 
CR Individual online relationship 
CH Internet 
VP Improved health through informed Nutrition, Exercise and Food 
RS Subscription to online service, personalised nutritional plan, healthy meals delivered to door 
KR  Phenotypic and genotypic data interpretation, algorithm for advice/meals 
KA Gathering info on dietary intake, self-reported parameters, organising physiological and genotypic sampling and 
testing, providing advice, monitoring progress, supplying meals 
KP Physiological and genomic data analysis specialists, diagnostic labs, dieticians, food producers, couriers, software 
developers 
CS Website/app maintenance, data analysis, personnel, marketing, sales, food production 
 
CS Customer segments, VP Value propositions, CH sales channels, CR Customer relationships, RS Revenue streams, KR Key resources, KA Key activities, KP Key partnerships and CS Cost 
structure 
 
Figure 8.1. Genomic Business Process Flow 
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Based on the present report, a SWOT analysis was constructed 
8.5 SWOT Analysis of Start-Up 
 
 
Figure 8.2 SWOT analysis of Genomic Businesses 
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9.1 Regulation of health claims for functional foods 
The food industry is heavily governed to ensure the safety of the consumer. However, 
functional food is a particularly restricted area to protect consumers against false or 
misleading health claims.  As regulatory control continues to tighten over labelling and 
statements made about functional benefits, this could cause barriers to the development, 
launch and marketing of functional food products. 
          The main law governing functional food is REGULATION (EC) No 1924/2006 on 
Nutrition and Health Claims Made on Foods.  This regulation states that the general 
principles for all claims for functional food products are that the use of nutrition and health 
claims shall not: 
(i) be false, ambiguous or misleading. 
(ii) give rise to doubt about the safety and the nutritional adequacy of other foods. 
(iii) encourage or condone excess consumption of a food. 
(iv) state, suggest or imply that a balanced and varied diet cannot provide appropriate 
quantities of nutrients in general. 
(v) refer to changes in bodily functions which could give rise to or exploit fear in the 
consumer, either textually or through pictorial, graphic or symbolic representations. 
          It is becoming increasingly more difficult and costly for manufacturers to launch new 
products due to requirement for health claims to be scientifically validated and restrictions 
on the marketing message. Europe is considered the hardest place to have a health claim 
approved, with only 254 health claims out of the 2,242 submitted being validated.  This 
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makes Europe a hard market to enter for manufacturers however it is also benchmarks the 
gold standard test for health claims.   
          Japan on the other hand, are far more lenient with demands for clinical evidence 
supporting the health claim, making it a relatively east test market for companies.  This 
approach has led Japan to considered the country central to functional innovation both 
regarding the positive regulatory attitude toward novel ingredients and also the 
population’s disposition to embrace new and unusual functional products (Langley, 2014).   
          The regulatory landscape is hard to predict however it has been suggested that 
following the recent scandals within the food industry, tighter regulations will be imposed to 
illustrate to the public that laws are in place to protect their wellbeing.  More specifically 
large emerging locations which have previously been quite lax are expected to adopt stricter 
regulations including India, China and Brazil.   
          Langley (2014) expresses how due to the length of time it takes to collate and express 
evidence from clinical trials; the approval process can be stalled from 6 to up to 10 years; as 
this gap closes, more definitive outcomes should be released on a range of new functional 
ingredients. 
          In conclusion, the only sufficient way for new products to have their health claims 
approved successfully, and within a sufficient timespan, is by providing conclusive scientific 
evidence which supports the health claims the manufacturer is claiming to convey.    
9.1.1 Food safety 
The general definition of additives is a substance added to something in small quantities, 
typically to improve or preserve it.  Functional foods may contain additives to produce a 
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health claim; this, however, is a key barrier along with scepticism preventing sales.  Mintel 
(2011) says 50% of consumers avoid foods, particularly functional foods, due to additive 
inclusion.  Even though additives have to be GRAS (Generally Recognised as Safe) before 
being commercially used, consumers believe they are too new to know the true long-term 
effects of consumption.   
          The food additive approval process can take up to 10 years.  This consists of five years 
of trial to ensure safety, two years of EFSA (European Food Safety Authority) analysing data 
from the testing process, and finally another three years for the additive to be approved for 
European wide use.  Despite this rigour, consumers may still remain sceptical.  Functional 
foods by their very nature contain various functional ingredients and additives to enhance 
numerous functions including flavour, colour, taste, consistency or to add a health claim.   
A study which found that ‘health-enhancing food’ could be harmful if regularly consumed 
due to the presence of additives, it is also believed that health claims were a technique to 
attract customers to the product (Bholah & Neergheen-Bhujun, 2013). Unwillingness to try 
functional foods related to cost (76.3%), chemical additives (75.8%), preference for natural 
products (68.8%) and scepticism regarding health improvement efficiency (68%).  It is 
apparent that functional foods which are ‘naturally’ functional, e.g. coconut water, are far 
more popular with customers due to their pure and unadulterated portrayal. Developments 
in this market to make products as pure as possible will be far more popular with health 
conscious consumers. 
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9.1.2 Lack of knowledge 
The rationale and reasoning behind the claims made on functional foods is the greatest 
barrier to growth.  Despite the general trend of consumers being more positive and 
accepting of functional foods, consumer engagement is impeded by a pervasive attitude of 
cynicism (Mintel, 2011).  In addition to this Mintel (2011) state that 20% of functional food 
users struggle to understand what health claims mean.   
          Many consumers do not understand the science behind the health benefits that 
certain functional foods promote. However, if the information was simplified, displayed in a 
basic format, consumers may be more inclined to purchase.  Much of the public believe that 
unsubstantiated claims are used as a tactic to charge a price premium which suggests that 
consumers have low trust in manufacturer’s health claims.  This is reflected in the results of 
the survey with 51% of consumers suggesting they would purchase functional food if they 
were more convinced of the health benefits (Mintel, 2011).   
          The scepticism stems from functional foods only being governed by one regulation - 
REGULATION (EC) No 1924/2006 on Nutrition and Health Claims Made on Foods.  Claims 
which are rejected by EFSA, are still allowed to be used for six months prior and withdrawn 
over the same period, which consumers are understandably aggravated about.   
The low trust of manufacturer’s claims prevents consumers from believing in functional 
food, if the rigorous and laborious testing procedure for claim verification was conveyed to 
the public it might encourage purchases based on greater confidence.   
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9.1.3 Public perspectives 
9.1.3.1 Consumers’ perspectives on functional foods 
Americans are believed to be overwhelmingly aware and accepting of functional foods and 
are doing more to include them into their diet. However, consumer studies reported lower 
healthy food consumption frequency and lower taste preference of healthy foods (Siro et 
al., 2008). In Europe, food choice of healthiness is continuously growing. however, 
Europeans are far more critical of new products and technologies. They are suspicious of the 
safety of novel foods and their production processes. Therefore, it is fair to hypothesise that 
Europeans’ acceptance of functional foods is less unconditional with more concerns and 
reserves compared to Americans. 
Consumer belief in the healthiness of a product greatly depended on the carrier product 
itself. The healthiness of the carrier products might override the effect of enrichments (Ares 
& Gambaro 2007). Surveys from different countries demonstrate different consumer 
attitudes and acceptance towards functional foods. Different socio-demographic 
parameters, gender, education also have an effect on customer acceptance level on 
functional foods (Siro et al., 2008) 
Consumer acceptance of the concept of functional foods has been widely recognised as a 
key factor for market orientation, consumer-led product development and successful 
exploitation of market opportunities. However, acceptance is determined by a few factors 
such as primary health concerns, familiarity with ‘functional food’ concepts, knowledge of 
the functional ingredients, the nature of the carrier product, and the manner of health 
benefit communication, etc. Consumer awareness of the health benefits of newly developed 
functional ingredients may be limited and there is a strong need for specific communication 
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activities that better inform consumers in this respect. The health benefit information of a 
specific product should be communicated in a relatively simple way, so that it is more easily 
understood and trusted by consumers (Siro et al., 2008). 
9.1.3.2 Consumers’ perspectives on health claims and food choice 
Some studies have shown that health claims do not influence purchasing decision as much 
as taste, brand, price, attractiveness and packaging of the product. Among the audited 
products, 25% of them that have nutritional claims printed on the front-of-pack, and 20% 
printed on the back-of-pack. In contrast, health claims that include disease risk reduction 
claims were used much less often on front-of-pack (2%) than back-of-pack (4%) (Wills et al., 
2012). Wills and her colleagues have created a framework (figure 9.1) on how health claims 
affect consumers.  
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Figure 9.1. Conceptual framework on how health claims affect consumers (Wills et al., 2011) 
 
          Purchasing intentions and ultimately purchasing behaviour may be affected by 
understanding and attitudes to the claim. Both product and consumer variables can affect 
understanding, attitudes and purchasing of the product. Product variables include food and 
drink category, format and wording of the health claim, the functional ingredient, benefit 
claimed, taste and sensory attributes of the product. Consumer variables include personal 
beliefs that are not related to specific claims and products (e.g. usefulness of functional 
food in general), personal relevance (e.g. health concerns or problems), familiarity with the 
functional ingredients that the product contains and nutrition knowledge. Products such as 
yoghurt and bread with an overall positive health images have a tendency for their health 
claims to be perceived more positively. However, no consistency exists for the most 
appropriate type of foods as health claims carrier. Consumers seem to prefer the 
combination of carrier products with a functional ingredient that is naturally present in the 
products. Several studies have shown that fortification of functional ingredients in products 
which are already recognised as healthful by itself, such as yoghurt, honey, juices and low-
fat products, do not benefit from carrying health claims. Conversely, products which are 
perceived as less healthful, such as sweets, spreads and high-fat products, were found to 
benefit from carrying health claims. Moreover, consumers with a family history of serious 
diseases such as cancer also positively influence the attitudes toward health claims relating 
to such disease. 
          Claims referring to specific food ingredients were found to be more convincing than 
merely stating the general health benefits of the product. Another factor which influences 
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the acceptance of the product was the terminology used in a health claim; short and concise 
wording was found to be more desirable to consumers. To enhance acceptance of the 
product, short and concise claims can be printed on the front of the package, and detailed 
explanation can be provided elsewhere on the package. Format and wording of claims 
impacted less on consumer attitudes than the familiarity and type of claimed benefit of the 
ingredient. Acceptance of the health claim is stronger when the health benefit of a 
functional ingredient is well known, e.g. calcium is beneficial for osteoporosis, and vitamin K 
is beneficial for hypertension.  Contentment from food products was also observed as a 
more important factor than the perceived healthiness of the product. Also, no willingness 
was reported to compromise taste for health in functional products. Some studies showed 
that previous unpleasant tasting experiences might even have a negative impact on product 
acceptance in the future. This signifies the importance of taste influencing consumers food 
choices. Willingness to try functional food is driven by its attractiveness, credibility and 
uniqueness, which suggests that not only the healthy image of a functional food determines 
the consumers’ acceptance (van Kleef et al., 2005). 
9.1.4   Regulation of health claims by the European Food Safety Authority (EFSA) 
EFSA is responsible for validating submitted claims based on scientific evidence for 
applicants, who want to use claims that are currently in use or propose claims for 
authorisation in the EU. Currently, there are 3 types of claims, their structure and function, 
health claim regulations are explained below: 
1) General function claims: this is under Article 13.1 of the EC Regulation on nutrition 
and health claims. Claims that fall into this category are the role of a nutrient or 
substance in growth, development and body functions, psychological and 
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behavioural functions, slimming and weight control, satiety or reduction of available 
energy from the diet. However, claims which are related to child development, 
health or disease risk reduction are not included in this category (EFSA, 2012).  
2) New function claims: this is under Article 13/5 of EC Regulation on nutrition and 
health claims. This category is for those which are based on newly developed 
scientific and/or for which protection of proprietary data is requested. Authorisation 
is required for these health claims on each case basis, subsequently the submission 
of a scientific dossier to EFSA for assessment.  
3) Disease risk reduction and child health and development claim: this is under Article 
14 of EC Regulation on nutrition and health claims. This category includes claims 
refer to disease risk reduction or children’s health and development.  
Table 9.1 shows some of the existing functional food products in the current market with 
approved health claims. 
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Table 9.1 Examples of products with health claims. 
Company Product name Functional food / 
ingredient / nutrients 
Health claims 
Innocent  Energise Vitamin B1, B2, B3, B6 and 
C 
“Reduce tiredness and 
fatigue.” 
Innocent Defence Vitamin C, D and Zinc “Contribute to the normal 
function of the immune 
system.” 
Innocent Antioxidant Vitamin C, E and selenium “Protection of cells from 
oxidative stress.” 
Benecol Yoghurt drinks, 
yoghurts and 
spreads 
Plant Stanol Ester “Proven to lower 
cholesterol.” 
Danon Activia yoghurt Bifidobacterium lactis “helps regulate your 
digestive system.” 
Quaker High fibre instant 
oatmeal 
Soluble fibre “helps reduce 
cholesterol.” 
Red Bull Red Bull Energy 
drink 
Caffeine, Taurine, B-group 
vitamins and sucrose and 
glucose 
“Vitalizes body and mind.” 
Fuel Fuel energy 
beverage 
CoQ10 and Gingko Biloba “Fire up energy levels.” 
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9.1.4.1 EFSA claim interventions and contraventions (see Appendix 1) 
Many of the products included in functional foods are plant/herbal extracts and therefore 
are regulated as botanicals and only need to be classed as food safe for inclusion in 
products. However, some of the ingredients used are subject to regulation under the EFSA 
Article 13 relating to health claims associated with ingredients. 
          Listed below are examples of the approvals/rejections relating to some of the common 
functional product ingredients that have been assessed by the NDA (The Panel on Dietetic 
Products, Nutrition and Allergies): See Table 9.2 Approvals from EFSA / NDA. 
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Product Approved by NDA / EFSA Rejected by NDA / EFSA
Glucomannan (Dietary Fibre) Reduction of blood cholesterol  concentrations Reduction of post-prandia l  glycaemic responses
(EFSA-a, 2009; EFSA-b, 2010) Reduction of body weight Maintenance of normal  blood glucose concentrations
Maintenance of normal  (fasting) blood concentrations  of triglycerides
Maintenance of normal  bowel  function 
Decreas ing potentia l ly pathogenic gastro-intestina l  microorganisms
Chromium Contribution to normal  macronutrient metabol ism Contribution to the maintenance or achievement of a  normal  body weight
(EFSA-c, 2010) Maintenance of normal  blood glucose concentrations Reduction of ti redness  and fatigue
Leci thin No cla ims  relating to the beneficia l  effects  of Leci thin have been approved Maintenance of normal  blood cholesterol  concentrations
(EFSA-d) Contribution to normal  fat metabol ism
Increase in the intestina l  absorption of glutamine
Faster recovery from muscle fatigue after exercise
Improvement of neuromuscular function
Contribution to normal  cognitive function
Maintenance of normal  neurologica l  function
Conjugated Linoleic Acid No cla ims  relating to the benefi ts  of CLA have been approved Contribution to the maintenance or achievement of a  normal  body weight
(EFSA-e, 2010) Increase in lean body mass  
Increase in insul in sens i tivi ty
Protection of DNA, proteins  and l ipids  from oxidative damage
Contribution to immune defences  by s timulation of production of protective 
antibodies  in response to vaccination
Selenium Maintenance of normal  ha ir Protection against heavy metals
(EFSA-f, 2010; EFSA-g, 2009) Maintenance of normal  na i l s Maintenance of normal  joints
Maintenance of normal  thyroid function The normal  function of the heart and blood vessels .
Protection of DNA, proteins  and l ipids  from oxidative damage Normal  cognitive function 
Maintenance of the normal  function of the immune system Normal  prostate function
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Product Approved by NDA / EFSA Rejected by NDA / EFSA
Iodine Normal  thyroid function Maintenance of normal  vis ion
(EFSA-h, 2009; EFSA-I, 2010) Normal  production of thyroid hormones Maintenance of normal  ha ir
Normal  energy-yielding metabol ism Maintenance of normal  na i l s
Maintenance of normal  skin.
Contribution to normal  cognitive and neurologica l  function
Contribution to normal  energy-yielding metabol ism
Contribution to normal  thyroid function and production of thyroid hormones
Niacin Normal  energy-yielding metabol ism Maintenance of normal  bone
(EFSA-J, 2009; EFSA-K, 2010) The normal  function of the nervous  system Maintenance of normal  teeth
Maintenance of normal  skin and mucous  membranes Maintenance of normal  ha ir
Reduction of ti redness  and fatigue Maintenance of normal  na i l s
Contribution to normal  psychologica l  functions Maintenance of normal  blood flow (encourages  excess  consumption)
Caffeine Increase in endurance performance Increase in phys ica l  performance during short-term high-intens i ty exercise
(EFSA-k, 2011; EFSA-m, 2011) Increase in endurance capaci ty Increased fat oxidation leading to a  reduction in body fat mass
Reduction in the rated perceived exertion/effort during exercise Increased energy expenditure leading to a  reduction in body weight
Increased a lertness
Increased attention
5 Hydroxytryptophan No cla ims  relating to the beneficia l  effects  of 5-HTP have been approved Enhancement of mood
(EFSA-n, 2009; EFSA-o, 2011) Concentration and reduction of restlessness
Increase in satiety leading to a  reduction in energy intake
Phenyla lanine No cla ims  relating to the beneficia l  effects  of phenyla lanine have been approved Increased a lertness
(EFSA-p, 2010) Enhancement of mood
Pain rel ief
Improvement of memory
Boron No cla ims  relating to the beneficia l  effects  of Boron have been approved Maintenance of bone
(EFSA-q, 2009; EFSA-r, 2011) Maintenance of joints
Prevention and treatment of prostate cancer
Maintenance of normal  thyroid function 
Contribution to normal  cognitive function 
L-orni thine No cla ims  relating to the beneficia l  effects  of L-orni tine have been approved Contribution to the regulation of the urea cycle.
(EFSA-s , 2011) Normal ization of l iver function
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Table 9.2 Approvals from EFSA / NDA 
Product Approved by NDA / EFSA Rejected by NDA / EFSA
L-Arginine Maintenance of normal  ammonia  clearance “Immune system functions .”
(EFSA-t, 2011) Growth or maintenance of muscle mass  
Normal  red blood cel l  formation 
Maintenance of normal  blood pressure
Improvement of endothel ium-dependent vasodi lation
“Phys ica l  performance and condition.”
“Système nervous” 
Maintenance of normal  erecti le function 
Contribution to normal  spermatogenes is  
L-Tyros ine Contribution to the normal  synthes is  of catecholamines  (s timulatory hormones) Increased attention
(EFSA-u, 2011) Contribution to normal  muscle function
Vitamin B5/Pantothenic acid Normal  energy-yielding metabol ism Maintenance of normal  bone
(EFSA-v, 2009; EFSA-w, 2011) Normal  mental  performance Maintenance of normal  teeth
Normal  synthes is  and metabol ism of s teroid hormones , vi tamin D and some 
neurotransmitters . Maintenance of normal  ha ir
Reduction of ti redness  and fatigue (not deficient in EU) Maintenance of normal  skin 
Maintenance of normal  na i l s .
Adrenal  function
Coenzyme Q10 No cla ims  regarding the beneficia l  effects  of coenzyme Q10 were approved Contribution to normal  energy-yielding metabol ism
(EFSA-x, 2010) Maintenance of normal  blood pressure
Protection of DNA, proteins  and l ipids  from oxidative damage
Contribution to normal  cognitive function
Maintenance of normal  blood cholesterol  concentrations
Increase in endurance capaci ty and/or endurance performance (ID 1913)
Green Coffee (Chlorogenic Acid) No cla ims  regarding the beneficia l  effects  of green coffee were approved Protection of DNA, proteins  and l ipids  from oxidative damage
(EFSA-y, 2011) Maintenance of normal  blood glucose concentrations
Contribution to the maintenance or achievement of a  normal  body weight
Cocoa No cla ims  regarding the beneficia l  effects  of cocoa were approved Protection of l ipids  from oxidative damage
(EFSA-z, 2010; EFSA-aa, 2011) Maintenance of normal  blood pressure
Enhancement of mood
White Kidney bean Extract 
(Phaseolamine)
No cla ims  regarding the beneficia l  effects  of white kidney bean extract were approved Inhibi t α-amylase activi ty, hindering the convers ion of complex carbohydrate to 
s imple sugars , which are s tored as  reservoir fats  i f not immediately uti l i sed by 
the organism; i t results  in a  lower ca lories  intake, contributing to weight loss
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9.1.5     Future functional food information regulation – the new FIR 
The European Parliament has approved the new Food Information for Consumers 
Regulation (FIR) on 6 July 2011, after reviewing both general food and nutrition labelling 
legislation. The main purpose of the new regulation is to simplify and consolidate the 
existing labelling legislation, bringing general and nutrition labelling of EU rules together 
into a single regulation (FSA, 2014) 
The main points and key areas of the new Food Information for Consumers Regulation 
include: 
1) Country of origin 
2) Nutrition labelling  
3) Manufacturers if possible to provide voluntary energy information.  
4) Data marking: ‘best before’ and ‘use by’dates.  
5) A date of first freezing shown for frozen items, i.e. meat and fish. 
6) Additional information for children or pregnant and breastfeeding women.  
7) The types of vegetable oil used in food products.  
8) Allergen information. 
9.2     Current issues facing the NHS 
Statistics and Segmentation of the rising cost of financing the NHS present a huge healthcare 
challenge looming within the UK. Resources struggle to cope with demand and costs are 
escalating as health issues increase within a growing UK population. 
9.2.1    Key NHS financial statistics 
NHS net expenditure has increased from £78.8bn in 2006/07 to £120.5bn in 2016/17. Planned 
expenditure for 2017/18 is £123.8bn and for 2018/19 is £126.2bn. In real terms, the budget 
is expected to increase from £120.5bn in 2016/17 to £123.202bn by 2019/20. 
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Health expenditure per capita in England has risen from £1,879 in 2011/12 to £2,106 in 
2015/16. The NHS net deficit for the 2015/16 financial year was £1.8bn. The provider deficit 
for the 2016/17 financial year has been confirmed at £791m.  (NHS statistics, 2017) 
9.2.2     Key NHS activity figures 
The NHS deals with over 1 million patients every 36 hours. In 2015/16 there were 40% more 
'procedures and interventions' (excluding diagnostic testing) completed by the NHS 
compared to 2005/06, with an increase from 7.2m to 10.1m. There were 16.2m total hospital 
admissions in 2015/16, 28% more than a decade earlier (12.6m). 
In 2016, 507,784 NHS patients were admitted to independent providers for their 
elective inpatient care. There were 891,717 referrals made by GPs to independent providers 
for outpatient care during the same period. 
 At the end of April 2017, there were 3.8 million patients on the waiting list for 
treatment. 382,618 (10.1%) had been waiting for longer than 18 weeks, compared to 302,901 
(8.4%) at the same point in 2016. 90.5% of people with non-admitted pathways were treated 
or discharged within 18 weeks of referral in April 2017, compared to 92.1% a year earlier. At 
the end of April 2017, 885,876 patients were on the waiting list for a diagnostic test. Of these, 
1.8% had been waiting more than six weeks (NHS statistics, 2017) 
9.2.3    Key UK obesity figures  
In 2015, 58% of women and 68% of men were overweight or obese. Obesity prevalence 
increased from 15% in 1993 to 27% in 2015.  In 2015/16, over 1 in 5 school children in 
Reception (4 years old), and over 1 in 3 children in Year 6 (11 years old) were measured as 
obese or overweight.  
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In 2015/16 there were 525,000 admissions in NHS hospitals where obesity was recorded as 
a factor. In 2015/16, there were 6,438 Finished Consultant Episodes (FCE’s) in NHS hospitals 
with a primary diagnosis of obesity and a main or secondary procedure of bariatric surgery. 
Over three-quarters of bariatric surgery patients were aged between 35 and 54, and over 
three-quarters of patients were female.  
26% of adults ate the recommended 5 or more portions of fruit and vegetables a day in 
2015 with females (27%) were more likely to do so than males (24%).  
In 2015/16, 26% of adults were classified as inactive (fewer than 30 minutes physical activity 
a week) £6.1bn p/year spent on obesity-related diseases. (Gov.uk, 2017) 
 
 
 
 
 
 
 
 
 
Figure 9.2 Adult obesity: UK Comparison with other OECD (Organisation for  
Economic Co-operation and Development) countries (Gov.uk, 2017).
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9.2.4       Implications for the future of the NHS 
Nearly two-thirds of adults (63%) in England were classed as being overweight. Failure to 
address the epidemic of obesity places an even greater burden on the resources of the NHS. 
Statistics show that the NHS spent £6.1bn on obesity-related diseases during 2014-2015, 
with poor nutrition being identified as a large causal factor (Public Health England, 2017). 
Functional foods have been identified as a promising treatment for obesity and associated 
comorbidities (Baboota et al., 2013). Furthermore, genetic research into the underlying 
biological mechanisms of functional foods may be informative for the public health sector 
when advising on nutritional health and disease (Warburton et al., 2017). 
The NHS suffered a 2016/17 year-end deficit of £791m due to operational challenges and 
additional financial burden (NHS statistics, 2017). Annual NHS costs for cancer services are 
reported to be at £5bn (Department of Health and Social Care, 2015). More than £6.8bn 
was spent on treatment of CVD within the NHS in England in 2012/13 (Bhatnagar et al., 
2015). The cost of type 2 diabetes was reported to be £8.8bn a year (NHS, 2017). The use of 
nutritional genomics in the healthcare system has the potential to maximise intervention for 
individuals with high risk of diseases such as cancer, cardiovascular disease (CVD) and type 2 
diabetes (Ordovas & Corella, 2004; Kaput & Rodriguez, 2004; Davis & Milner, 2004). 
Research and innovation within the NHS have focused on genomics with the annual report 
showing an investment in genomics with NHS genomic medical centres increasing from 11 
to 13 centres in 2015/16 (NHS England, 2016). This exemplifies the rapid development and 
importance of understanding public perception of genomic science into society.  
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10.1 The Effect of diet on health  
The role of diet in promoting health and wellbeing is a concept that dates back to over 
400 BC: “Let food be thy medicine and medicine be thy food” (Hippocrates). Poor diet is a 
major cause of global morbidity and mortality from chronic non-communicable diseases as 
opposed to undernutrition (de Onis et al., 2004, Lim et al., 2012, Lozano et al., 2012, Imamura 
et al., 2015). This worldwide transition to more unhealthy eating patterns is of great concern 
and highlights the need for improvements to food policies and overall diet quality on a global 
scale (Hawkes, 2006, Vandevijvere et al., 2013). A systematic review of the effects of diet on 
general health and wellbeing was undertaken and correlated with global dietary patterns and 
disease trends. Also, pathway analysis was performed to identify major biological processes 
associated with non-communicable diseases and pathways targeted by the functional foods 
omega-3, flavonoids and resveratrol to inform on the therapeutic potential of diet in the 
prevention and treatment of chronic disease.    
10.2 The health benefits of the Mediterranean Diet 
Since olive oil is an important component of this dietary pattern, much effort has been 
devoted to understanding the effect of MUFA, the major components of this oil. The 
replacement of SFA with MUFA reduced metabolic stress and prevented the expression of 
inflammatory genes in different tissues (PBMC, adipocytes, coronary artery smooth muscle, 
and human prostate cancer cells), and consequently to a less atherogenic profile and control 
of tumour progression when compared to other sources of fat.  
Minor components of virgin olive oil have been particularly studied and have found that the 
consumption of virgin olive oil with phenolic compounds, either in a postprandial regimen or 
over a relatively short period, influences the expression of genes related to atherosclerosis 
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progression, and that this effect is observed at the moderate doses consumed in this dietary 
pattern. Whether this action is due to a single, or a combination of phenolic compounds 
awaits an answer. Not much effort has been devoted to the translation of these 
transcriptional changes into proteins. However, in vitro studies indicate that extracts enriched 
in hydroxytyrosol, secoiridoids, and lignans can inhibit cell proliferation by modulating cell 
cycle expression.  
Despite being more abundant than phenolic compounds in virgin olive oil, terpenes have 
received less attention. In animal models, oleanolic and maslinic acids were particularly active 
in controlling the circadian clock and inflammation genes, respectively.  
The results reviewed provide at least a partial molecular basis for the reduced risk of 
cardiovascular disease, and cancer observed in Mediterranean countries. The nutrient 
complexity of the Mediterranean diets, differences among the studies and the diversity in the 
responses depending on the specific genetic makeup makes this field an open arena with 
enormous possibilities. Increasing and consolidating the nutrigenomic knowledge of this diet 
warrants further research to provide sound, personalised, and optimised nutritional 
recommendations. 
The Mediterranean Diet is the inspiration for the Gene Overlapping Study in this review 
assessing the key functional components of the diet. 
10.3 Altering dietary patterns to prevent disease 
To provide an up-to-date overview on the beneficial and adverse effects of diet on 
some phenotypic outcomes relevant to general health and wellbeing, and risk of chronic non-
communicable disease. The systematic review of the literature confirms that diets high in 
fruit, vegetables, whole-grains, low-fat dairy, oily fish, protein (including nuts, legumes and 
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pulses) and certain vitamins and minerals, and low in salt, processed meats, refined grains, 
sugary beverages and TFAs may have a protective effect against several chronic diseases 
including CVD, hypertension, high cholesterol, type-2 diabetes, obesity, stroke, cancer and 
risk of depression (Figures 3.2,3.3,3.4).  
10.4 UK dietary trends 
UK dietary trends show an over consuming of saturated fat, salt and added sugar, but 
not enough fruit, vegetables, oily fish and fibre, figure 3.6. This may be reflective of the rising 
costs of living as it was shown that household income influences what we eat, with lower-
income quintiles associating with poorer quality diet (NDNS, 2015). In 2012, the mean cost 
per unit of healthy and unhealthy products was £7.49 and £2.50, respectively, with the prices 
of healthier foods and beverages rising at a significantly faster rate than unhealthy products 
(Jones et al., 2014). Low-income households may, therefore, be more at risk of following 
unhealthy dietary choices. This is a major concern considering the rising trends in adult and 
child obesity rates in the UK (Stevens et al., 2012, LGA, 2014). However, it has been reported 
that the type of retailer (i.e. budget supermarket verses independent shops) plays more of a 
role in determining the cost of food rather than differences in healthy or unhealthy food 
choices (Banks et al., 2012). This raises opportunities for marketing healthier food choices in 
the movement towards prevention of dietary-related diseases. 
10.5 Global dietary trends 
Globally, healthier diet choices are generally increasing. However the consumption of 
unhealthy food products is outpacing this trend across all income quintiles (Imamura et al., 
2015). As with high-income countries, the cost of healthier food choices, particularly fruit and 
vegetables, in emerging economies such as Brazil, China, Korea and Mexico mean that energy-
dense processed foods are being consumed at greater rates (ODI, 2015). Adequate 
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consumption of fruit and vegetables reduces the risk of CVD, diabetes and certain cancer 
types (Wang et al., 2014, Muraki et al., 2013, Yokoyama et al., 2014, Aune et al., 2012, Amir 
Shaghaghi et al., 2013, Liu et al., 2014). Global analysis of morbidity and mortality rates for 
non-communicable diseases showed a positive correlation between lower quality diets based 
on consumption of more unhealthy products and increased risk of disease burden (Figures 
3.8,3.9,3.10). Worldwide estimates of nutritional transitions across the world will help to 
inform on global food policies and priorities for reducing the health and economic impacts of 
poor quality diets. 
10.6 The role of functional foods 
The term ‘functional food’ originated in Japan in 1984 to describe food products 
fortified with special constituents that possess advantageous physiological effects (Siro et al., 
2008). The most recent redefinition of this term states that functional foods are natural or 
processed foods that contain known or unknown biologically-active compounds; which, in 
defined, effective non-toxic amounts, provide a clinically proven and documented health 
benefit for the prevention, management or treatment of chronic disease (Martirosyan, 2015). 
However the exact biological mechanisms underpinning the functional aspects of these 
bioactive compounds are little understood.  
10.7 The role of nutraceuticals 
Nutraceuticals are food products and supplements which have nutritional value and 
are proven to be beneficial to disease prevention. There is increasing demand for natural 
products with health benefits. The increase in consumer understanding, attitudes and 
acceptance of functional food is generating market growth in nutraceuticals. Innovative 
technology such as microencapsulation and capsule-in-capsule technology is enabling the 
Chapter 10                                                                                                                     Discussion 
219 
 
creations of new foods and supplements with enhanced organoleptic properties and 
bioavailability. 
10.8 The influence of diet in epigenetics 
Epigenetic phenomena are inheritable and can affect gene expression without base 
pair changes. Abnormalities are believed to occur before the onset of diseases and might 
contribute to disease pathogenesis. Therefore, it is of great importance to discover markers 
that might be associated with an increased risk of disease development. Modification of 
chromatin is critical in controlling DNA transcription, giving rise to a variety of epigenetic 
effects. Due to its reversible character, epigenetics becomes attractive to nutritional 
intervention. Some nutrients have been studied and shown that they can modify gene 
expression via physiological and pathological processes in the epigenetic mechanism. 
Adjusting these processes by changing diet or consumption of specific nutrients may either 
prevent diseases, maintain health or promote the development of serious diseases. It is 
difficult to delineate the specific function for each epigenetic modulation on each type of 
nutrient. Nevertheless, nutrients with a positive effect health via epigenetic mechanisms 
have the least harmful effect to the human body; therefore, it is possible to develop 
nutraceutical products based on an individual’s gene expression to construct a personalised 
treatment and target specific health condition. 
10.9    Insights into the overlapping genetics of biology, diet and disease:  
Nutrigenomics with dietary composition is not well understood. This study took key 
nutritional elements from the Mediterranean diet and researched the overlapping genetics 
of each individually and in combination to assess their synergistic effect. 
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Pathway analysis using candidate genes for CVD, diabetes and obesity (collectively termed 
diabesity) was performed to identify disease-specific and common biological processes 
associated with these conditions. The gene sets were enriched for developmental and 
immune response pathways relating to angiogenesis and inflammation, respectively, Figure 
6.1. Angiogenesis plays a crucial role in the pathogenesis and treatment of cardiovascular 
disease (Liao et al., 2014). The immune system plays an important role in regulating 
angiogenesis both during development and in adult processes such as wound healing, tissue 
repair and multiple disease pathways including cancer and disorders of the cardiovascular 
system (Lavine et al., 2014, Epelman et al., 2015, De Martin et al., 2000, Tartour et al., 2011, 
Frantz & Nahrendorf, 2014). The bidirectional link between angiogenesis and the immune 
response is therefore of major clinical importance for the prevention and treatment of 
chronic diseases which associate with these key biological systems. 
Comparative analysis of the CVD and diabesity gene sets identified insulin/IGF-1 
signalling as the top significant pathway, Figure 6.3. This pathway has been demonstrated to 
underlie interactions between nutrition, metabolism and longevity (Cameron et al., 2008, van 
Heemst, 2010). Western dietary patterns typically high in grains, sugar and dairy, have been 
shown to over-stimulate the insulin/IGF-1 signalling pathway, which has in turn been linked 
to CVD and cancer (Melnik et al., 2011, Xie & Wang, 2013, Kleinridders et al., 2014, Massoner 
et al., 2010, Cohen & LeRoith, 2012, Verburgh, 2015, Higashi et al., 2012). In contrast, reduced 
activation of the insulin/IGF-1 pathway is associated with protection against age-related 
neurotoxicity seen in Alzheimer’s disease (Cohen et al., 2009, de la Monte, 2012).  
There is a growing interest in the role of polyphenol-rich foods in the prevention of 
chronic diseases (Stoclet et al., 2004, Pandey & Rizvi, 2009, Manach et al., 2005, Edwards & 
Kroon, 2014, Sagar et al., 2006). The protective role of these bioactive compounds has been 
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attributed to their antioxidant and anti-apoptotic effects which are in part regulated along 
the insulin/IGF-1 pathway (Tulio et al., 2012, Cameron et al., 2008, Wang et al., 2003), Figure 
6.4. The importance of this pathway in regulating biological processes necessary for normal 
cellular growth, survival and maintenance, in addition to its overlap into many disease 
pathways, offers rationale for following diets which avoid persistent over-stimulation of 
insulin/IGF-1 signalling and exaggerated insulin production, especially in individuals at risk of 
developing CVD, diabesity and cancer. 
Diet not only influences cardiovascular and metabolic processes but can also affect 
our mental health and wellbeing (Van de Weyer, 2005). Comparative enrichment analysis of 
gene sets for CVD, diabesity and neurogenesis using the PANTHER pathway analysis suite 
identified angiogenesis and hormonal signalling pathways to be important (Figure 6.5). 
Alzheimer’s disease and Huntington’s disease were identified as common disease pathways 
associated with the neurogenesis and CVD gene sets, Figure 6.5. Like CVD, neurodegenerative 
disorders are associated with increasing age and can occur as comorbidities with several 
pathological conditions, including those affecting the cardiovascular system (Snowdon et al., 
1997, Blennow et al., 1991, Chiu & Alexander, 1982, Lanska et al., 1988, Sorensen & Fenger, 
1992, Amar et al., 1996, Poblador-Plou et al., 2014). Several studies have demonstrated 
overlap in the genetic and biological mechanisms operating between neurodegeneration and 
disorders of the heart (Li et al., 2006, Abildtrup & Shattock, 2013, Melkani et al., 2013, van 
der Burg et al., 2009, Bradford et al., 2010, Willis & Patterson, 2013). In addition to lowering 
the risk of CVD, healthy dietary patterns have been associated with a reduced risk of dementia 
and Alzheimer’s disease, and dietary intake has been correlated with the onset of 
Huntington’s disease (Eskelinen et al., 2011, Marder et al., 2013). A better understanding of 
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the role that nutrition plays in complex pathological processes is therefore essential for the 
development of dietary advice for the prevention and management of the disease. 
10.10 The therapeutic role of functional foods in the targeting of biological and disease 
pathways. 
The therapeutic potential of the functional foods omega-3, flavonoids and resveratrol 
in the prevention and treatment of chronic disease has been suggested from the literature 
(Simopoulos, 2002, Dragan et al., 2007, Shukla & Singh, 2011, Petro, 2011, Ramos-Romero et 
al., 2012, Batra & Sharma, 2013, Laviano et al., 2013, Tanaka, 2014, Fabian et al., 2015). A 
better understanding of the biological mechanisms underpinning these therapeutic effects 
would be of great public interest and could be used by medical professions to inform on 
dietary recommendations as an alternative to pharmaceutical intervention in the treatment 
of common pathological conditions. Pathway analysis of genes significantly regulated in 
response to treatment interventions with these functional foods identified several 
overlapping pathways important for immune responses, between omega-3 and flavonoids, 
and cell cycle and cancer mechanisms, between omega-3 and resveratrol (Figure 6.6). Filters 
for immunological disease and cancer were overlaid onto these common pathways (Figures 
6.8 and 6.9) which identified several potentially important therapeutic targets, for example, 
PTEN; a key target gene in cancer therapy (Li et al., 2013, Dillon & Miller, 2014). Analysis of 
disease pathways associated with these functional foods indicated anti-viral, anti-tumorigenic 
and pro-survival properties for omega-3, Table 6.3, which is supported by the literature 
(Petrik et al., 1999, Notarnicola et al., 2013, Cockbain et al., 2012). Flavonoids were linked to 
developmental, immune and inflammatory responses (Table 6.4), whereas resveratrol was 
enriched for processes involved in cell structure and cell cycle (Table 6.5). Net effects of gene 
expression changes about toxicity functions suggested a beneficial role for omega-3 in 
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reducing hypertrophy of the heart and liver cancer, and flavonoids in reducing inflammation 
of the liver (Table 6.6).  
Our diet is influenced by many factors including age, sex, education, ethnicity and 
socioeconomic pressures. Psychological determinants of diet such as mood and stress levels 
are also very influential (Adam and Epel, 2007, Torres & Nowson, 2007, Mikolajczyk et al., 
2009, Ganasegeran et al., 2012). To address overlap between nutrition and key biological 
processes and common diseases potentially modified by dietary interventions, GWAS 
datasets for ageing, cognition, breast cancer, CVD, diabesity, neurodegeneration and 
psychiatric disorders were compared against gene expression changes associated with 
omega-3, flavonoids and resveratrol.  Significant overlap was observed between the omega-
3 and breast cancer gene sets (Figure 6.10A), emphasising the anti-tumorigenic properties of 
this functional food. 
Dietary intervention with the functional foods omega-3, flavonoids and resveratrol target 
important biological and disease pathways, suggesting a potentially important role for these 
bioactive compounds in the prevention and treatment of dietary-related disease such as 
cancer. 
10.11 Consumer attitudes to health interventions based on personal genetic testing. 
               The present study aimed to assess UK consumer attitudes and acceptance towards 
nutritional genomics, its services and activities with consideration on how demographics 
affect these factors. Results showed that the UK population had a high level of interest in 
nutritional genomics. Demographic factors did affect attitudes and acceptance, with those 
aged 55+ showing the most agreement towards nutritional genomics; this was followed by 
the age group 25-34 years. Gender did not affect overall response agreement towards the 
survey. The results of the present study suggest a positive overall outlook towards genomic-
Chapter 10                                                                                                                     Discussion 
224 
 
based nutrition, its services and activities within the UK population. Previous research 
suggests that knowledge and education may aid in mainstreaming genomic-based nutrition 
to the public as knowledge is reported to be a driving factor in consumer acceptance of 
genetic testing. This informs the need for health education programmes to improve consumer 
understanding of nutrigenomics. The NHS is also funding the expansion of more genomic 
centres and education may be imperative to ensure the public are better informed of the 
benefits of this continually evolving science which has the potential to bring significant savings 
to the health service within the UK. 
Further research would be useful to inform on other demographic factors such as 
income, education level and ethnicity to gain a greater understanding of the complex reasons 
which affect attitudes towards genetic testing and nutritional genomics. However, there have 
been a significant number of recent genomic business start-ups that prove that there is a 
growing consumer demand in this area and this is creating an important market opportunity 
for the food and healthcare sectors.  
10. 12    Genomic business applications 
A successful business model is a key to the successful commercialisation of a 
nutrigenomic start-up business. Combining the right business models with the appropriate 
consumer research indicates the likely consumer acceptance towards the business activities. 
A key factor is engagement and clarity with the consumer to reduce avoidance towards 
genetic testing. A complete business model in the UK which provides a full complete service 
from genotype testing, personal nutrition advice, to providing a delivered healthy meal based 
on personal genetic data was not identified. ‘Habit’, a US-based company is the only company 
identified which currently provides full holistic service.   
Chapter 10                                                                                                                     Discussion 
225 
 
The public is increasingly reflective in matters of health and willing to adopt health-oriented 
changes in their eating habits. Developing and marketing new functional food products 
require significant research efforts. It is a multistage process which involves identifying 
functional components and their physiological effects; developing a food matrix which is 
suitable for this compound taking into account its bio-availability, potential changes during 
food preparation and processing, and finally clinical trials on product efficacy in order to 
gain approval for health marketing claims (Siro et al., 2008).  
Education and knowledge level of the product end users is very important in determining 
the possibility of market success. The health effect message of a specific product should be 
communicated in a manner which consumers can easily comprehend. Therefore, specialist 
terminology or medical details should be avoided. Consumers are interested in 
understanding the benefits, rather than the ‘science’ behind the product. The role of 
educating consumers is therefore crucial because, unlike taste and other sensory attributes, 
consumers cannot perceive the benefit of the product directly and immediately.  
10.13 Implications for public health the NHS 
The cost of public and private healthcare systems in the UK like many other 
countries continues to escalate. The cost of the NHS is likely to rise from 7.7% of GDP in 
2016 to 12.2% of GDP in 2066 (OECD, 2018).  However, the combined public and private 
cost of healthcare in the UK was 9.7% of GDP in 2016. 
Public Health England provides guidance on nutritional levels of salt, sugar and 
saturated fat and connects with the food industry to reduce the intrinsic amounts of each in 
processed food. However, these efforts have failed to produce a ‘population effect’ 
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improvement in health. In fact, the main NCDs drivers of poor health (CVD, Obesity, Mental 
Health) are expected to increase.  
The UK government has recognised the importance of genetics in healthcare by 
funding Genomics England to deliver the ‘100,000 genome project’. The project will collect 
genetics from patients and families focusing on rare disease and cancer. In parallel, the 
private sector is using more targeted genomic profiling of selected polymorphisms in 
commercial ventures in the areas of diet, psychology, exercise and health & wellbeing.  
 This study provides a rationale for the greater understanding of functional foods, 
nutrigenomic pathway analysis and consumer acceptance of genomic profiling for health 
benefits. If a sustainable population effect in health improvement is achievable, then 
functional nutrition designed from a combination of personalised genetic analysis and 
functional nutrigenomic interventions represents an important new nexus for improving 
public health and the future of disease prevention. 
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Appendices 
Appendix 1.  Nutrient Interventions for Disease (table 4.7 – Appendix 1) 
 
  
Disease Dietary/Lifest
yle Prevention 
Ingredients 
Prevention 
Journal Title Conclusion  Year URL Citation  
Metabolic 
Syndrome, 
Alzheimer's 
Disease 
- - Metabolic Syndrome 
and Risk for Incident 
Alzheimer's Disease 
or Vascular Dementia 
The observed relation between high 
triglycerides, diabetes, and vascular 
dementia emphasises the need for 
detection and treatment of vascular 
risk factors in older individuals to 
prevent the likelihood of clinical 
dementia. 
2009 https://ww
w.ncbi.nlm
.nih.gov/p
mc/articles
/PMC2606
808/ 
Raffaitin, C., Gin, H., Empana, 
J.-P., Helmer, C., Berr, C., 
Tzourio, C., … Barberger-
Gateau, P. (2009). Metabolic 
Syndrome and Risk for Incident 
Alzheimer’s Disease or 
Vascular Dementia: The Three-
City Study. Diabetes 
Care, 32(1), 169–174. 
http://doi.org/10.2337/dc08-
0272 
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Alzheimer's Ketogenic 
diet,  
- Ketogenic diets and 
Alzheimer’s disease 
At present, there is only limited 
evidence of the usefulness of 
ketogenic diets in AD. However, this 
dietary approach seems to be 
promising and deserves further 
clinical investigations 
2017 https://ac.
els-
cdn.com/S
221345301
6301355/1
-s2.0-
S22134530
16301355-
main.pdf?
_tid=202fa
7c4-d99f-
11e7-
923a-
00000aacb
362&acdn
at=151246
6501_5674
8ec591062
Lange, K., Lange, K., Makulska-
Gertruda, E., Nakamura, Y., 
Reissmann, A., Kanaya, S. and 
Hauser, J. (2017). Ketogenic 
diets and Alzheimer’s 
disease. Food Science and 
Human Wellness, 6(1), pp.1-9. 
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7341f8693
56b626eee
4 
CVD, 
Alzheimers 
- - Cardiovascular 
disease and 
Alzheimer's disease: 
common links. 
The substantial overlap in risk 
factors points to new avenues for 
research and prevention. 
2006 https://ww
w.ncbi.nlm
.nih.gov/p
ubmed/16
918818 
Stampfer MJ. Cardiovascular 
disease and Alzheimer's 
disease: Common links. J 
Intern Med. 2006;260:211–
223. 
Carotid 
atherosclero
sis, 
Alzheimer's 
- - Carotid 
atherosclerosis 
promotes the 
progression of 
Alzheimer's disease: 
A three-year 
prospective study. 
The present prospective study 
showed that carotid atherosclerosis 
is a predictive factor regarding the 
progression of cognitive impairment 
in AD patients, suggesting that early 
detection and treatment of vascular 
risk factors may prevent or at least 
postpone the evolution of the 
disease. 
2017 https://ww
w.ncbi.nlm
.nih.gov/p
ubmed/28
810593 
Xiang, J. (2017). Carotid 
atherosclerosis promotes the 
progression of 
ofï¿½Alzheimer's disease: A 
three-year prospective 
study. Experimental and 
Therapeutic Medicine. 
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glucose 
regulation 
aerobic and 
resistance 
training,  
 
12 weeks' aerobic 
and resistance 
training without 
dietary intervention 
did not influence 
oxidative stress, but 
aerobic training 
decreased 
atherogenic index in 
middle-aged men 
with impaired 
glucose regulation. 
Improved lipid profile remained a 
predictor of decreased MetS score 
only in NW group, and it seems that 
Nordic walking has more beneficial 
effects on cardiovascular disease 
risks than RT training. 
2013 https://ww
w.ncbi.nlm
.nih.gov/p
ubmed/23
623841 
Venojärvi, M., Korkmaz, A., 
Wasenius, N., Manderoos, S., 
Heinonen, O., Lindholm, H., 
Aunola, S., Eriksson, J. and 
Atalay, M. (2013). 12 Weeks’ 
aerobic and resistance training 
without dietary intervention 
did not influence oxidative 
stress, but aerobic training 
decreased atherogenic index in 
middle-aged men with 
impaired glucose 
regulation. Food and Chemical 
Toxicology, 61, pp.127-135. 
 alzheimers Lutein  - Advances in the 
researches of lutein 
and Alzheimer's 
disease 
In this article, we systematically 
reviewed the literature on the role 
of lutein in age-related cognitive 
decline and Alzheimer's disease and 
2015 https://ww
w.ncbi.nlm
.nih.gov/p
Xu X, Lin X. (2015). Advances in 
the researches of lutein and 
Alzheimer's disease. Zhonghua 
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its possible mechanisms. It may 
prove some benefit information for 
the advanced research and 
prevention of AD. 
ubmed/26
081713 
Yu Fang Yi Xue Za 
Zhi.;49(5):456-60. 
- High carb 
diet, 
Alzheimer's 
- High carbohydrate 
diets and Alzheimer's 
disease. 
A change in diet emphasising 
decreasing dietary carbohydrates 
and increasing essential fatty acids 
(EFA) may effectively prevent AD. 
Interventions that restore lipid 
homeostasis may treat the disease, 
including drugs that increase fatty 
acid metabolism, EFA repletion 
therapy, and ketone body 
treatment. 
2004 https://ww
w.ncbi.nlm
.nih.gov/p
ubmed/15
082091 
Henderson, S. (2004). High 
carbohydrate diets and 
Alzheimer's disease. Medical 
Hypotheses, 62(5), pp.689-
700. 
Diabetes and 
Alzheimers 
- - Impairment of 
synaptic plasticity 
and memory 
formation in GLP-1 
Results demonstrate that the murine 
GLP-1R plays an important role in 
the control of synaptic plasticity and 
some forms of memory formation. 
2009 http://ww
w.scienced
irect.com/
science/art
Abbas, T., Faivre, E. and 
Hölscher, C. (2009). 
Impairment of synaptic 
plasticity and memory 
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receptor KO mice: 
Interaction between 
type 2 diabetes and 
Alzheimer's disease 
The results shed light on the 
molecular processes that underlie 
the neuroprotective properties of 
GLP-1 analogues in animal models of 
Alzheimer's disease. 
icle/pii/S0
166432809
003970 
formation in GLP-1 receptor 
KO mice: Interaction between 
type 2 diabetes and 
Alzheimer's 
disease. Behavioural Brain 
Research, 205(1), pp.265-271. 
alzheimers High 
carbohydrate,  
- A high-glycemic diet 
is associated with 
cerebral amyloid 
burden in cognitively 
normal older adults. 
A high-glycemic diet was associated 
with greater cerebral amyloid 
burden, which suggests diet as a 
potentially modifiable behaviour for 
cerebral amyloid accumulation and 
subsequent Alzheimer disease risk.  
2017 https://ww
w.ncbi.nlm
.nih.gov/p
ubmed/29
070566 
Taylor, M., Sullivan, D., 
Swerdlow, R., Vidoni, E., 
Morris, J., Mahnken, J. and 
Burns, J. (2017). A high-
glycemic diet is associated 
with cerebral amyloid burden 
in cognitively normal older 
adults. The American Journal 
of Clinical Nutrition, 106(6), 
pp.1463-1470. 
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alzheimers Ketogenic 
diet,  
- Neuroprotective and 
Anti-inflammatory 
Activities of 
Ketogenic Diet on 
MPTP-induced 
Neurotoxicity 
KD was neuroprotective and anti-
inflammatory against MPTP-
neurotoxicity. 
2010 https://lin
k.springer.
com/articl
e/10.1007/
s12031-
010-9336-
y#citeas 
Yang, X. and Cheng, B. (2010). 
Neuroprotective and Anti-
inflammatory Activities of 
Ketogenic Diet on MPTP-
induced Neurotoxicity. Journal 
of Molecular Neuroscience, 
42(2), pp.145-153. 
inflammatio
n 
Intermittent 
fasting,  
- Intermittent fasting 
during Ramadan 
attenuates 
proinflammatory 
cytokines and 
immune cells in 
healthy subjects. 
results indicate that RIF attenuates 
inflammatory status of the body by 
suppressing proinflammatory 
cytokine expression and decreasing 
body fat and circulating levels of 
leukocytes. 
2012 https://ww
w.ncbi.nlm
.nih.gov/p
ubmed/23
244540/ 
Faris, MA., Kacimi, S., Al-Kurd, 
R., Fararjeh, M., Bustanji, Y., 
Mohammad, M. and Salem, M. 
(2012). Intermittent fasting 
during Ramadan attenuates 
proinflammatory cytokines 
and immune cells in healthy 
subjects. Nutrition Research, 
32(12), pp.947-955. 
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hypocholest
erolemic 
Negative 
effect - 
intermittent 
fasting,  
- Food restriction 
by intermittent fastin
g induces diabetes 
and obesity and 
aggravates 
spontaneous 
atherosclerosis 
development in 
hypercholesterolaemi
c mice. 
the IF regimen induced obesity and 
diabetes and worsened the 
development of spontaneous 
atherosclerosis in LDL-receptor 
knockout mice. Although being 
efficient in a wild-type background, 
this type of food restriction is not 
beneficial in the context of genetic 
hypercholesterolaemia. 
2014 https://ww
w.ncbi.nlm
.nih.gov/p
ubmed/24
176004 
Dorighello, G., Rovani, J., 
Luhman, C., Paim, B., Raposo, 
H., Vercesi, A. and Oliveira, H. 
(2013). Food restriction by 
intermittent fasting induces 
diabetes and obesity and 
aggravates spontaneous 
atherosclerosis development 
in hypercholesterolaemic 
mice. British Journal of 
Nutrition, 111(06), pp.979-
986. 
- CVD Mediterranea
n diet,  
- Mediterranean 
diet and 
cardiovascular 
disease: a systematic 
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Appendix 2. European Food Safety Association – Assessment of health claims 
 
EFSA- I Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to iodine and contribution to normal 
cognitive and neurological function (ID 273), contribution to normal energy-yielding 
metabolism (ID 402), and contribution to normal thyroid function and production of 
thyroid hormones (ID 1237) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. 
EFSA Journal 2010;8(10):1800. [15 pp.]. doi:10.2903/j.efsa.2010.1800. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA- l Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to caffeine and increase in physical 
performance during short-term high-intensity exercise (ID 737, 1486, 1489), increase in 
endurance performance (ID 737, 1486), increase in endurance capacity (ID 1488) and 
reduction in the rated perceived exertion/effort during exercise (ID 1488, 1490) 
pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2053. 
[24 pp.]. doi:10.2903/j.efsa.2011.2053. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the 
substantiation of health claims related to cocoa flavanols and protection of lipids from 
oxidative damage (ID 652, 1372, 1506, 3143), and maintenance of normal blood 
pressure (ID 1507) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA 
Journal 2010;8(10):1792. [21 pp.]. doi:10.2903/j.efsa.2010.1792. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the 
substantiation of health claims related to caffeine and theobromine in cocoa 
(Theobroma cacao L.) and enhancement of mood (ID 4276) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2269. [14 pp.]. 
doi:10.2903/j.efsa.2011.2269. Available online: www.efsa.europa.eu/efsajournal  
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the 
substantiation of health claims related to phaseolamine and reduction in body weight 
(ID 1701) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 
2011;9(6):2253. [13 pp.]. doi:10.2903/j.efsa.2011.2253. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA-a Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to glucomannan and maintenance of normal 
blood cholesterol concentrations (ID 836, 1560) pursuant to Article 13(1) of Regulation 
(EC) No 1924/2006. EFSA Journal 2009; 7(9):1258. [14 pp.]. 
doi:10.2903/j.efsa.2009.1258. Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-b Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to konjac mannan (glucomannan) and 
reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic 
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responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 
3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), 
maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance 
of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic 
gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006. EFSA Journal 2010;8(10):1798. [27 pp.]. doi:10.2903/j.efsa.2010.1798. 
Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-c Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to chromium and contribution to normal 
macronutrient metabolism (ID 260, 401, 4665, 4666, 4667), maintenance of normal 
blood glucose concentrations (ID 262, 4667), contribution to the maintenance or 
achievement of a normal body weight (ID 339, 4665, 4666), and reduction of tiredness 
and fatigue (ID 261) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA 
Journal 2010;8(10):1732. [23 pp.]. doi:10.2903/j.efsa.2010.1732. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA-d  Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to soy phosphatidyl choline and maintenance 
of normal blood cholesterol concentrations (ID 709, 1308, 1630, 1961, 3138, 3187, 
4687), contribution to normal fat metabolism (ID 1597), increase in the intestinal 
absorption of glutamine (ID 4251), faster recovery from muscle fatigue after exercise (ID 
4249), improvement of neuromuscular function (ID 4250), contribution to normal 
cognitive function (ID 710, 1596, 1631, 1983) and maintenance of normal neurological 
function (ID 1596) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA 
Journal 2010;8(10):1741. [26 pp.]. doi:10.2903/j.efsa.2010.1741. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA-e Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to conjugated linoleic acid (CLA) isomers and 
contribution to the maintenance or achievement of a normal body weight (ID 686, 726, 
1516, 1518, 2892, 3165), increase in lean body mass (ID 498, 731), increase in insulin 
sensitivity (ID 1517), protection of DNA, proteins and lipids from oxidative damage (ID 
564, 1937), and contribution to immune defences by stimulation of production of 
protective antibodies in response to vaccination (ID 687, 1519) pursuant to Article 13(1) 
of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1794. [26 pp.].  
doi:10.2903/j.efsa.2010.1794. Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-f Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to selenium and maintenance of normal hair 
(ID 281), maintenance of normal nails (ID 281), protection against heavy metals (ID 383), 
maintenance of normal joints (ID 409), maintenance of normal thyroid function (ID 410, 
1292), protection of DNA, proteins and lipids from oxidative damage (ID 410, 1292), and 
maintenance of the normal function of the immune system (ID 1750) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1727. [18 pp.]. 
doi:10.2903/j.efsa.2010.1727. Available online: www.efsa.europa.eu/efsajournal  
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EFSA-g Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to selenium and protection of DNA, proteins 
and lipids from oxidative damage (ID 277, 283, 286, 1289, 1290, 1291, 1293, 1751), 
function of the immune system (ID 278), thyroid function (ID 279, 282, 286, 1289, 1290, 
1291, 1293), function of the heart and blood vessels (ID 280), prostate function (ID 284), 
cognitive function (ID 285) and spermatogenesis (ID 396) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006 . EFSA Journal 2009; 7(9):1220. [24 pp.]. 
doi:10.2903/j.efsa.2009.1220. Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-h Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to iodine and thyroid function and production 
of thyroid hormones (ID 274), energy-yielding metabolism (ID 274), maintenance of 
vision (ID 356), maintenance of hair (ID 370), maintenance of nails (ID 370), and 
maintenance of skin (ID 370) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. 
EFSA Journal 2009; 7(9):1214. [17 pp.]. doi:10.2903/j.efsa.2009.1214. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA-J Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to niacin and energy-yielding metabolism (ID 
43, 49, 54), function of the nervous system (ID 44, 53), maintenance of the skin and 
mucous membranes (ID 45, 48, 50, 52), maintenance of normal LDL-cholesterol, HDL 
cholesterol and triglyceride concentrations (ID 46), maintenance of bone (ID 50), 
maintenance of teeth (ID 50), maintenance of hair (ID 50, 2875) and maintenance of 
nails (ID 50, 2875) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA 
Journal 2009; 7(9):1224. [22 pp.]. doi:10.2903/j.efsa.2009.1224. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA-k Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to niacin and reduction of tiredness and 
fatigue (ID 47), contribution to normal energy-yielding metabolism (ID 51), contribution 
to normal psychological functions (ID 55), maintenance of normal blood flow (ID 211), 
and maintenance of normal skin and mucous membranes (ID 4700) pursuant to Article 
13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1757. [17 pp.]. 
doi:10.2903/j.efsa.2010.1757. Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-m Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to caffeine and increased fat oxidation 
leading to a reduction in body fat mass (ID 735, 1484), increased energy expenditure 
leading to a reduction in body weight (ID 1487), increased alertness (ID 736, 1101, 1187, 
1485, 1491, 2063, 2103) and increased attention (ID 736, 1485, 1491, 2375) pursuant to 
Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011; 9(4):2054. [29 pp.]. 
doi:10.2903/j.efsa.2011.2054. Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-n Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to 5 hydroxytryptophan and enhancement of 
mood (ID 1575) and attention (ID 1828) pursuant to Article 13(1) of Regulation (EC) No 
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1924/2006. EFSA Journal 2009; 7(9):1273. [11 pp.]. doi:10.2903/j.efsa.2009.1273. 
Available online: www.efsa.europa.eu/efsajournal  
EFSA-o Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to 5-hydroxytryptophan (5-HTP) and increase 
in satiety leading to a reduction in energy intake (ID 4223) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006. EFSA Journal 2011;9(6):2198. [14 pp.]. 
doi:10.2903/j.efsa.2011.2198. Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-p Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to L phenylalanine and increased alertness (ID 
708, 1629), enhancement of mood (ID 657), pain relief (ID 657) and improvement of 
memory (ID 658) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA 
Journal 2010;8(10):1748. [14 pp.]. doi:10.2903/j.efsa.2010.1748. Available online: 
www.efsa.europa.eu/efsajournal  
 
EFSA-q Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to boron and maintenance of bone (ID 218, 
219) and maintenance of joints (ID 219, 220) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006. EFSA Journal 2009; 7(9):1261. [16 pp.]. doi:10.2903/j.efsa.2009.1261. 
Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-r Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to boron and prevention and treatment of 
prostate cancer (ID 221), maintenance of normal thyroid function (ID 222) and 
contribution to normal cognitive function (ID 223) pursuant to Article 13(1) of Regulation 
(EC) No 1924/2006. EFSA Journal 2011;9(6):2209. [14 pp.]. doi:10.2903/j.efsa.2011.2209. 
Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-s Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of a health claim related to L-ornithine and contribution to the 
regulation of the urea cycle (ID 4270) pursuant to Article 13(1) of Regulation (EC) No 
1924/2006. EFSA Journal 2011;9(6):2251. [12 pp.]. doi:10.2903/j.efsa.2011.2251. 
Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-t Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to L arginine and “immune system functions” 
(ID 455, 1713), growth or maintenance of muscle mass (ID 456, 1712, 4681), normal red 
blood cell formation (ID 456, 664, 1443, 1712), maintenance of normal blood pressure 
(ID 664, 1443), improvement of endothelium-dependent vasodilation (ID 664, 1443, 
4680), “physical performance and condition” (ID 1820), “système nerveux” (ID 608), 
maintenance of normal erectile function (ID 649, 4682), contribution to normal 
spermatogenesis (ID 650, 4682), “function of the intestinal tract” (ID 740), and 
maintenance of normal ammonia clearance (ID 4683) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2051. [30 pp.]. 
doi:10.2903/j.efsa.2011.2051. Available online: www.efsa.europa.eu/efsajournal  
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EFSA-u Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to L-tyrosine and contribution to normal 
synthesis of catecholamines (ID 1928), increased attention (ID 440, 1672, 1930), and 
contribution to normal muscle function (ID 1929) pursuant to Article 13(1) of Regulation 
(EC) No 1924/2006. EFSA Journal 2011;9(6):2270. [16 pp.]. doi:10.2903/j.efsa.2011.2270. 
Available online: www.efsa.europa.eu/efsajournal  
 
EFSA-v Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on 
the substantiation of health claims related to pantothenic acid and energy-yielding 
metabolism (ID 56, 59, 60, 64, 171, 172, 208), mental performance (ID 57), maintenance 
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of skin (ID 61), maintenance of nails (ID 61) and synthesis and metabolism of steroid 
hormones, vitamin D and some neurotransmitters (ID 181) pursuant to Article 13(1) of 
Regulation (EC) No 1924/2006. EFSA Journal 2009; 7(9):1218. [19 pp.]. 
doi:10.2903/j.efsa.2009.1218. Available online: www.efsa.europa.eu/efsajournal  
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1924/2006. EFSA Journal 2010;8(10):1758. [16 pp.]. doi:10.2903/j.efsa.2010.1758. 
Available online: www.efsa.europa.eu/efsajournal  
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